Mechanisms and quantitative prediction of Efavirenz metabolism, pharmacogenetics and drug interactions by Xu, Cong
 
 
 
 
MECHANISMS AND QUANTITATIVE PREDICTION OF EFAVIRENZ 
METABOLISM, PHARMACOGENETICS AND DRUG INTERACTIONS 
 
 
 
Cong Xu 
 
 
 
 
 
 
 
 
 
 
Submitted to the faculty of the University Graduate School 
in partial fulfillment of the requirements 
for the degree 
Doctor of Philosophy 
in the Department of Pharmacology and Toxicology,  
Indiana University 
 
 
August 2013 
 
 
ii 
 
Accepted by the Faculty of Indiana University, in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy. 
 
 
 
  ____________________________________ 
  Sherry F. Queener, Ph.D., Chair 
 
  ____________________________________ 
  Zeruesenay Desta, Ph.D. 
 Doctoral Committee 
  ____________________________________ 
  Lang Li, Ph.D 
  
  ____________________________________ 
  David R. Jones, Ph.D. 
 March 28, 2013 
  ____________________________________ 
  Jian-Ting Zhang, Ph.D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
DEDICATION 
This work is dedicated to my thesis mentor, Dr. Zeruesenay Desta and my friends 
and family, especially my parents, Zhangsun Xu and Wanling Chai. 
  
 
 
iv 
 
ACKNOWLEDGEMENTS 
I would not have completed my Ph.D. dissertation without the tremendous 
support and guidance of many people who have influenced my life and shaped my 
experience both personally and professionally. 
First and foremost, I would like to sincerely thank my family. To my mother, 
Wanling, and father, Zhangsun, who have always supported me to pursue my career 
interests and encouraged me during periods of struggles.  
I especially would like to thank my mentor, Dr. Zeruesenay Desta. I sincerely 
appreciate that Dr. Desta granted me the opportunity to grow into a mature professional. 
Dr. Desta introduced me into the arena of clinical pharmacology by his favorite efavirenz 
project. He provided expert assistance during periods of trouble shooting, gave freedom 
to develop an independent research project, allowed me to cultivate collaboration project 
and helped improving my scientific writing and presentation skills as an international 
student. I would like to particularly thank for his support to my internship in Pfizer Inc. 
during the summer of 2012. I feel extremely fortunate to have Dr. Desta as my Ph.D. 
mentor, who helped me to grow not only scientifically but also mentally during my 
graduate training.  
I would also like to thank the members of my thesis committee, Dr. Sherry 
Queener, Dr. Jianting Zhang, Dr. David Jones and Dr. Lang Li for their guidance, 
suggestions, and constructive critiques. 
Besides my committee, I would like to thank the faculty and staff of the Clinical 
Pharmacology division and department of Pharmacology and Toxicology for all their 
guidance and help. I would like to acknowledge Dr. David Flockhart for his generous
 
 
v 
 
 support for me to take additional scientific trainings, e.g. online classes and scientific 
conferences. I would like to acknowledge Dr. David Jones who generously shared his 
resources and experiences of microsomal incubation and mass spectrometry 
quantification. I would like to acknowledge Dr. Lang Li and Dr. Sara Quinney for their 
guidance and support to learn Simcyp and apply it in my dissertation project. I would like 
to acknowledge the significant help from Evan Ogburn, a former lab technician of my 
laboratory. My experimental part of dissertation would not have been made possible 
without him. I would also like to acknowledge Jessica Lu and Yvonne Kreutz for their 
support as lab colleagues and friends.
  
 
 
vi 
 
ABSTRACT 
Cong Xu 
Mechanisms and quantitative prediction of efavirenz metabolism, 
pharmacogenetics and drug interactions 
 
The antiretroviral drug efavirenz remains a cornerstone for treatment-naïve HIV 
patients. Subsequent to the demonstration that efavirenz is a substrate of cytochrome 
P450 (CYP) 2B6, a number of clinical studies found that the CYP2B6*6 allele is 
significantly associated with higher efavirenz exposure and/or adverse reactions. 
However, the mechanism of reduced efavirenz metabolism by this genetic variant is not 
fully understood and whether this variant exhibits differential susceptibility to metabolic 
inhibition is also unknown. Ths use of efavirenz is further complicated by the drug 
interactions associated with it. Therefore, I hypothezised that 1) the CYP2B6*6 allele 
reduces efavirenz metabolism by altering catalytic properties of CYP2B6; 2) efavirenz 
alters the pharmacokinetics of co-administered drugs by inhibiting drug metabolizing 
enzymes. A series of studies was carried out in hepatic microsomal preparations to 
determine the functional consequences of the CYP2B6*6 allele and to assess inhibition 
potency of efavirenz on 8 CYPs. The major findings for these studies include: 1) the 
CYP2B6*6 allele reduces efavirenz metabolism by decreasing substrate binding and 
catalytic efficiency; 2) functional consequences of the CYP2B6*6 allele appear to be 
substrate- and cytochrome b5-dependent; 3) the CYP2B6*6 allele confers increased 
susceptibility to metabolic inhibition; and 4) efavirenz inhibits the activities of CYP2B6, 
2C8, 2C9 and 2C19 at therapeutically relevant concentrations. In addition, I explored the 
hypothesis that the incorporation of in vitro mechanism by which the CYP2B6*6 allele
 
 
vii 
 
 reduced efavirenz metabolism predicts the genetic effect of this allele on efavirenz 
clearance after a single oral dose by modeling approach. A pharmacogenetics-based in 
vitro-in vivo extrapolation (IVIVE) model was developed to predict human efavirenz 
clearance. Taken together, results from this dissertation provide new mechanistic 
information on how the CYP2B6*6 allale alters substrate metabolism and drug 
interactions; demonstrate new mechanisms of efavirenz-mediated inhibition interactions; 
and demonstrate the utility of a pharmacogenetics-based predictive model that can serve 
as a basis for future studies with efavirenz and other CYP2B6 substrates. Overall these 
data provide improved understanding of genetic and non-genetic determinant of efavirenz 
disposition and drug interactions associated with it. 
 
Sherry F. Queener, Ph.D., Chair 
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Chapter I: Introduction 
1. HIV epidemic and anti-HIV therapy 
The world first became aware of acquired immunodeficiency syndrome (AIDS), a 
disease of the human immune system, in 1981. A growing number of homosexual 
patients and injection drug users were developing rare types of opportunistic infections, 
Kaposi’s sarcoma, and pneumonia in New York and California (Weiss, 2008). In 1983, 
scientists have established the causative organism from AIDS patients when two separate 
research groups independently isolated a novel retrovirus from AIDS patients named 
human T-lymphotropic viruses-III (HTLVs-III) (Gallo et al., 1983) and 
lymphadenopathy-associated virus (LAV) (Barre-Sinoussi et al., 1983), respectively. 
These two retroviruses were the same (Ratner et al., 1985) and were renamed human 
immunodeficiency virus infection (HIV) by the International Committee on Taxonomy of 
Viruses in 1986. Two types of HIV have been characterized: HIV-1 and HIV-2. HIV-1 is 
the virus that causes the majority of HIV infections globally (De Cock et al., 1993; 
Marlink et al., 1994).  
Following its recognition in 1981, the HIV epidemic has evolved to become a 
great challenge in global health. In 2011, more than 34.2 million people were infected 
with HIV, and more than 25 million lives lost over the last 30 years (World Health 
Organization, July 2012). The most affected region of the worldis sub-Saharan African, 
where over 60% of HIV patients are living (World Health Organization, July 2012). 
HIV primarily infects CD4
+ 
T cells, macrophages, and dendritic cells (Wu and 
KewalRamani, 2006; Carter and Ehrlich, 2008). HIV begins its life cycle when it binds to 
a CD4 receptor and one of two co-receptors (CCR5 and CXCR4) on the surface of target 
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cells (Alkhatib et al., 1996; Feng et al., 1996) (Figure 1.1). Then the virus fuses with the 
host cell and viral RNA and proteins are injected into cell. An HIV enzyme called reverse 
transcriptase converts the single-stranded HIV RNA to double-stranded HIV DNA. The 
newly formed HIV DNA enters the host cell’s nucleus, and is integrated into the host 
cell’s own DNA by integrase to use the host cells’ genetic machinery to produce new 
virus. The integrated HIV DNA is called provirus and may remain inactive for several 
years. When the host cell receives a signal to become active, the provirus uses a host 
enzyme called RNA polymerase to create copies of the HIV genomic material, as well as 
shorter strands of RNA called messenger RNA (mRNA). The mRNA is used as a 
blueprint to make long chains of HIV proteins. The newly assembled virus pushes out 
("buds") from the host cell. During budding, the new virus steals part of the cell's outer 
envelope. This envelope, which acts as a covering, is studded with protein/sugar 
combinations called HIV glycoproteins. These HIV glycoproteins are necessary for the 
virus to bind CD4 and co- receptors. The final step of HIV life cycle is maturation of 
virion, where the polyprotein is cut into proper size by protease, and the new copies of 
HIV can now move on to infect other cells (Debouck et al., 1987; Kohl et al., 1988). 
Zidovudine, nucleoside reverse transcriptase inhibitors (NRTIs), was the first 
anti-HIV agent approved by the Food and Drug Administration (FDA) in 1987. This drug 
prevents HIV-1 replication by competitively inhibiting RT, leading to chain termination 
of the viral DNA. Despite the initial high hopes of zidovudine therapy, physicians have 
quickly realized that its use as a single agent (monotherapy) resulted in rapid emergence 
of viral drug resistance and treatment failure. In 1991, didonasine, another NRTI, was 
developed and dual NRTI therapy was tested, no therapeutic breakthrough could be 
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achieved and HIV treatment remained unsuccessful. By 1993, HIV-1 became the number 
one killer of the USA young population. Thus, developing new drugs and refining 
combination regimens that are safe and effective continues to this date. However, the 
demonstration, in 1994, that zidovudine monotherapy during pregnancy prevents HIV-1 
transmission to the neonates (decrease from 25.5 to 8.3%) remained a landmark 
therapeutics approach (Connor et al., 1994). As improved understanding of the molecular 
biology of the virus is achieved, additional drug targets, including viral protease (the 
enzyme responsible for the maturation of viral particles to infectious virons ready to 
infect new host cells), were identified. Through advanced drug discovery processes, 
potent protease inhibitors that bind to the active site of the enzyme where protein 
cleavage occurs were synthesized and tested for efficacy. By 1995, there was preliminary 
understanding that combination of PIs with NRTIs shows clinical efficacy, and this has 
paved the way for the start of the era of a three-drug combination in 1996, also known as 
the highly active antiretroviral therapy (HAART). By 1997, there were convincing 
clinical data regarding the effectiveness of HAART (Gulick et al., 1997; Hammer et al., 
1997). HAART was quickly incorporated into clinical practice and rapidly showed 
significant decrease in the incidence, death and hospitalization rate caused by AIDS 
(Palella et al., 1998). Despite certain intial limitations of HAART in terms of adverse 
effects, pill burden or development of resistant virus, HAART represented landmark 
treatment approach for this otherwise deadly disease because these drug combinations 
significantly decreased incidence of HIV-1 and mortality from AIDS.   
Currently, 26 antiretroviral drugs are approved by the FDA that targets different 
steps of the HIV life cycle: fusion inhibitors, co-receptor inhibitors, reverse transcriptase 
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inhibitors (RTIs), integrase inhibitors (InSTI) and protease inhibitors (PIs). There are 
three subgroups under RTIs: nucleoside reverse transcriptase inhibitors (NRTIs), 
nucleotide reverse-transcriptase inhibitors (NtRTIs) and non-nucleoside reverse 
transcriptase inhibitors (NNRTIs). NRTIs compose the first class of antiretroviral drugs 
developed. They are analogues of the naturally occurring deoxynucleotides and compete 
with the natural deoxynucleotides for incorporation into the growing viral DNA chain. In 
order to be incorporated into the viral DNA, NRTIs must be activated in the cell by the 
addition of three phosphate groups to their deoxyribose moiety, to form NRTI 
triphosphates. Since NRTIs lack a 3’-OH moiety in the ribose ring, this incorporation 
results in the termination of transcription. The mode of action of NtRTIs is essentially the 
same to NRTIs. All NRTIs and NtRTIs are classified as competitive inhibitors. In 
contrast, NNRTIs inhibit reverse transcriptase by a completely different mechanism, 
which bind to a specific pocket binding site within the HIV-1 reverse transcriptase 
distinct from the catalytic site (Broder, 2010). The availability of these drugs has 
significantly contributed to refine drug combinations of HAART in terms of improved 
efficacy, safety and adheremce. As a result, HIV-1 infection has now become a chronic 
illness in patients as long as continued treatment access and long-term adherence is 
ensured.         
All adults with HIV infection should be offered antiretroviral therapy (ART) 
regardless of CD4 cell count, based on recent observational cohort data that all patients 
may benefit from ART and data from a randomized controlled trial showing that ART 
reduces the likelihood of HIV transmission while providing clinical benefit to treated 
individuals (Cohen et al., 2011b). Recommended initial regimens include 2 NRTIs 
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(tenofovir/emtricitabine or abacavir/lamivudine) plus a NNRTI (efavirenz), a ritonavir-
boosted PIs (atazanavir or darunavir), or an integrase strand transfer inhibitor (raltegravir) 
or rarely, an agent that blocks the CCR5 (Thompson et al., 2012). Suppression of plasma 
HIV-1 RNA to less than 50 copies/ml by 24 weeks should occur with effective therapy, 
regardless of prior treatment experience (Thompson et al., 2012).  
The introduction of HAART in clinics has dramatically decreased morbidities and 
mortalities of AIDS (Palella et al., 1998; Porter et al., 2003; Broder, 2010). However, the 
effective and safe use of HAART is compromised by the wide intra and interindividual 
variability observed both in responses to therapy and in the adverse effects of certain 
antiretroviral drugs. This variability can be attributed to factors that regulate the 
availability of drugs (pharmacokinetics), effects on the host (pharmacodynamics), and the 
activity of the virus itself (viral pharmacodynamics), including adherence, drug 
resistance, tolerability, co-morbidity and concomitant treatment (Michaud et al., 2012a). 
Adherence is a major predictor of the success of HAART, with higher adherence rates 
leading to a lower risk of viral rebound and resistance development (Maggiolo et al., 
2007). The complexity of the treatment regimen is an important barrier to good adherence 
and patients generally prefer the simplicity of once-daily regimen (Maggiolo, 2009). The 
effectiveness of therapy is also affected by potency of viral suppression and more 
importantly the viral sensitivity to a drug. HIV has very high genetic variability coupled 
with a high mutation rate, thereby enabling the virus to easily adapt. The consequences of 
drug resistance include treatment failure, the need to start more costly second-line 
treatment for patients, and the spread of resistant strains of HIV. Tolerability is another 
important factor that affects adherence. Different categories of anti-retroviral agents are 
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associated with different toxicity profiles. NRTIs are more often associated with lactic 
acidosis, hepatic steatosis and lipodystropy, while NNRTIs are more likely associated 
with rash, neuropsychiatric symptoms and hepatotoxicity. All PIs are associated with 
metabolic abnormalities, dyslipidemia, hyperglycemia, insulin resistance, and 
lipodystrophy (Thompson et al., 2012). Co-morbid conditions such as metabolic 
disorders (diabetes mellitus), malignancies and renal, hepatic or cardiac dysfunctions may 
also interfere with the drug metabolism and/or require treatments that may interact with 
antiretroviral drugs. As a consequence, management of HAART should take into account 
together with all the aforementioned factors.  
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Figure 1.1 HIV life cycle and antiretroviral drug targets. The virus first attaches to the 
cell membrane of the target cell by interacting with the receptors. Then the virus fuses 
with the target cell and viral DNA and proteins are injected into cell. The viral RNA is 
transcribed to DNA by reverse transcriptase. Efavirenz is an inhibitor targeting at this 
enzyme. Viral DNA is integrated into the DNA of host cell by integrase. The final step is 
maturation of virion, where the polyprotein is cut into proper size by protease. Targeting 
at these key steps, entry inhibitors, fusion inhibitors, co-receptor inhibitors, reverse 
transcriptase inhibitors, integrase inhibitors and protease inhibitors were developed.  
Efavirenz 
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(This figure was modified from HIV Replication Cycle, National Institue of Allergy and 
Infectious Diseases) 
2. Efavirenz-based anti-HIV regimen 
Efavirenz (Sustiva
®
) [(S)-6-chloro-4-(cyclopropylethynyl)-1, 4-dihydro-4-
(trifluoromethyl)-2H-3, 1-benzoxazin-2-one] is a NNRTI approved for the treatment of 
HIV-1 infection by FDA in 1998 (Maggiolo, 2009). Subsequent study established the role 
of efavirenz with 2 NRTIs in the management of HIV-1 infections (Staszewski et al., 
1999). The chemical structure of efavirenz is shown in Figure 1.2. Efavirenz is the most 
commonly prescribed NNRTI in treatment naïve patients, in combination with 2 NRTIs 
and is recommended regimen for initial therapy in the current US and UK guidelines of 
antiretroviral treatment for adult HIV infection (Gazzard et al., 2008; Thompson et al., 
2012). The efficacy of efavirenz has been established in numerous randomized clinical 
trials and observational studies in HAART-naïve patients, including those with advanced 
infection. Efavirenz-based regimen was superior to or as effective as unboosted PIs 
(Maggiolo et al., 2003; Squires et al., 2004; Yeni et al., 2006). The AIDS Clinical Trial 
Group (ACTG) performed a landmark comparison study of efavirenz versus ritonavir-
boosted lopinavir, where efavirenz showed greater virological efficacy than the boosted 
PI (Riddler et al., 2008). Efavirenz is also more effective as a third agent than the 
nucleoside analogue abacavir (Gulick et al., 2004).  
There are another four NNRTIs currently in the market, i.e. delavirdine, 
nevirapine, etravirine and rilpivirine. Nevirapine and efavirenz, both as first generation 
NNRTIs, are cornerstones of first line HAART. Delavirdine is less used due to common 
and serious adverse drug interactions. The first generation NNRTIs are characterized by a 
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lower genetic barrier to the development of drug resistance compared to second 
generation NNRTIs, i.e. rilpivirine and etravirine. Some, but not all, studies have 
suggested that efavirenz is more effective than nevirapine (Keiser et al., 2002; van Leth et 
al., 2004). Patients also tolerated efavirenz better than nevirapine, since nevirapine is 
associated with more adverse events than efavirenz. Rash is more common and usually 
more severe with nevirapine than with efavirenz (van Leth et al., 2004). Severe 
hepatotoxicity is also more common among the patients prescribed nevirapine 
(Sulkowski et al., 2002; van Leth et al., 2004). The clinical development of etravirine was 
conducted exclusively in treatment experienced patients. Therefore, extravirine is only 
recommended to be used as as sequential therapy in patients with NNRTI resistant HIV-
1. Rilpivirine was non-inferior to efavirenz, although rates of virologic failure were 
higher with rilpivirine, while rates of adverse events were higher with efavirenz (Cohen 
et al., 2011a; Molina et al., 2011). 
Efavirenz is generally well tolerated: rash and neuropsychiatric disturbances are 
the most notable adverse events. Neuropsychiatric disturbances (such as dizziness, 
insomnia, nightmares, lack of concentration and drowsiness) generally develop early in 
treatment among more than 50% of patients and they tend to resolve with continued 
administration, but they are persistent in about 5 ~ 9 % of patients [Product Information 
of Efavirenz (Sustiva), Bristol-Myers Squibb Company, June 2012]. However, severe 
events such as depression, psychosis, mania, and paranoid have also been reported in 
some patients. Efavirenz has less effect on plasma lipid profiles than some boosted PIs. 
Lipodystrophy can occur under treatment with efavirenz, but it may be reduced if the 
concurrent use of thymidine analogues is avoided. However, there is concern regarding 
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the use of efavirenz during the first trimester of pregnancy because of animal data and 
rare case reports in humans indicating a potential association with neural tube defects (De 
Santis et al., 2002; Saitoh et al., 2005). Thus efavirenz has been assigned to pregnancy 
category D by the FDA. Recently, efavirenz was co-formulated with tenofovir disoproxil 
fumarate and emtricitabine in one tablet marketed as Atripla 
TM
, providing the most 
convenient HAART regimen in one pill once a day. In light of these features, efavirenz-
based therapy remains the preferred intial therapy for treatment naïve HIV-1 patients 
(Thompson et al., 2012).  
Efavirenz exhibits narrow therapeutic range. The proposed therapeutic range of 
efavirenz is 1-4 mg/L. Clinical studies have suggested that patients with plasma 
concentrations below 1 mg/L are at increased risk for failure of antiretroviral therapy 
(Marzolini et al., 2001; Csajka et al., 2003), and those with concentrations higher than 4 
mg/L experience more frequent CNS side effects (Marzolini et al., 2001; Haas et al., 
2004; Rotger et al., 2005; Motsinger et al., 2006). Therefore, the goal of efavirenz-based 
therapy is to maintain maximum virally suppressive efavirenz concentrations that will 
prevent the emergence of resistance and avoid treatment failure, while also ensuring an 
adverse event profile. However, the achievement of this goal is made difficult by the 
large interindividual variability associated with efavirenz pharmacokinetics (Csajka et al., 
2003; Rotger et al., 2007). Wide interindividual variations in efavirenz pharmacokinetics 
may occur during absorption and distribution, but the most frequent and dramatic effects 
are due to changes in drug metabolism and excretion, which is probably driven by the 
genetic and nongenetic (e.g., drug interactions) factors. The current knowledge of the 
contribution of genetic polymorphisms in drug metabolizing enzymes and drug 
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transporters to wide variability in efavirenz pharmacokinetics is discussed in details in 
Chapter I-4.  
Besides the large interindividual variability in efavirenz pharmacokinetics, 
complex and unpredictable drug interactions compromise rational use of efavirenz-bsaed 
regimen. The likelihood of these pharmacokinetic drug interactions in HIV patients is 
particularly high, because efavirenz is always used in combination therapy, frequently in 
the presence of herbal and nutritional supplements or in concert with drugs directed at the 
treatment of opportunistic infections and other HIV-related disorders. Co-administered 
drugs could influence efavirenz disposition, while efavirenz is known to alter the 
pharmacokinetics of several drugs through not only induction but also inhibition of drug 
metabolizing enzymes and drug transporters (discussed in Chapter I-3). The drug 
interactions with efavirenz mediated by the inhibition/induction of the drug metabolizing 
enzymes involved in efavirenz metabolism are discussed in Chapter I-5. It is worthy to 
notice the bidirectional drug interaction phenomenon in efavirenz-based anti-HIV 
therapy. For example, voriconazole is used to treat the opportunistic fungal infections in 
HIV patients. At steady state, efavirenz substantially decreased voriconazole exposure, 
while voriconazole increased efavirenz exposure by about 40% (Liu et al., 2008). 
Therefore, with voriconazole, it is suggested to decrease efavirenz dose to 300 mg once 
daily and increase voriconazole maintenance dose to 400 mg every 12 hours [Product 
Information of Efavirenz (Sustiva), Bristol-Myers Squibb Company, June 2012].  
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3. Clinical pharmacology of efavirenz 0 
3.1 Efavirenz absorption 
Efavirenz is a crystalline lipophilic solid (log octanol water partition coefficient of 
4.6) with a molecular mass of 315.68 and an aqueous solubility of 9.0 μg/ml (Maurin et 
al., 2002). It is a class II drug (low solubility, high permeability) according to the 
biopharmaceutical classification system guidance by the FDA (Kasim et al., 2004). 
Highly permeable, poorly soluble drugs often demonstrate poor gastrointestinal (GI) 
absorption due to inadequate drug solubility in GI fluids. Furthermore, efavirenz has a 
considerably low intrinsic dissolution rate of 0.037 mg/cm
2
/min (Sathigari et al., 2009), 
which suggests dissolution rate-limited absorption problems for this drug. Peak efavirenz 
plasma concentrations of 1.6-9.1 µM were attained by 5 hours following single oral dose 
of 100 mg to 1600 mg administered to uninfected volunteers [Product Information of 
Efavirenz (Sustiva), Bristol-Myers Squibb Company, June 2012]. Dose-related increases 
in Cmax and AUC were seen for doses up to 1600 mg; the increases were less than 
proportional suggesting diminished absorption in higher doses. Since there is no 
intravenous formulation of efavirenz available, the bioavailability of efavirenz is not 
known. A one-month mass balance/excretion study using 400 mg efavirenz once daily 
with a 14C-labeled dose administered on Day 8 may provide some hints about the 
bioavailability. Approximately 14~ 34% of the radiolabel was recovered in the urine and 
16-61% was recovered in the feces. Nearly all of the urinary excretion of the radio-
labeled drug was in the form of metabolites. Efavirenz accounted for the majority of the 
total radioactivity measured in feces [Product Information of Efavirenz (Sustiva), Bristol-
Myers Squibb Company, June 2012]. However, it is unclear that the excretion of 
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efavirenz in feces is from biliary excretion after it was first absorbed or it was not 
absorbed from the GI tract in the first place. The food intake was associated with a mean 
increase of about 20% in efavirenz AUC and a mean increase of 50% in efavirenz Cmax, 
respectively (Lamorde et al., 2012). Therefore, it is recommended that efavirenz be taken 
on an empty stomach. 
3.2 Efavirenz distribution 
Efavirenz is highly bound (approximately 99.5-99.75%) to human plasma 
proteins, predominantly albumin and distributed well to sanctuary sites including 
cerebrospinal fluid and testicles, reaching therapeutic levels in just a few days after 
initiating treatment (Avery et al., 2013). In HIV-1 infected patients (n=9) who received 
efavirenz 200 to 600 mg once daily for at least one month, cerebrospinal fluid 
concentrations ranged from 0.26 to 1.19% (mean 0.69%) of the corresponding plasma 
concentration. This proportion is approximately 3-fold higher than the non-protein bound 
(free) fraction of efavirenz in plasma. Efavirenz has been reported to accumulate in cells, 
reaching intracellular concentrations well above its 90% inhibitory concentration 
(Almond et al., 2005). 
3.3 Efavirenz metabolism and excretion 
The scheme of human efavirenz metabolism pathways is depicted in Figure 1.2. 
Efavirenz is mainly cleared by oxidation via cytochrome P450s (CYPs) (Mutlib et al., 
1999). The metabolites identified in human plasma and urine (almost exclusively as 
glucuronide or sulfate conjugates) were 7- and 8-hydroxyefavirenz (primary metabolites) 
and 8, 14-dihydroxyefavirenz (secondary metabolite). Direct N-glucuronidation of 
efavirenz was also observed (Mutlib et al., 1999). Less than 1% of efavirenz is excreted 
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unchanged in the urine. The metabolites undergo further conjugation by UDP-
glucuronosyltransferase (UGT) (Mutlib et al., 1999). In vitro studies have shown that 8-
hydroxylation catalyzed predominantly by CYP2B6, with minor contributions from 
CYP1A2, CYP2A6 and CYP3A4/5, represents the main clearance pathway of efavirenz 
(Ward et al., 2003; Desta et al., 2007). Our laboratory provide direct evidence that 
CYP2A6 is the sole enzyme responsible for 7-hydroxylation that accounts for ~23% of 
total efavirenz metabolism in vitro (Ogburn et al., 2010). Recent clinical studies in HIV 
patients implicate that CYP2A6 may play a role in efavirenz 7-hydroxylation (Arab-
Alameddine et al., 2009; di Iulio et al., 2009; Kwara et al., 2009a; Kwara et al., 2009b). 
We also found that efavirenz is metabolized sequentially to novel dihydroxylated 
metabolite (s), via CYP2B6-mediated 7- and 8-hydroxyefavirenz hydroxylation as 
intermediary; and 8, 14-dihydroxyefavirenz is formed in vivo but not in vitro, suggesting 
novel metabolic reactions and challenging previous notion that it is formed through direct 
14-hydroxylation of 8-hydroxyefavirenz (Mutlib et al., 1999; Ward et al., 2003; Ogburn 
et al., 2010). UGT2B7-mediated N-glucuronidation represents an additional minor 
clearance route of efavirenz (Belanger et al., 2009). However, its contribution to overall 
efavirenz clearance appears to be minimal in vivo (Cho et al., 2011).  
The gender effect on the pharmacokinetics of efavirenz is controvercial. While no 
significant gender effect was observed in previous study (Csajka et al., 2003), some more 
recent studies suggest that females have higher efavirenz exposure compared to males 
(Burger et al., 2006; Floridia et al., 2008). The pharmacokinetics of efavirenz has not 
been studied in patients with renal insufficiency; however, less than 1% of efavirenz is 
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excreted unchanged in the urine, so the impact of renal impairment on efavirenz 
elimination should be minimal. 
 
Figure 1.2 Human metabolism of efavirenz. Efavirenz is predominantly metabolized to 
8-hydroxyefavirenz via CYP2B6 (Mutlib et al., 1999; Ward et al., 2003; Ogburn et al., 
2010), while CYP2A6-catalyzed 7-hydroxylation to 7-hydroxyefavirenz represents the 
alternative pathway (Ogburn et al., 2010). Once primary metabolites form, they will 
undergo further hydroxylation and conjugation. All these pharmacologically inactive 
metabolites or their conjugates are excreted in the urine. Besides the oxidation pathways, 
efavirenz can undergo direct conjugation by UGTs (Belanger et al., 2009), although the 
contribution of this route to the overall clearance remains to be marginal (Cho et al., 
2011). In sum, CYP2B6 is the main enzyme responsible for the major clearance pathway 
of efavirenz. 
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3.4 Efavirenz induction and inhibition on drug metabolizing enzymes and drug 
transporters 
Efavirenz has a terminal elimination half-life of 52-76 hours after a single dose 
and 40-55 hours after multiple doses, mainly due to its ability to induce CYP2B6 
expression and thus accelerate its own metabolism (auto-induction) (Zhu et al., 2009). 
Examples of auto-induction for other CYP2B6 substrates include the widely used 
anticonvulsant carbamazepine (Kudriakova et al., 1992), anticancer drug 
cyclophosphamide (Hassan et al., 1999) , anti-HIV agent nevirapine (Faucette et al., 
2007) and antimalarial artemisinin (Burk et al., 2005). Previous study demonstrates that 
human constitutive androstane receptor (hCAR), alone or in cross-talk to human 
pregnane X receptor (hPXR), mediates the auto-inductive effects of efavirenz, as well as 
its ability to alter the pharmacokinetics and efficacy of other drugs (Faucette et al., 2007). 
Efavirenz auto-induction has important clinical implications because enhanced drug 
metabolism results in lower drug exposure at the site of action and may lead to a 
suboptimal therapeutic response or the development of drug resistance (Ngaimisi et al., 
2011). The inductive effect of efavirenz on the metabolism of co-administered drugs has 
also been reported. Efavirenz has been associated with decreased exposure of methadone 
(Kharasch et al., 2012), statins (Gerber et al., 2005), omeprazole (Michaud et al., 2012b), 
voriconazole (Liu et al., 2008), proguanil (van Luin et al., 2010), etravirine (Boffito et al., 
2009), protease inhibitors (Staszewski et al., 1999), and bupropion (Robertson et al., 
2008), which can be primarily explained by its induction of CYP3A, CYP2B6 and 
CYP2C19 activities (Hariparsad et al., 2004; Faucette et al., 2007).  
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Induction of most drug metabolizing gene expression is predominantly regulated 
at the transcriptional level by PXR and CAR. Both PXR and CAR are orphan (or ‘X’) 
receptors, grouped into the nuclear receptor subfamily 1, group I (NR1I) play an 
important role in detecting xenobiotics and stimulating genes involved in drug 
disposition, including phase I and phase II enzymes such as CYPs, UGTs, 
sulfotransferases as well as drug transporters. PXR and CAR are predominately 
expressed in the liver, but also expressed in the intestine, lung and other tissues (Willson 
and Kliewer, 2002). Several studies demonstrate that CAR and PXR can mutually bind to 
and activate response elements in the promoter regions of several P450 genes, suggesting 
that cross-talk occurs between these receptors in the regulation of these genes (Xie et al., 
2000; Goodwin et al., 2001; Goodwin et al., 2002). The role of CAR as a xenobiotic 
sensor was first suggested by the work of Negishi and colleagues, who characterized the 
transcription factor that regulate the expression of CYP2B (Zelko and Negishi, 2000; 
Sueyoshi and Negishi, 2001). In primary hepatocytes and intact liver, hCAR is 
predominately localized in cytoplasm and translocates to the nucleus upon activation by 
either direct ligand binding or indirect mechanisms (Kawamoto et al., 1999). Most 
findings to date suggest that CAR binds to a phenobarbital-responsive enhancer module 
(PBREM) located approximately 2 kb upstream from the CYP2B gene transcriptional 
start site as a heterodimer with retinoid X receptor (RXR) (Honkakoski et al., 1998; 
Zelko and Negishi, 2000). CAR response elements have been mapped in a number of 
human genes, including CYP2B6, CYP3A4, members of the CYP2C family, UGT1A1 and 
ABCB1 (Swales and Negishi, 2004). Efavirenz induction of CYP2B6 is mediated 
preferentially through CAR and it induced nuclear translocation of CAR at levels 
 
 
18 
 
comparable with or greater than well known hCAR activators, phenobarbital and 
imidazole derivative 6-(4-chlorophenyl)imidazo[2,1-β][1,3]thiazole-5-carbaldehyde-O-
(3,4 dichlorobenzyl)oxime (CITCO), in cell-based reporter gene assay (Faucette et al., 
2007). CAR also binds to a xenobiotic-responsive enhancer module (XREM) in the distal 
region of the CYP2B6 promoter together with the PBREM mediates optimal drug-
induced expression of CYP2B6 (Wang et al., 2003).  
Like CAR, PXR regulates the expression of target genes by binding to xenobiotic 
response elements as a heterodiner with RXR (Kliewer et al., 1998). The target genes of 
PXR broadly overlap with those of CAR hPXR is capable of binding to the same 
response elements in the promoter regions of the CYP3A4 and CYP2B6 genes (Goodwin 
et al., 1999; Wang et al., 2003). 
Besides drug metabolizing enzymes, efavirenz also has been shown to induce the 
expressions of multiple drug transporters in Jurkat cells (Weiss et al., 2009). The results 
from a recent collaborative study from our laboratory also provide strong evidence that 
exposure to efavirenz significantly increases markers of hepatic drug metabolism and 
target gene expression in peripheral blood mononuclear cells (PBMCs) but not the CAR 
target genes in the intestine in vivo (Meyer zu Schwabedissen et al., 2012). However, 
these findings are in contrast to those recently reported by Burhenne et al., who found no 
significant induction of ABCB1 and ABCC2 expression in PBMCs after 14 days of 
efavirenz treatment (Burhenne et al., 2010).  
Although many drug-drug interactions associated with efavirenz can be explained 
by its induction potential, some of them may be attributed to direct enzymatic inhibition 
effect. In vitro evidence shows that efavirenz may directly inhibit the activities of certain 
 
 
19 
 
CYPs, including CYP2B6 (Hesse et al., 2001), CYP2C8 (Parikh et al., 2007), CYP2C9 
and CYP2C19 (von Moltke et al., 2001). Indeed, scattered clinical cases of adverse drug 
interactions, e.g., with CYP2C8 substrate amodiaquine (German et al., 2007; Soyinka et 
al., 2013), CYP2C9 substrates warfarin (Bonora et al., 2008) and phenytoin (Robertson et 
al., 2005) suggest that efavirenz may alter the pharmacokinetics of co-administered drugs 
through inhibition of CYPs. The clinical significance of efavirenz inhibition effect on 
drug transporters is unclear currently. Efavirenz is known to inhibit breast cancer 
resistant protein (BCRP) coded by ABCG2 gene in vitro (Weiss et al., 2007), but the 
chronic treatment with efavirenz induces the expression of ABCG2 in a leukemia cell line 
without modification in intracellular accumulation of the drug  (Weiss et al., 2009). The 
same founding was reported in rats (Peroni et al., 2011).  
4. Pharmacogenetics of efavirenz 
Emerging evidence suggest that the large interindividual variability in efavirenz 
exposure and clinical responses may be primarily attributed to the large variability in the 
expression and activity of the drug metabolizing enzymes and/or drug transporters 
involved in its disposition mainly due to genetic polymorphisms.  
4.1 CYP2B6  
As described above, CYP2B6 is the main enzyme responsible for catalyzing 
efavirenz 8-hydroxylation, the principal metabolic pathway of the drug. Studies have 
shown that there is a large interindividual variation in CYP2B6 protein expression (20- to 
280-fold) and activity (25- to 100-fold) among human livers, in part due to extensive 
genetic polymorphisms in the CYP2B6 gene and non-genetic factors, e.g., induction and 
inhibition drug interactions (Code et al., 1997; Stresser and Kupfer, 1999; Lang et al., 
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2001; Zanger et al., 2007). The CYP2B6 gene is highly polymorphic. To date, 37 alleles 
of CYP2B6 (*1A [wild type to *37) and multiple sub-alleles have been reported in the 
CYP2B6 upstream sequence, introns and 9 exons, which have extensive linkage 
disequilibrium causing complex haplotype structures 
(http://www.cypalleles.ki.se/cyp2b6.htm).  
The first systematic analysis of genetic polymorphisms in CYP2B6 gene identified 
nine SNPs of CYP2B6 gene in a Caucasian population, resulting in six different alleles 
designated as CYP2B6*2 (c.64C>T), CYP2B6*3 (c.777C>A), CYP2B6*4 (c.785A>G), 
CYP2B6*5 (c.1459C>T), CYP2B6*6 (c.516G>T and c.785A>G) and CYP2B6*7 
(c.516G>T, c.785A>G and c.1459C>T) (Lang et al., 2001). Some of these variants have 
been shown to change CYP2B6 hepatic expression and activity (Lang et al., 2001). 
Subsequent studies have confirmed that genetic polymorphisms in CYP2B6 gene are 
associated with enzyme expression and activity in vitro (Lamba et al., 2003; Hesse et al., 
2004; Lang et al., 2004; Desta et al., 2007), efavirenz exposure in HIV patients (Haas et 
al., 2004; Tsuchiya et al., 2004; Rotger et al., 2005; Wang et al., 2006; Rotger et al., 
2007; Arab-Alameddine et al., 2009; Holzinger et al., 2012) and CNS adverse effect 
(Haas et al., 2004). Most of these studies focused on the CYP2B6*6 allele, which is 
defined by two amino acid alterations, Q172H (516G>T) and K262R (785A>G). This 
variant occurs at high frequencies in all ethnic populations studied to date, ranging from 
about 15% in Asian, 25% in Caucasians, to almost 50% among black individuals (Zanger 
et al., 2007; Li et al., 2012) (Figure 1.3). The CYP2B6*6 allele is consistently associated 
with efavirenz clearance (Tsuchiya et al., 2004; Rotger et al., 2007), CNS side effects 
(Haas et al., 2004), hepatic toxicity (Yimer et al., 2011), treatment discontinuation (Wyen 
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et al., 2011), virological failure (Motsinger et al., 2006), and drug interactions (Ngaimisi 
et al., 2011). More CYP2B6 novel variants (e.g. *11, *15, *16, *18, *27 and *28) with 
diminished or loss of CYP2B6 functions have been reported recently via candidate gene 
approach (Wang et al., 2006; Rotger et al., 2007). A recent genome-wide association 
analyses replicates the association of 516G>T (*9) and 983T>C (*4) with efavirenz 
plasma concentrations and also identifies a new intron variant associated with efavirenz 
pharmacokinetics (Holzinger et al., 2012). The 983T>C SNP is found mainly in subjects 
of African descent, but rare in other ethnic groups. All these findings together 
demonstrate the significant contribution of the CYP2B6 genetic polymorphism to the 
variable pharmacokinetics and clinical responses of efavirenz and lay the foundation of 
CYP2B6 genotype-based efavirenz dose adjustment.   
The second most frequent candidate SNP 1459C>T  in allele *5, which has been 
previously linked to reduced expression in human liver microsomes (Lang et al., 2001), 
did not affect efavirenz kinetics (Rotger et al., 2007). This is in agreement with another 
report that could not find an effect of this allele on bupropion kinetics in health 
populations (Kirchheiner et al., 2003). The apparently unaffected in vivo activity of *5 
may indicate a compensation of reduced expression by enhanced metabolism through the 
variant enzyme (Zanger et al., 2007; Zhang et al., 2011b).  
The CYP2B6*4 allele occurs more frequently in Caucasian and Asian population  
(approximately 2-6%), whereas this allele appears to be virtually absent in African-
Americans and Africans (Zanger et al., 2007) (Figure 1.3). The observed trend for lower 
efavirenz AUC in *1/*4 heterozygotes compared to *1/*1 carriers (Rotger et al., 2007) is 
in agreement with increased specific activity of the recombinant K262R variant towards 
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efavirenz compared to the wild type protein (Ariyoshi et al., 2011). However, 
inconsistent effect of this allele was observed on bupropion kinetics between in vitro and 
in vivo. Higher bupropion clearance after single-dose administration is observed in the 
individuals with CYP2B6*4 allele (Kirchheiner et al., 2003), while lower catalytic 
efficiency of bupropion was characterized in the CYP2B6.4 (Zhang et al., 2011b). This 
inconsistence may be due to that the N-terminally truncated CYP2B6 protein was used in 
Zheng et al.’s study and its has been shown that the modified protein had significantly 
reduced Km for bupropion compared with that of human liver microsomes (Zanger et al., 
2007).  
The CYP2B6*9 allele (516G>T) occurs at very low frequency (below 1%) in most 
populations (Zanger et al., 2007). The substrate-dependent effect of this allele on enzyme 
function was noticed. While the expressed N-terminally modified enzyme displayed 
increased turnover of 7-ethoxycoumarin O-deethylase activity (Ariyoshi et al., 2001), the 
decreased catalytic efficiency of this mutant was observed in the metabolism of several 
other substrates (Watanabe et al., 2010).  
The CYP2B6*18 allele (983T>C) (Klein et al., 2005) and related CYP2B6*16 
allele (785A>G and 983T>C) (Wang et al., 2006) were not found in Caucasians, but were 
found in various African populations with frequencies of about 7% and in African-
Americans with frequencies of approximately 4% (Zanger et al., 2007). The SNP resulted 
in undetectable expression and activity in COS-1 cells (Klein et al., 2005) and COS-7 
cells (Watanabe et al., 2010), but a protein with reduced activity could be expressed in 
insect cells (Klein et al., 2005). The 983T>C polymorphism is reported to be significantly 
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associated with higher efavirenz plasma concentrations and toxicity (Rotger et al., 2007; 
Wyen et al., 2008; Ribaudo et al., 2010). 
The CYP2B6*2/*2 genotype is very rare but the association between this 
genotype and a case of efavirenz-induced neurological symptoms has been reported 
(Usami et al., 2007). Mean expression and activity levels in liver heterozygous 
CYP2B6*2 carriers were similar to wild type. In expressed enzymes, no significant 
difference in the expression and activity was observed for this variant protein either 
(Watanabe et al., 2010).  
The -82T>C promoter variant, characterizing the *22 allele, with frequency of 
about 3% in Caucasion (Zukunft et al., 2005; Rotger et al., 2007) and 7% in black 
population (Zukunft et al., 2005; Rotger et al., 2007). This genetic variant allele has 
previously been reported to be associated with enhanced transcription, and to result in 
increased expression/activity of the protein at baseline (Zukunft et al., 2005).It also 
appears to enhance induction of CYP2B6 by rifampin.But no significant difference in 
efavirenz plasma exposure was found in the CYP2B6*22 carrier in vivo, probably due to 
the small sample size (Rotger et al., 2007). 
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Figure 1.3 Frequency and structure of the most common CYP2B6 alleles (modified 
from Zanger, et al. 2007 and Li, et al. 2012). On the left, allele frequencies across four 
major ethnic groups are indicated as filled fractions of the respective circles (completely 
filled circle representing a frequency of 100%). On the right, corresponding amino acid 
variants are shown, which are above the exons represented by black rectangles. CA: 
White European or North American of Caucasian origin; AA: African-American; AF: 
African (Ghanaian and other West African, Tanzanian); AS: Asians (Chinese, Korean 
and Japanese).
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4.2 CYP2A6, CYP3A4/5, CYP1A2 and UGT2B7  
Most previous pharmacogenetic studies related to efavirenz pharmacokinetics 
focused on CYP2B6, which is the main catalyst of efavirenz metabolism and responsible 
for the major metabolic pathway (8-hydroxylation). However, not all the efavirenz 
pharmacokinetic variability can be explained by the CYP2B6 or 8-hydroxylation pathway 
alone. The identified CYP2B6 genetic polymorphisms can explain up to about 30% of the 
interindividual variability in efavirenz pharmacokinetics and a large inter-subject 
variability in efavirenz plasma concentrations remains after accounting for known 
CYP2B6 genetic variations (Rotger et al., 2007; Arab-Alameddine et al., 2009; Holzinger 
et al., 2012). This unexplained variability suggests the contribution of genetic 
polymorphisms in other genes involved in efavirenz metabolism, such as CYP2A6, 
CYP3A4/5, CYP1A2 and UGT2B7 (Ward et al., 2003; Ogburn et al., 2010). Indeed, the 
predictive value of patient genotype of efavirenz plasma concentrations can be enhanced 
by taking into account of the genetic status of CYP2A6*9B and/or *17 polymorphism 
(Kwara et al., 2009b). Also, Kwara et al. reported that UGT2B7 polymorphisms along 
with CYP2A6 genetic variations demonstrate independent effects on efavirenz disposition 
after accounting for the CYPB6 genetic polymorphisms (Kwara et al., 2009a). The effect 
of CYP2A6 and CYP3A4 genetic polymorphisms on efavirenz metabolism, especially in 
CYP2B6 slow metabolizers, also has been replicated by other studies (Arab-Alameddine 
et al., 2009; di Iulio et al., 2009). However, other investigators were unable to replicate 
the role of polymorphisms in these candidate genes in efavirenz clearance (Cabrera et al., 
2009; Elens et al., 2010; Maimbo et al., 2012) or their effects are small that genotype-
phenotype associations are susceptible for confounding factors, particularly in HIV 
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patients taking multiple drugs. As described above, in a recent GWAS study, only 
variants in the CYP2B6 locus predicted efavirenz concentrations (Holzinger et al., 2012). 
Other variants in other genes did not reach a statistically significant level.  
4.3 Drug transporters 
Drug transporters fall into two groups: the ABC superfamily of transporters 
(ATP-binding cassette proteins) and the SLC superfamily of transporters (solute carrier 
proteins). These pumps located in the intestinal epithelium actively remove drugs in the 
basolateral-apical direction, against a concentration gradient. The influence of genetic 
variations of ABCB1 gene on efavirenz pharmacokinetics and pharmacodynamics is not 
clearly defined since contradictory results were reported. Most of the studies focused on 
the most common SNP, i.e. 3435C>T. Clinical studies showed that 3435C>T 
polymorphism in ABCB1 gene may predict plasma concentrations (Fellay et al., 2002; 
Mukonzo et al., 2009), responses (Haas et al., 2005; Elens et al., 2010) and toxicities 
(Yimer et al., 2011) in HIV patients. However, conflicting results also exist (Nasi et al., 
2003; Haas et al., 2004; Tsuchiya et al., 2004). Recently, a new variant allele in ABCB1 
gene (c.4036A>G) was identified as a major predictor of efavirenz pharmacokinetics in 
healthy subjects (Mukonzo et al., 2009), which indicates that further investigation of the 
influence of ABCB1 polymorphism on efavirenz pharmacokinetics may be warranted. A 
recent study showed that efavirenz is a substrate of BCRP (Peroni et al., 2011), but no 
effect of genetic variants of BCRP on efavirenz pharmacokinetics was identified in HIV 
patients (Sanchez et al., 2011). Instead, a SNP of ABCC4 (1497C>T) encoding multidrug 
resistance protein 4 (MRP4) was identified as a major factor influencing efavirenz oral 
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clearance, suggesting the potential importance of MRP4 in the distribution of efavirenz 
(Sanchez et al., 2011). 
4.4 Nuclear receptors 
Efavirenz is known to induce its own metabolism and the metabolism of other co-
administered drugs through activation of CAR and/or PXR. At least CYP3A4 
(Hariparsad et al., 2004), CYP2B6 (Faucette et al., 2007), CYP2C19 (Liu et al., 2008; 
Michaud et al., 2012b) and multiple drug transporters (Weiss et al., 2009) can be induced 
by efavirenz. Most of the pharmacogenetic studies so far have been focused on genetic 
variations in oxidation/conjugation drug metabolizing enzymes and drug transporters, but 
genetic variations in nuclear receptor can also contribute to the observed variability in the 
expression of genes involved in drug disposition and drug interactions, particularly for 
efavirenz which is known for its induction potential (Zhu et al., 2009). It has been shown 
that hPXR (Lamba et al., 2010) and hCAR (Ikeda et al., 2005) variants affect the 
transactivation of CYP3A4 and thus contribute to the high variability of inducibility. A 
recent study also has shown that the genetic polymorphism in CAR contributes to early 
treatment discontinuation for efavirenz-based regimens (Wyen et al., 2011), which 
indicates that genetic polymorphisms of nuclear receptors may play an important role in 
the large interindividual variability of efavirenz pharmacokinetics and clinical response. 
In a recent study, CAR variants have been shown to alter efavirenz exposure, but the 
effect seems modest (Cortes et al., 2013).   
5. Human CYP2B6  
The CYP gene superfamily currently consists of 57 functional genes and 58 
pseudogenes (Nelson et al., 2004). The members of families CYP1, CYP2, and CYP3 are 
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localized in the endoplasmic reticulum of both liver and extrahepatic tissues, where they 
catalyze a variety of biotransformations of numerous endogenous and exogenous 
substrates, including many drugs currently in use. The family member CYP2B6 was first 
described in 1989 (Yamano et al., 1989) as the human ortholog to the phenobarbital-
inducible CYP2B genes in rodents. Located on the long arm of chromosome 19, CYP2B6 
is mapped with closely related pseudogene CYP2B7 and several other members of the 
CYP2 gene family (Yamano et al., 1989). The CYP2B6 gene is composed of 9 exons, 
coding for a protein of 48 KDa with 491 amino acids (Yamano et al., 1989). Like most 
other CYP isoforms, CYP2B6 is primarily expressed in the liver and involved in the 
metabolism of ingested drugs, but has also been detected in several extrahepatic tissues 
including brain, kidney, intestine, endometrium, bronchoalveolar macrophages, 
peripheral blood lymphocytes and skin (Gervot et al., 1999; Janmohamed et al., 2001; 
Ding and Kaminsky, 2003). Initially underestimated, recent studies using more sensitive 
and specific immunochemical detection methods demonstrate that the average expression 
of CYP2B6 ranges from 2% to 10% of the total hepatic CYP content (Code et al., 1997; 
Ekins et al., 1998; Stresser and Kupfer, 1999; Hesse et al., 2000).  
5.1 CYP2B6 substrates 
The number of drugs recognized as CYP2B6 substrates has been constantly 
increasing, and several clinically important drugs are now known to be metabolized by 
this enzyme. These include the anticancer prodrug cyclophosphamide (Chang et al., 
1993; Roy et al., 1999); the ansthetics ketamine (Yanagihara et al., 2001; Desta et al., 
2012) and propofol (Court et al., 2001); the antidepressant bupropion (Faucette et al., 
2000; Hesse et al., 2000); the antimalarial drug artemisinin (Svensson and Ashton, 1999); 
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and anti-HIV drugs efavirenz (Ward et al., 2003) and nevirapine (Erickson et al., 1999); 
synthetic opioids methadone (Kharasch et al., 2004) and meperidine (Ramirez et al., 
2004). Other substrates are listed in the following reviews (Wang and Tompkins, 2008; 
Mo et al., 2009). 
Until recently, progress on the clinical relevance of CYP2B6 was hampered by 
the lack of selective and safe in vivo probes of its activity. Bupropion is generally 
accepted as the traditional CYP2B6 probe. However, the contribution of CYP2B6-
mediated pathway to the overall clearance is small and non-CYP2B6 mediated 
metabolism contributes significantly to the overall clearance of this drug (Turpeinen et 
al., 2005; Loboz et al., 2006). The metabolism of bupropion by CYP2B6 has also been 
shown to be stereoselective. Bupropion is used clinically as a racemic mixture of R- and 
S-enantiomers and CYP2B6 selectively catalyzes the hydroxylation of (S)-bupropion 
over that of (R)-bupropion. Given the documented limitations of bupropion as an in vivo 
probe for CYP2B6 activity, the stereo-specific catalysis allowed researchers to identify 
the (S, S)-hydroxybupropion metabolite as a more specific in vivo probe (Kharasch et al., 
2008). The stereo-selective behavior of CYP2B6 suggests that other chiral substrates of 
CYP2B6 catalysis could exhibit similar stereo-specific outcomes. Besides bupropion, 
efavirenz is the other sensitive in vivo CYP2B6 substrate recommended by the FDA 
(Guidance for Industry, Drug Interaction Studies- Study Design, Data Analysis, 
Implications for Dosing and Labeling Recommendations, February, 2012). Efavirenz is 
not only an in vitro and in vivo activity probe, but may also serve as a prototype model 
drug for evaluating the clinical relevance of CYP2B6 genetic polymorphisms, because of 
the association between the CYP2B6 genetic polymorphisms and efavirenz 
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pharmacokinetics and pharmacodynamics (Haas et al., 2004; Tsuchiya et al., 2004; 
Rotger et al., 2007).    
In addition to drugs, CYP2B6 is able to both detoxify and bioactivate a number of 
procarcinogens and environmental agents including pesticides and herbicides (Mo et al., 
2009). CYP2B6 also catalyzes the metabolism of several endogenous compounds 
(Rendic, 2002). These include arachidonic acid, lauric acid, 17ß-estradiol, estrone, and 
testosterone. The role of CYP2B6 in the metabolism of these endogenous compounds is 
minor compared to other CYPs such as CYP3A members play a more important role in 
the oxidative metabolism of these substances.  
5.2 CYP2B6 inhibitors and inducers 
In addition to genetic polymorphisms, drug-drug interactions mediated by 
inhibition and induction of CYP2B6 are also major factors that may contribute to the 
large inter-individual variability in efavirenz pharmacokinetics. [2-phenyl-2-(1-
piperidinyl) propane (PPP) (Chun et al., 2000), cytostatic triethylenethiophosphoramide 
(thioTEPA) (Rae et al., 2002; Richter et al., 2005), antiplatelet agents clopidogrel 
(Richter et al., 2004), ticlopidine (Richter et al., 2004; Walsky et al., 2006) and prasugrel 
(Nishiya et al., 2009) have been shown to inhibit CYP2B6 activity. All of them are 
mechanism-based inhibitors of CYP2B6, while ThioTEPA is not only a mechanism-
based inhibitor but also a non-competitive inhibitor of CYP2B6 (Rae et al., 2002). Under 
a reversible inhibition experimental protocol, clopidogrel seems to possess adequate 
selectivity for CYP2B6 (Walsky and Obach, 2007). Our recent study showed that 
ticlopidine seems to possess greater inhibition potency of CYP2B6 than ThioTEPA and 
less inhibits CYP2A6-mediated 7-hydroxylation of efavirenz (Ogburn et al., 2010), but it 
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potently inhibits CYP2C19 activity (Walsky and Obach, 2007). Besides CYP2B6, 
thioTEPA also inhibits CYP3A and CYP2A6 (Walsky and Obach, 2007; Ogburn et al., 
2010). Under an irreversible inactivation condition, PPP, clopidogrel and ticlopidine 
displayed significant selectivity, while thioTEPA demonstrated a minimal selectivity for 
CYP2B6. PPP served as a selective probe for CYP2B6 inhibition, but restricted its use to 
in vitro studies only, as PPP is not approved for human administration. The next selective 
inhibitors, clopidogrel and ticlopidine, already approved as clinical agents, could be used 
in clinical studies under circumstances that promote selectivity (Walsky and Obach, 
2007). To date, all the in vivo CYP2B6 inhibitors (clopidogrel, ticlopidine and prasugrel) 
are classified as weak inhibitors, since less than 2-fold increase in AUC was observed 
(Guidance for Industry, Drug Interaction Studies- Study Design, Data Analysis, 
Implications for Dosing and Labeling Recommendations, February, 2012). Recently, our 
laboratory showed that voriconazole is a highly potent competitive inhibitor of CYP2B6 
in vitro (Jeong et al., 2009). The investigation of its inhibition potency of CYP2B6 
activity in humans is ongoing in our laboratory.  
A number of drugs have been shown to induce CYP2B6 in vitro and in vivo. The 
mechanism of CYP2B6 induction has been discussed in 3.4 of this chapter. The most 
prototypical CYP2B6 inducer is phenobarbital (Mo et al., 2009). Other known CYP2B6 
inducers include cyclophosphamide (Gervot et al., 1999), rifampicin (Goodwin et al., 
2001), phenytoin (Wang et al., 2004), artemisinin (Burk et al., 2005), carbamazepine 
(Oscarson et al., 2006), nevirapine (Faucette et al., 2007), ritonavir and efavirenz 
(Faucette et al., 2004). 
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6. The CYP2B6*6 allele 
As described above, the CYP2B6*6 allele is the most frequent allele across 
different ethnic populations among all the CYP2B6 variant alleles identified so far 
(Zanger et al., 2007; Li et al., 2012). It is established that this allele is associated with 
increased risk for higher efavirenz exposure (Haas et al., 2004; Tsuchiya et al., 2004), 
CNS side effects (Haas et al., 2004), hepatic toxicity (Yimer et al., 2011), treatment 
discontinuation (Wyen et al., 2011) and virological failure (Motsinger et al., 2006). 
Recently, it also has been shown that this allele plays a significant role in determining the 
extent of CYP2B6 induction (Ngaimisi et al., 2011). 
Consistent to the association with the reduced efavirenz metabolism in vivo, the 
CYP2B6*6 allele also markedly reduces efavirenz metabolism in expressed CYP2B6 
(Ariyoshi et al., 2011; Zhang et al., 2011b) and human liver micrsomes (HLMs) (Desta et 
al., 2007). In HLMs, the CYP2B6*6 allele is associated with reduced  CYP2B6 protein 
expression (Xie et al., 2003; Hesse et al., 2004; Desta et al., 2007), probably due to the 
aberrant splicing of pre-mRNA of CYP2B6 (Lamba et al., 2003; Hofmann et al., 2008). 
However, mounting evidence indicate that reduced protein expression alone may not 
explain the functional consequences of this allele. For substrates that include 
cyclophosphamide, this allele is associated with enhanced metabolism despite reduced 
protein expression (Xie et al., 2003), which appears due to substantially lower Km in the 
variant versus wild type protein (Ariyoshi et al., 2011). Other in vitro studies, mostly in 
expression systems, have also reported that the CYP2B6*6 allele or the amino acids 
harbored in it influence catalytic properties, although the extent and direction of effect 
appears to depend on the substrate and the enzyme sources used (Ariyoshi et al., 2001; 
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Jinno et al., 2003; Bumpus and Hollenberg, 2008; Watanabe et al., 2010; Zhang et al., 
2011b). Therefore, in addition to reduced protein expression, altered enzyme function by 
the CYP2B6*6 allele may contribute to altered substrate metabolism. 
Previous studies show that the two amino acid mutations at residues of 172 and 
262 harbored by the CYP2B6*6 allele are not within the active site of the enzyme 
depicted in Figure 1.4 (Gay et al., 2010; Shah et al., 2011). Therefore, it is very likely that 
they are involved in the ligand binding and substrate catalysis indirectly. Indeed, a recent 
publication characterizing the crystal structure of CYP2B6 genetic variant (Y226H, 
K262R) indicates that the side chain of residue 172 may interact with the residues at 
active site and thus could affect the orientation of active site residues on the I-helix and 
substrate binding affinity (Gay et al., 2010; Shah et al., 2011). It is noteworthy that the 
other mutated amino acid carried by CYP2B6*6 allele, K262R, is located at the G/H loop 
and is part of a small hydrogen-bonding network (Gay et al., 2010). The concerted 
movement of the G and H helices, which could be affected by this hydrogen-bonding 
network, may influence the orientation of active site residues on the G helix (Gay et al., 
2010). In addition, part region of G helix forms substrate recognition sequence and 
substrate egress channels, which may both affect substrate specificity (Cojocaru et al., 
2007). Indeed, substrate-dependent effects of the CYP2B6*6 allele on pharmacokinetics 
have been observed in vivo. In vivo, the CYP2B6*6/*6 genotype is associated with 3-fold 
increase in efavirenz exposure compared with CYP2B6*1/*1 genotype (Rotger et al., 
2007), but its effect on plasma exposure of bupropion or 4-hydroxybupropion was 
marginal (Kirchheiner et al., 2003) and its effect on exposure of cyclophosphamide was 
opposite (Nakajima et al., 2007). K262R may also involve in the interaction between the 
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enzyme and its redox partner, CYP reductase (Bumpus and Hollenberg, 2008; Gay et al., 
2010). The oxidation reaction catalyzed by CYPs requires transferring of two electrons 
from NADPH. The first electron is generally thought to be transferred by CYP reductase, 
while the second can be transferred by either CYP reductase or cytochrome b5. That 
altered electron transfer from CYP reductase to CYP2B6 variant proteins may influence 
substrate metabolism was suggested by a recent study (Zhang et al., 2011b). It is, 
therefore, reasonable to suggest that amino acid changes by the CYP2B6*6 allele may 
influence the interaction between the CYPs and electron transfer proteins and thus alter 
the catalysis of substrates in cytochrome b5- and substrate-dependent manner. 
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Figure 1.4 Ribbon diagram showing the location of amino acid residues with known 
mutations (yellow sticks) in CYP2B6. The heme is shown as red sticks; 4-CPI, cyan 
sticks. The majority of the known 2B6 coding sequence variants contain substitutions that 
occur relatively far away from the active site, and none of them actually lies within the 
active site, and none of them actually lies within the active site The two amino acid 
residues harbored by the variant protein coded by the CYP2B6*6 allele are highlighted in 
red circles. (This figure is modified from Gay et al., 2010). 
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7. Hypothesis and specific aims: 
Efavirenz, a potent non-nucleoside reverse transcriptase inhibitor (NNRTI), 
remains a preferred component of highly active antiretroviral therapy (HAART) for 
treatment naïve patients despite an emergence of second generation of NNRTIs and new 
classes of antiretroviral agents. However, the optimal and safe use of efavirenz is 
impaired by its large interindividual variability in pharmacokinetics, and by the 
unpredictable drug interactions associated with it. Thus, better understanding of 
mechanisms controlling systemic exposure of efavirenz and its interactions with other 
medications used in HIV/AIDS therapy is critical to avoid adverse reactions and 
optimizing beneficial effects. 
Efavirenz is primarily metabolized by cytochrome P450 (CYP) 2B6 and to some 
extent CYP2A6 and UDP-glucuronosyl transferase (UGT) 2B7. In vitro and population 
pharmacokinetic studies in HIV patients have shown that CYP2B6 genetic 
polymorphisms, particularly the CYP2B6*6 allele, which is the most frequent variant 
across different populations, significantly alters efavirenz plasma concentrations and/or 
adverse effects. However, the mechanism of reduced efavirenz metabolism by the 
CYP2B6*6 allele is not fully understood and whether this variant exhibits differential 
susceptibility to metabolic inhibition is also unknown. In addition, some in vitro and in 
vivo evidences also indicate that the functional consequences of the CYP2B6*6 allele 
appear to be substrate- and cytochrome (Cyt) b5-dependent.  
In addition, efavirenz alters the pharmacokinetics of many drugs co-administered 
with it and are often associated with reduced efficacy or increased toxicity of the affected 
drugs. It has been well documented that some of the drug interactions are mediated 
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through efavirenz induction activity of certain drug metabolizing enzymes and 
transporters via the constitutive androstane receptor (CAR) and pregnane X receptor 
(PXR). However, not all pharmacokinetic drug interactions involving efavirenz can be 
explained by its known inductive effect. Scatter clinical cases of adverse drug 
interactions were reported, suggesting that efavirenz may also directly inhibit the 
activities of certain CYPs. The in vitro studies describing inhibition of CYPs by efavirenz 
provide only qualitative information, without generating in vitro inhibition parameters 
that will allow quantitative prediction of in vivo condition and without taking the 
contribution of time-dependent inactivation into account. 
The main objectives of this proposal are: 1) to identify mechanisms that 
contribute to the reduced efavirenz metabolism by the CYP2B6*6 allele, and 2) to 
determine mechanisms by which efavirenz alters the pharmacokinetics of co-
administered drugs. This work explores the hypothesis that the CYP2B6*6 allele reduces 
efavirenz metabolism by altering catalytic properties of CYP2B6 and efavirenz alters the 
pharmacokinetics of co-administered drugs by inhibiting drug metabolizing enzymes. To 
test this hypothesis, we will pursue the following specific aims: 
1. Determine whether the CYP2B6*6 allele alters catalytic properties and susceptibility to 
metabolic inhibition of CYP2B6. 
2. Determine whether the functional consequences of the CYP2B6*6 allele are substrate- 
and Cyt b5-dependent.  
3. Explore whether the incorporation of in vitro mechanism of reduced efavirenz 
metabolism by the CYP2B6*6 allele can predict genetic effect on efavirenz 
pharmacokinetics after a single dose by modeling approach. 
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4. Determine whether efavirenz inhibits the activities of eight major human CYP 
isoforms in vitro and determine the mechanisms involved. For those isoforms that are 
inhibited in pilot experiments, inhibition constants (Ki values) will be estimated with 
which the extent of in vivo drug interactions is quantitatively predicted.  
Together, this proposal will improve the safe and effective use of HIV 
medications through better understanding of genetic and non-genetic determinants of 
efavirenz disposition and the drug interactions associated with it. The accomplishment of 
this proposal will also allow the prevention of deleterious drug interactions that currently 
appear idiosyncratic and the optimization of dosing for a growing number of important 
HIV medications. 
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Chapter II: Materials and methods 
This section describes common methods and specific materials utilized in experimental 
research sections that follow.  
1. Chemicals  
Efavirenz, 7, 8-hydroxyefavirenz, bupropion, 4-hydroxybupropion, nevirapine, 
ritonavir, voriconazole, clopidogrel, 7-hydroxycoumarin, desethylamodiaquine, S-
mephenytoin, 4-hydroxy-S-mephenytoin, R-omeprazole, R-hydroxyomeprazole, R-
lansoprazole and ritonavir were obtained from Toronto Research Chemicals Inc. 
(Ontario, Canada). Acetaminophen, chloroquine, coumarin, dextromethorphan, 
dextrorphan, desmethyldiazepam, 8-methoxypsolaren, phenacetin, tolbutamide, 4-
hydroxytolbutamide, chlorpropamide, testosterone, 6β-hydroxytestosterone, glucose-6-
phosphate, nicotinamide adenine dinucleotide phosphate (NADP), glucose-6-phosphate 
dehydrogenase and glycine were purchased from Sigma-Aldrich (St. Louis, MO). 
Amodiaquine and levallorphan were purchased from the United States Pharmacopeia 
(Rockville, MD). Monobasic and dibasic sodium phosphate, monobasic potassium 
phosphate, magnesium chloride, acetonitrile and methanol were purchased from Fisher 
Scientific (Pittsburgh, PA). All drug solutions were prepared by dissolving each 
compound in methanol or acetonitrile, and were stored at -20°C. All the other chemicals 
were of high performance liquid chromatography (HPLC) grade.  
2. Microsomal preparations 
2.1 Expressed CYP2B6.1 and CYP2B6.6 proteins  
CYP2B6.1 and CYP2B6.6 proteins without and with co-expression of 
cytochrome b5 (Cyt b5) and plasmid-transfected negative controls were produced by BD 
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Biosciences (Woburn, MA) and kindly provided by Dr. Guo (Eli Lilly and Company, 
Indianapolis, IN). Briefly, CYP2B6 is expressed from human CYP2B6 cDNA using a 
baculovirus expression system. Baculovirus infected insect cells were used to prepare 
these microsomes. These microsomes also contain cDNA-expressed human P450 
oxidoreductase (POR). In those proteins expressed without Cyt b5, the protein content, 
CYP 450 content using spectral assay and Cyt c reductase activity were 26.6 mg/ml, 1451 
pmol/ml and 1739 nmol/(min*mg protein) for CYP2B6.1, and 33.5 mg/ml, 1582 pmol/ml 
and 1489 nmol/(min*mg protein) for CYP2B6.6. Assuming that a specific activity of 3.0 
micromoles of Cyt c reduced per minute per nanomole of reductase (Parikh et al., 1997), 
the molar ratios of CYP 450 : reductase for CYP2B6.1 and CYP2B6.6 were 1 : 10.6 and 
1:10.5, respectively. In those proteins co-expressed with Cyt b5, the protein content, CYP 
450 content, Cyt c reductase activity and Cyt b5 content were 9.0 mg/ml, 1000 pmol/ml, 
1900 nmol/(min*mg protein) and 220 pmol/mg protein for CYP2B6.1, while they were 
2.7 mg/ml, 1000 pmol/ml and 851 nmol/(min*mg protein) and 370 pmol/mg protein for 
CYP2B6.6. The molar ratio of CYP 450 : reductase : Cyt b5 of CYP2B6.1 was 1 : 5.4 : 2 
and that of CYP2B6.6 was 1: 0.73 : 1. All microsomal preparations were stored at -80°C 
until analysis. 
2.2  Human liver microsomes (HLMs) genotyped for the CYP2B6*6 allele  
HLMs obtained from liver tissues with CYP2B6*1/*1, *1/*6 and *6/*6 genotypes 
were used for the metabolism and inhibition studies. Two HLMs sources were used. 
HLMs that were obtained from Medical College of Wisconsin (Milwaukee, WI), Medical 
College of Virginia (Richmond, VA), Indiana University School of Medicine 
(Indianapolis, IN) and University of Pittsburgh (Pittsburgh, PA) under protocols 
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approved by the appropriate committees for the conduct of human research were prepared 
by Eli Lilly and Company (Indianapolis, IN) and kindly provided by Dr. Guo. Liver 
microsomes were prepared by differential centrifugation (van der Hoeven and Coon, 
1974). Additional HLMs for inhibition study to evaluate the effect of the CYP2B6*6 
allele on the inhibition susceptibility of CYP2B6 were obtained from in-house human 
liver tissues, which were medically unsuitable for transplantation and were prospectively 
collected in the Division of Clinical Pharmacology by Dr. Hall through the liver 
transplantation units of Indiana University hospitals. HLMs were prepared from these 
liver tissues by ultracentrifugation and protein concentrations were determined using 
standard protocols (Desta et al., 1998). Genotyping for the CYP2B6*6 allele was 
performed in those human liver tissues from which HLMs were prepared. Liver samples 
were homogenized and genomic DNA was isolated using a QIAamp DNA Mini Kit 
(QIAGEN, Valencia, CA) according to the manufacturer’s protocol. The concentration of 
DNA was determined using the PicoGreen assay and the quality of DNA was checked by 
Agarose gel and PCR. The DNA samples were stored at -80˚C until analysis. The two 
SNPs tagging CYP2B6*6 allele, 516G>T and 785A>G, were genotyped using either the 
Affymetrix DMET Premier Pack (Santa Clara, CA) or TaqMan
®
 SNP genotyping assays 
(Foster City, CA) according to the respective manufacturer’s protocols. CYP2B6*1 was 
designated as the allele without these two tagging SNPs. All microsomal preparations 
were stored at -80°C until analysis. 
2.3  HLMs for efavirenz inhibition study 
Pooled HLMs from 24 individual donors, HLMs with CYP2C8*3/*3 genotype, 
and other HLMs were obtained from BD Biosciences (Woburn, MA). Human CYP2B6 
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and CYP2C8 expressed in baculovirus infected insect cells with oxidoreductase and 
without co-expression of Cyt b5 were obtained from BD Biosciences. All microsomal 
preparations were stored at -80°C until analysis. 
3. General incubation conditions 
3.1 General incubation conditions of efavirenz and bupropion kinetics study 
Efavirenz 8-hydroxylation and bupropion 4-hydroxylation (Figure 2.1) have been 
shown to be mainly catalyzed by CYP2B6 (Faucette et al., 2000; Ward et al., 2003). 
Therefore, we used these two probe reactions to determine CYP2B6 activity in expressed 
CYP2B6 proteins (CYP2B6.1 and CYP2B6.6) and HLMs obtained from human liver 
tissues genotyped for the CYP2B6*6 allele. Efavirenz 7-hydroxylation is a minor 
pathway of its metabolism and solely catalyzed by CYP2A6 (Ogburn et al., 2010). 
Therefore, the formation of 7- and 8-hydroxyefavirenz from efavirenz incubations in 
HLMs obtained from liver tissues genotyped for the CYP2B6*6 allele were 
simultaneously quantified by LC/MS/MS. All incubations were carried out using 
incubation times and protein concentrations that were within the linear range for reaction 
velocity. The key steps of the enzyme incubation are depicted in the Figure 2.2. Efavirenz 
and bupropion were dissolved and diluted in methanol to the required concentrations (1 
to 200 μM efavirenz and 10 to 1000 µM bupropion), and methanol was removed by 
drying in speed vacuum before the addition of the incubation components. The reaction 
components contain 200 mM sodium phosphate buffer (pH 7.4), expressed CYP2B6 (10 
to 15 pmol) or 25µl of HLMs (2.5 mg/ml) and a substrate (efavirenz or bupropion) (total 
incubation volume of 250 µl). The incubation mixture was pre-warmed for 5 min at 
37°C. The reaction was initiated by adding a NADPH-regenerating system (1.3 mM 
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NADP, 3.3 mM glucose-6-phosphate, 3.3 mM MgCl2, and 1 µl/ml glucose-6-phosphate 
dehydrogenase). Reaction was allowed to proceed for 15 min and then was terminated by 
placing tubes on ice and immediate addition of 500 µl acetonitrile. After an internal 
standard was added, the sample was vortex mixed and centrifuged at 14,000 rpm for 5 
min. Ritonavir (50 µl of 0.01 mg/ml) and nevirapine (50 µl of 500 ng/ml) were used as an 
internal standard for 7, 8-hydroxyefavirenz assay by HPLC/UV and LC/MS/MS methods, 
respectively. For 4-hydroxybupropion assay, nevirapine (25 µl of 50 µM) was used as an 
internal standard for the HPLC/UV assay and 25 µl of 5 µM of nevirapine for the 
LC/MS/MS assay. The supernatant layer was moved to a clean tube and was extracted 
with 500 µl of 0.5 ml glycine/ NaOH buffer (pH 11.3) and 6 ml of ethyl acetate and then 
centrifuged at 36,000 rpm for 15 min. The organic layer was removed and evaporated to 
dryness. The residue was reconstituted with 100 µl of mobile phase, and an aliquot was 
injected into an HPLC or LC/MS/MS. The stock solutions of 7, 8-hydroxyefavirenz and 
4-hydroxybupropion were prepared at a concentration of 1mg/ml in methanol. For HPLC 
assays, dilutions prepared in methanol at concentrations of 0.1 to 5 µM were used to 
prepare standard curves of 7, 8-hydroxyefavirenz, while concentrations of 0.5 to 20 µM 
were used for 4-hydroxybupropion. For LC/MS/MS assays, dilutions prepared in 
methanol at concentrations of 0.01 to 2.5 µM were used to prepare standard curves of 7, 
8-hydroxyefavirenz, while concentrations of 0.1 to 10 µM were used for 4-
hydroxybupropion. Efavirenz and bupropion metabolites were quantified by using the 
ratio of peak area of the metabolite to peak area of internal standard and standard curves 
that were constructed using known metabolite concentrations. Negative control 
incubations were run in parallel that included exclusion of efavirenz and bupropion, a 
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NADPH-generating system, or microsomes (bovine serum albumin was used instead) 
from the incubation mixture. 
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Figure 2.1 Structure of probe substrate reactions: CYP2B6-mediated 8-
hydroxylation of efavirenz and CYP2B6-mediated 4-hydroxylation of bupropion. 
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Figure 2.2 Key steps of enzyme incubation method. Substrates were dissolved and 
diluted in methanol to the required concentrations, and methanol was removed by drying 
in speed vacuum before the addition of the incubation components. The reaction 
components contain 200 mM sodium phosphate buffer (pH 7.4), microsomal enzymes 
and a substrate (total incubation volume of 250 µl). The incubation mixture was pre-
warmed for 5 min at 37°C. The reaction was initiated by adding a NADPH-regenerating 
system (1.3 mM NADP, 3.3 mM glucose-6-phosphate, 3.3 mM MgCl2, and 1 µl/ml 
glucose-6-phosphate dehydrogenase). Reaction was allowed to proceed for 15 min and 
then was terminated by placing tubes on ice and immediate addition of 500 µl 
acetonitrile. After an internal standard was added, the sample was vortex mixed and 
centrifuged at 14,000 rpm for 5 min. The supernatant layer was moved to a clean tube 
and was extracted and then centrifuged at 36,000 rpm for 15 min. The organic layer was 
removed and evaporated to dryness. The residue was reconstituted with mobile phase, 
and an aliquot was injected into an HPLC or LC/MS/MS. The amount of metabolites 
were quantified by using the ratio of peak area of the metabolite to peak area of internal 
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standard and standard curves that were constructed using known metabolite 
concentrations. 
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3.2 General incubation conditions of efavirenz inhibition study  
Using incubation conditions specific to each isoform that were linear for time, 
substrate and protein concentrations, isoform selective substrate probes were incubated in 
duplicate at 37°C with HLMs (or with expressed CYP when required), 200 mM sodium 
phosphate reaction buffer (pH 7.4) and NADPH-regenerating system (1.3 mM NADP, 
3.3 mM glucose-6-phosphate, 3.3 mM MgCl2, and 1 µl/ml glucose-6-phosphate 
dehydrogenase) in the absence or presence of varying concentrations of efavirenz (or 8-
hydroxyefavirenz). The test inhibitors were dissolved and diluted in methanol to required 
concentrations and methanol was removed by drying in speed vacuum before the addition 
of the incubation components. The following HLMs concentrations were used: 1 mg 
protein/ml for CYP1A2, CYP2C9, CYP2C19 and CYP2D6; 0.5 mg protein/ml for 
CYP2A6, 0.25 mg protein/ml for CYP2B6 and CYP3A; and 0.1 mg/ml for CYP2C8 
incubations. Inhibition constants (Ki values) were determined in expressed CYP2C8 (26 
pmol) and CYP2B6 (5 pmol). 
The inhibitory effects of efavirenz on the activities of different CYP isoforms 
were studied in HLMs, expressed CYP2B6 and CYP2C8 using the following selective 
reaction probes: phenacetin O-deethylation (CYP1A2); coumarin 7-hydroxylation 
(CYP2A6); bupropion 4-hydroxylation (CYP2B6); amodiaquine N-desethylation 
(CYP2C8); tolbutamide 4-hydroxylation (CYP2C9); S-mephenytoin 4-hydroxylation/R-
omeprazole 5-hydroxylation (CYP2C19); dextromethorphan O-demethylation 
(CYP2D6); and testosterone 6β-hydroxylation (CYP3A). Kinetic analysis was performed 
for each substrate probe reaction before initiation of the inhibition experiments, and the 
data generated were used as a guide for selection of the appropriate concentrations of the 
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substrate probes in the subsequent inhibition experiments. Thus, the kinetic parameters 
for the metabolism of each probe substrate were determined by incubating a range of 
different concentrations of the substrate (without the inhibitor) at 37°C in duplicate with 
HLMs (or expressed enzymes) and the NADPH-generating system. Phenacetin (5 to 1000 
µM), coumarin (0.1 to 50 µM), bupropion (1 to 1000 µM), amodiaquine (0.1 to 100 µM), 
tolbutamide (5 to 500M), S-mephenytoin (5 to 100 µM), R-omeprazole (1 to 200 µM), 
dextromethorphan (1 to 200 µM), and testosterone (1 to 200 µM) were used. Formation 
rates of metabolite versus the substrate concentrations were fit to appropriate enzyme 
kinetic equations to estimate the apparent kinetic parameters.  
4. Specific enzyme assays 
The substrate reactions to determine the activities of different CYP isoforms and 
specific inhibitors for each CYP isoform are summarized in Table 2.1. The specific 
enzyme assays of 8 major human CYP isoforms were described below. 
4.1 CYP1A2 activity (phenacetin O-deethylation to acetaminophen) 
HLMs (1 mg/ml), different concentrations of phenacetin, the NADPH-generating 
system, and phosphate reaction buffer (pH 7.4) were incubated at 37°C for 30 min. 
Acetonitrile (500 µl) was used to terminate the reaction. 25 µl of 50 µM nevirapine was 
used as an internal standard. After centrifugation at 14,000 rpm for 5 min, the supernatant 
layer was moved to a clean tube and was extracted with 500 µl of 0.5 ml glycine/NaOH 
buffer (pH 11.3) and 6 ml of ethyl acetate and then centrifuged at 36,000 rpm for 15 min. 
The organic layer was removed and evaporated to dryness. The residue was reconstituted 
with 150 µl of mobile phase, and an aliquot of 50 µl was injected into an HPLC. The 
HPLC system consisted of a Shimadzu LC-10AT pump, SIL-10AD auto-sampler, SCL-
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10A system controller and SPD-10A UV-VIS detector. The HPLC eluates 
(acetaminophen and nevirapine) were separated with a Zorbax SB-C18 column (150 × 4.6 
mm, 3.5-μm particle size; Phenomenex, Torrance, CA), a Luna C18 Guard column (30 × 
4.6 mm, 5 μm; Phenomenex), and a mobile phase composed of 85% 50 mM KH2PO4 (pH 
4.5)  and 15% (v/v) acetonitrile (flow rate, 0.7 ml/min). Detection was performed with 
UV detection at 245 nm. The retention time of phenacetin, acetaminophen and nevirapine 
(IS) was 21.6, 4.5 and 13.0 min.  
4.2 CYP2A6 activity (coumarin 7-hydroxylation to 7-hydroxycoumarin) 
Coumarin was dissolved in methanol (stock, 100 mM) and was serially diluted in 
distilled water to the required concentration (final methanol concentration, ≤ 0.1%). 
Coumarin, 0.5 mg/ml HLMs, the NADPH-generating system, and phosphate reaction 
buffer (pH 7.4) were incubated at 37°C for 15 min. The reaction was terminated by 
adding 100 µl of acetonitrile. The solution of internal standard, 8-methoxypsolaren, 
should be made fresh before the experiment, because it may degrade over time. After the 
internal standard (50 µl of 20 µg/ml) was added, the mixture was vortex mixed and 
centrifuged and an aliquot (150 µl) of the supernatant was transferred to HPLC vials; 100 
µl of this aliquot was injected onto the HPLC system. The HPLC and separation column 
was the same as that used for the CYP1A2 assay described above. The mobile phase 
composed of 70% 10 mM KH2PO4 (pH 3.0) and 30% (v/v) acetonitrile (flow rate, 0.8 
ml/min). The column eluate was monitored by UV detection at 280 nm (internal 
standard) or with a fluorescence detector at an excitation wavelength of 370 nm and an 
emission wavelength of 450 nm (7-hydroxycoumarin). The retention time of coumarine, 
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7-hydroxycoumarine and 8-methoxypsolaren (IS) was approximately 9.1, 4.6 and 17.7 
min. 
4.3 CYP2B6 activity (efavirenz 8-hydroxylation to 8-hydroxyefavirenz and bupropion 4-
hydroxylation to 4-hydroxybupropion) 
8-Hydroxyefavirenz formed from efavirenz incubations in expressed CYP2B6 
was quantified by HPLC/UV system with slight modification as described previously 
(Ward et al., 2003). Briefly, the HPLC system consisted of a Shimadzu LC-10AT pump, 
SIL-10AD auto-sampler, SCL-10A system controller and SPD-10A UV-VIS detector. 
The separation system consisted of a Zorbax SB-C18 column (150 × 4.6 mm, 3.5-μm 
particle size; Phenomenex, Torrance, CA), a Luna C18 Guard column (30 × 4.6 mm, 5 
μm; Phenomenex), and a mobile phase composed of 55% 10 mM KH2PO4 (adjusted to 
pH 2.7 with 1% phosphoric acid) and 45% (v/v) acetonitrile (flow rate, 1 ml/min). The 
column eluate was monitored by UV detection at 245 nm. The retention time of 
efavirenz, 8-hydroxyefavirenz and ritonavir (IS) was 21.6, 12.0 and 16.7 min. 8-
Hydroxyefavirenz was quantified by using the ratio of peak area of the metabolite to peak 
area of internal standard and standard curves that were constructed using known 8-
hydroxyefavirenz concentrations. 
Due to the slow formation rates of 8-hydroxyefavirenz in HLMs samples, 
particularly in those with CYP2B6*6/*6 genotype, a sensitive and selective LC/MS/MS 
method was developed to assay 8-hydroxyefavirenz from HLMs incubation and 
implemented as described in our previous publication (Ogburn et al., 2010). 7-
Hydroxyefavirenz, a minor metabolite catalyzed solely by CYP2A6 in HLM incubations 
(Ogburn et al., 2010), was also simultaneously quantified by the same LC/MS/MS 
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method. The MS/MS system was an API 2000 MS/MS triple quadruple system (Applied 
Biosystems, Foster City, CA) equipped with a turbo ion spray and was coupled with a 
Shimadzu HPLC system (Columbia, MD) consisting of an LC-20AB pump and SIL-20A 
HT autosampler, all controlled by Analyst 1.4.2 software (Applied Biosystems/MDS 
Sciex, Foster City, CA) in conjunction with Windows 2000 (Microsoft, Redmond, WA). 
7, 8-Hydroxyefavirenz and nevirapine were detected using multiple reactions monitoring 
(MRM) at a m/z of 332.2/248.3 and 267.1/226.4 in positive ion mode, respectively. The 
separation of 7, 8-hydroxyefavirenz are based on their different retention times. A 
representative MRM trace chromatogram of 7, 8-hydroxyefavirenz and nevirapine (IS) 
are depicted in Figure 2.3.  
An HPLC assay method with UV detection was developed for the quantification 
of 4-hydroxybupropion from bupropion incubation in expressed enzymes. The HPLC and 
separation column were the same as those used for quantification of 8-hydroxyefavirenz. 
The mobile phase composed of 85% 10 mM KH2PO4 (adjusted to pH 3 with 85% 
phosphoric acid) and 15% (v/v) acetonitrile (flow rate, 1 ml/min). The column eluate was 
monitored by UV detection at 214 nm for 4-hydroxybupropion and 282 nm for internal 
standard (nevirapine). A LC/MS/MS assay was developed for the quantification of 
bupropion metabolite in HLMs incubation samples. The MS/MS system was the same as 
for efavirenz described above. In brief, bupropion, 4-hydroxybupropion and the internal 
standard (nevirapine) were separated using a Zorbax SB-C18 column (100 × 2.00 mm, 3 
µm particle size; Phenomenex, Torrance, CA), a Luna C18 guard column (30 × 4.6 mm, 5 
µm; Phenomenex), and an isocratic mobile phase that consisted of 75% formic acid 
(0.1% in H2O) and 25% acetonitrile (flow rate, 0.3 ml/min). 4-Hydroxybupropion and 
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nevirapine were detected using multiple reactions monitoring at a m/z of 256.1/238.0 and 
267.2/224.4 in positive ion mode, respectively. A representative MRM trace 
chromatogram of 4-hydroxybupropion and nevirapine (IS) are depicted in Figure 2.4.  
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Figure 2.3 Multiple reactions monitoring (MRM) trace chromatograms of 7, 8-
hydroxyefavirenz and nevirapine (IS) in microsomal incubates. Efavirenz was 
incubated in HLM samples and cofactors for 15 min at 37°C. Subsequent sample 
processing and LC/MS/MS conditions were described under Materials and Methods. 7, 
8-Hydroxyefavirenz and nevirapine were detected using multiple reactions monitoring 
(MRM) at a m/z of 332.2/248.3 and 267.1/226.4 in positive ion mode, respectively. The 
separation of 7, 8-hydroxyefavirenz are based on their different retention times.  
8-Hydroxyefavirenz 
7-Hydroxyefavirenz 
Nevirapine (IS) 
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Figure 2.4 Multiple reactions monitoring (MRM) trace chromatograms of 4-
hydroxybupropion and nevirapine (IS) in microsomal incubates. Bupropion was 
incubated in HLM samples and cofactors for 15 min at 37°C. Subsequent sample 
processing and LC/MS/MS conditions were described under Materials and Methods. 4-
Hydroxyefavirenz and nevirapine were detected at a m/z of 256.1/238.0 and 267.2/224.4 
in positive ion mode, respectively. 
  
4-Hydroxybupropion 
Nevirapine 
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4.4 CYP2C8 activity (amodiaquine desethylation to desethylamodiaquine) 
A mixture of amodiaquine, HLMs (0.1 mg/ml) or expressed CYP2C8 (26 
pmol/ml), and the NADPH-generating system was incubated at 37°C for 15 min. The 
reaction was terminated by addition of 100 µl acetonitrile, and chloroquine (50 µM) was 
added as an internal standard. The methods for further processing of the sample and the 
separation column were the same as those used in the CYP2A6 assay. We used a mobile 
phase that consisted of water, 16% (v/v) methanol, and 0.1% (v/v) triethylamine (pH 
2.2); a flow rate of 1 ml/min; and UV detection at 340 nm. The retention time of 
amodiaquine, desethylamodiaquine and chloroquine (IS) was 15.4, 12.4 and 9.4 min. 
4.5 CYP2C9 activity (tolbutamide 4-hydroxylation to 4-hydroxytolbutamide) 
Tolbutamide, HLMs (1 mg/ml), and the NADPH-generating system were 
incubated for 60 min at 37°C. The reaction was terminated by addition of 100 µl 10% 
perchloric acid (HClO4) and 50 µl of the internal standard, chlorpropamide (10 µg/ml), 
was added. After centrifugation at 14,000 rpm for 5 min, the supernatant layer was 
moved to a clean tube and was extracted with 500 µl of H2O and 3 ml of ethyl acetate and 
then centrifuged at 36,000 rpm for 15 min. The organic layer was removed and 
evaporated to dryness. The residue was reconstituted with 150 µl of mobile phase, and an 
aliquot of 50 µl was injected into an HPLC. The separation column was the same as that 
used for the CYP1A2 assay. A mobile phase that consisted of 70% 10 mM ammonium 
acetate (pH 5.4) and 30% (v/v) acetonitrile (flow rate, 0.7 ml/min) and UV detection at 
230 nm were used. The retention time of tolbutamide, 4-hydroxytolbutamide and 
chlorpropamide (IS) was 19.0, 4.6 and 8.0 min. 
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4.6 CYP2C19 activity (S-mephenytoin 4-hydroxylation to 4-hydroxy-S-mephenytoin and 
R-omeprazole 5-hydroxylation to R-hydroxyomeprazole) 
S-Mephenytoin, HLMs (0.5 mg/ml), and the NADPH-generating system were 
incubated for 60 min at 37°C. The reaction was terminated by addition of 100 µl 
acetonitrile. The sample was centrifuged after addition of phenytoin (5 µg/ml) as an 
internal standard, and the supernatant was extracted with dichloromethane (2 ml). The 
organic layer was removed and evaporated to dryness with a speed vacuum. The residue 
was reconstituted in mobile phase (75% 50 mM KH2PO4 [pH 4.0], 25% [v/v] 
acetonitrile), and 100 µl was injected into an HPLC system. The separation columns were 
the same as those used for the CYP1A2 assay. The mobile phase was delivered at 0.7 
ml/min, and the column eluate was monitored by UV detection at 211 nm. The retention 
time of S-mephenytoin, 4-hydroxy-S-mephenytoin and phenytoin (IS) was 21.0, 6.6 and 
33.5 min.  
A LC/MS/MS assay was developed for the quantification of the formation of R-
hydroxyomeprazole. First, 25 μl of 1μg/ml R-lansoprazole was added to each sample as 
an internal standard. The incubation mixture was then extracted by the addition of 500 µl 
of 0.025 M NaCl (pH 7.5) and 6 ml of ethyl acetate. After centrifugation at 36,000 rpm 
for 15 min, the organic layer was evaporated to dryness and then reconstituted in 100 μl 
of mobile phase. The separation column used was Chiral-AGP (150 × 4.60 mm; 5 μM; 
Phenomenex). A gradient elution profile was used: initial mobile phase: 95% (v/v) 20 
mM ammonium acetate (pH 6.5) and 5% acetonitrile; secondary mobile phase: 10% 20 
mM ammonium acetate (pH 6.5) and 90% acetonitrile. The secondary mobile phase was 
increased from 0% to 40% linearly between 0 and 8 min; the initial mobile phase was 
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resumed after 9 min and remained constant for an additional 6 min, allowing the column 
to equilibrate. The eluate was introduced, without splitting, at 0.5 ml/min to the turbo ion 
source. R-hydroxyomeprazole and R-lansoprazole were detected using multiple reactions 
monitoring at m/z values of 362.13/214.10 and 370.25/252.30, respectively. 
4.7 CYP2D6 activity (dextromethorphan O-demethylation to dextrorphan) 
Dextromethorphan, HLMs (1 mg/ml), and the NADPH-generating system were 
incubated at 37°C for 30 min. The reaction was terminated by addition of 20 µl 60% 
HClO4. Levallorphan (40 µl of 16 µM) was added as an internal standard and was 
processed further as described above for the CYP2A6 assay. An aliquot of the 
supernatant (100 µl) was injected into the HPLC system, which consisted of the 
separation column described above for the CYP2A6 assay; the mobile phase was 10 mM 
KH2PO4 with 0.114% triethylamine (pH 4.0), 23% (v/v) acetonitrile, and 20% (v/v) 
methanol (flow rate, 0.5 ml); and fluorescence detection was performed at an excitation 
wavelength of 200 nm and an emission wavelength of 304 nm. The retention time of 
dextromethorphan, dextrorphan and levallorphan was 13.3, 5.3 and 7.1 min. 
4.8 CYP3A activity (testosterone hydroxylation to 6β-hydroxytestosterone) 
Testosterone, HLMs (1 mg/ml), and the NADPH-generating system were 
incubated at 37°C for 30 min. The reaction was terminated by addition of 20 µl 60% 
HClO4. Levallorphan (40 µl of 16 µM) was added as an internal standard and was 
processed further as described above for the CYP2A6 assay. An aliquot of the 
supernatant (100 µl) was injected into the HPLC system, which consisted of the 
separation column described above for the CYP2A6 assay; the mobile phase was 40% 30 
mM ammonium acetate (pH 6.3) and 60% (v/v) methanol (flow rate, 1 ml); and UV 
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detection was set at 254 nm. The retention time of testosterone, 6β-hydroxytestosterone 
and desmethyldiazepam was 10.0, 5.0 and 10.4 min. 
Table 2.1 Summary of substrate reactions and inhibitors for 8 major human 
cytochrome P450 enzymes 
Cytochrome P450s Substrate reactions Inhibitors 
CYP1A2 phenacetin O-deethylation furafylline 
CYP2A6 coumarin 7-hydroxylation pilocarpine 
CYP2B6 bupropion 4-hydroxylation 
efavirenz 8-hydroxylation 
thioTEPA, clopidogrel, 
voriconazole  
CYP2C8 amodiaquine N-desethylation quercetin 
CYP2C9 tolbutamide 4-hydroxylation sulfaphenazole 
CYP2C19 S-mephenytoin 4-hydroxylation 
R-omeprazole 5-hydroxylation 
ticlopidine 
CYP2D6 dextromethorphan O-demethylation quinidine 
CYP3A testosterone 6β-hydroxylation ketoconazole 
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5. Inhibition of CYP2B6 by voriconazole and clopidogrel in HLMs 
To test the impact of the CYP2B6*6 allele on metabolic inhibition of CYP2B6, 
inhibition experiments were performed in HLMs obtained from human liver tissues 
genotyped for the CYP2B6*6 allele. IC50 values for the inhibition of CYP2B6 by 
voriconazole and clopidogrel were determined by incubating efavirenz (10 µM) with a 
NADPH-generating system and 25µl of HLMs (2.5 mg/ml) at 37°C for 15 min in the 
absence or presence of voriconazole (0.01 to 4 µM) and clopidogrel (0.003 to 2.5 µM) 
(total incubation volume of 250 µl). Dixon plots for the inhibition of CYP2B6 by 
voriconazole were determined by incubating efavirenz (10 to 100 µM) with a NADPH-
generating system and 25µl of HLMs (2.5 mg/ml) at 37°C for 15 min in the absence or 
presence of voriconazole (0.1 to 10 µM) (total incubation volume of 250 µl). The 
samples were processed and 8-hydroxyefavirenz formed was quantified by LC/MS/MS as 
described above. 
6. Determination of efavirenz in vitro Clint in HLMs and expressed CYP2B6 
Efavirenz is primarily cleared by CYP2B6-mediated 8-hydroxylation and partially 
by CYP2A6-mediated 7-hydroxylation (Ward et al., 2003; Ogburn et al., 2010). 
Therefore, the formation rates of 7- and 8-hydroxyefavirenz from efavirenz incubations 
in HLMs obtained from liver tissues genotyped for the CYP2B6*6 allele (n=5 for each 
genotype) as well as CYP2B6.1 and CYP2B6.6 without co-expression of Cyt b5 were 
determined by a LC/MS/MS method described above. Metabolism data from expressed 
CYP2B6 without co-expression of Cyt b5 was selected for the present study. Because Cyt 
b5 affects catalytic properties of CYP2B6 in a genotype- and substrate-dependent manner 
(Xu et al., 2012). The details of microsomal preparations, incubation conditions and assay 
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method have been described above. Briefly, 1-200 µM efavirenz were incubated with 200 
mM potassium phosphate buffer (pH 7.4), expressed CYP2B6 (10-15pmol) or 25 µl of 
HLMs (2.5 mg/ml) and a NADPH-generating system (1.3 mM NADP, 3.3 mM glucose 
6-phosphate, 3.3 mM MgCl2, and l µl/ml glucose-6-phosphate dehydrogenase) for 15 min 
at 37°C. The formation rates of 7- and 8-hydroxyefavirenz were simultaneously measured 
with the quantifier MRM and confirmed with the qualifier MRM transition. The parent 
and daughter ions were the same for 7- and 8-hydroxyefavirenz and therefore these two 
metabolites were quantified based on chromatographic separation (Figure 2.1). Apparent 
kinetic constants (Km and Vmax) were estimated by fitting formation rates of metabolites 
versus efavirenz concentrations to simple single-site Michaelis-Menten equation by 
nonlinear regression analysis using Prism version 5.0 software (GraphPad Software Inc., 
San Diego, CA). In vitro intrinsic clearance (Clint) was given as Vmax/Km.  
7. Prediction of efavirenz clearance by Simcyp 
7.1 Simcyp population physiologically-based pharmacokinetic (PBPK) modeling 
The in vitro-in vivo extrapolation (IVIVE) of efavirenz single-dose 
pharmacokinetics was performed using the Simcyp
®
 Population-based ADME Simulator 
(version 11.00; Simcyp Ltd., Sheffield, UK). The algorithm, physiological basis, and 
differential equations used by the software have been described in previous publications 
(Rostami-Hodjegan and Tucker, 2007; Jamei et al., 2009). Input parameters including the 
physicochemical properties of efavirenz, in vitro Clint in HLMs and expressed enzymes 
are listed in Table 2.2. All other parameters used for simulations were set to default 
Simcyp values. Although UGT 2B7 has been suggested to be also involved in efavirenz 
metabolism in vitro (Belanger et al., 2009) and in vivo (Kwara et al., 2009a), the 
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contribution of N-glucuronidation pathway to efavirenz overall metabolism seems 
minimal (Cho et al., 2011). Therefore, the present study did not take UGT2B7-mediated 
pathway into account. Simulations were performed using a virtual population consisted of 
the built-in Sim-healthy volunteers population in 20 trials, and in each trial the number of 
subjects was matched to that in the clinical trial (CYP2B6*1/*1: n=8; CYP2B6*1/*6: n=9, 
CYP2B6*6/*6: n=3). The total number of 160 subjects were simulated for the 
CYP2B6*1/*1 genotype; the total number of 180 subjects were simulated for the 
CYP2B6*1/*6 genotype; the total number of 60 subjects were simulated for the 
CYP2B6*6/*6 genotype. Mean, median and standard deviation of key pharmacokinetic 
parameters were determined. Simulations were done on an exclusive extensive 
metabolizer (EM) CYP2B6 population and an exclusive slow metabolizer (SM) CYP2B6 
population. Initially, all combinations of the three models for absorption and two models 
for distribution, i.e. minimal and full PBPK models embedded within Simcyp
®
, were 
tested and simulated efavirenz time-concentration profiles were compared with the 
observed plasma concentrations in the clinical trial. The final model was selected based 
on visual predictive checks and comparison between the mean (5
th
 and 95
th
 percentile) of 
simulated and observed key pharmacokinetic parameters (Cmax, Tmax, AUC 0-∞ and CLpo).   
7.2 Recalculation of intersystem extrapolation factors (ISEFs) 
Intersystem extrapolation factors (ISEFs) built in the Simcyp were calculated on 
the basis of Vmax for each individual CYP. The default values of ISEFs for BD CYP2B6 
and CYP2A6 supersomes are 0.43, and were initially tested in our model. Then, the 
ISEFs for CYP2B6.1 and CYP2B6.6 were recalculated on the basis of Vmax and Clint of 
efavirenz 8-hydroxylation determined in HLMs with CYP2B6*1/*1 and *6/*6 genotypes 
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and expressed CYP2B6 proteins, respectively. The CYP2B6 abundance was assumed to 
be 17 pmol/mg and 6 pmol/mg in the wild type and homozygote according to Simcyp. In 
addition, ISEF for CYP2A6 was also recalculated using Vmax and Clint of efavirenz 7-
hydroxylation determined in HLMs and expressed CYP2A6. Since no significant 
difference in Vmax and Clint of efavirenz 7-hydroxylation determined in the HLMs with 
different CYP2B6*6 genotypes was observed and CYP2A6 was suggested to be the sole 
enzyme responsible for 7-hydroxylation in vitro (Ogburn et al., 2010), mean value 
calculated from Vmax and Clint determined in individual HLM was used in the 
recalculations of ISEF for CYP2A6. 
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Table 2.2 In vitro input parameters of efavirenz in Simcyp 
PhysicoChem  Value Reference CLint from HLMs (Pathway) 
µl/min/mg protein 
CLint from rhCYP (Pathway) 
µl/min/pmol P450 
MW 315.67  CYP2B6*1/*1 (8-OH)
a
 14.5 CYP2B6.1 (8-OH)
a
 0.39 
LogP 4.6 (Drug Bank) CYP2B6*1/*6 (8-OH)
a
 6.4 CYP2B6.6 (8-OH)
 a
 0.19 
B/P ratio 0.74 (Balani et al., 1999) CYP2B6*6/*6 (8-OH)
a
 2.4 CYP2A6 (7-OH)
c
 0.05 
f u,plasma 0.029 (Shou et al., 2008) CYP2B6*1/*1 (7-OH)
b
 1.1 CYP2A6 (8-OH)
 c
 0.08 
f umic 
 
0.30 (Rekic et al., 2011) CYP2B6*1/*6 (7-OH)
 b
 1.5 CYP3A4 (8-OH)
d
 0.007 
Plasma binding 
protein 
 
albumin  CYP2B6*6/*6 (7-OH)
b
 1.3 CYP3A5 (8-OH)
 d
 0.03 
Caco-2 
permeability (10
-5
 
cm/s) 
8.92 (Takano et al., 2006)   CYP1A2 (8-OH)
 d
 0.07 
a
 Data from Xu, et al. (2012) 
b
 Data from the present study 
c
 Data from Ogburn, et al. (2011) 
d
 Data from Ward, et al. (2003)
 
 
65 
 
8. Prediction of efavirenz clearance by Well-stirred liver model 
Prediction of mean efavirenz CLpo extrapolated from in vitro Clint determined in HLMs 
and expressed CYP2B6 was also performed by Well-stirred liver model. 
8.1 Extrapolation of expressed CYP metabolism data 
ISEFs were applied to account for the differences in turnover number between 
expressed proteins and HLMs (Proctor et al., 2004). ISEFs were defined with respect o 
either the Vmax of metabolite formation of a probe substrate or Clint using equations as 
described below: 
VIS F  
 Vmax (HLM)
Vmax  rhCYP × CYP abundance (HLM)
                                  (1) 
CLIS F  
Clint (HLM)
Clint  rhCYP × CYP abundance (HLM)
                                 (2) 
The in vivo Clint was scaled on the basis of measured in vitro Clint in expressed CYPs and 
ISEFs using equation 3 modified from Proctor et al.: 
Clint  
Clint   rhCYP  × CYP  abundance × IS F(CYP )
fumic
n
  1
   × MPPGL × liver weight  (3) 
where the values of milligrams of microsomal protein per gram of liver (MPPGL) and 
total liver weight are both set to the same as Simcyp for the purpose of comparison. The 
mean of MPPGL value built in Simcyp is 39.8 mg/g and the average liver weight is 1717 
g, which are similar to published values (Obach, 1999; Wilson et al., 2003). The 
importance of correcting for nonspecific protein binding in IVIVE has been shown 
(Obach, 1996; Ito and Houston, 2005). Therefore, the prediction of Clint was corrected for 
nonspecific protein binding in equation 3. 
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8.2 Extrapolation of HLM metabolism data 
Assuming that 7- and 8-hydroxylation are the main clearance mechanisms of 
efavirenz and that other elimination pathways are negligible and that sequential 
metabolism is minimal in the incubation conditions used in this study. The total in vitro 
Clint of efavirenz in HLMs was calculated as the summation of Clint estimated from these 
two pathways:  
 Clint, HLM Clint, 8- H FV  Clint,  - H FV                         (4)                                                                                                                                         
The overall in vivo Clint of efaivrenz was scaled from in vitro Clint generated from HLMs 
using equation 5: 
Clint  
Clint,HLM
fumic
 × MPPGL × liver weight                  (5) 
where the values of scaling factors are the same as described above. 
8.3 Prediction of efavirenz clearance by Well-stirred liver model 
When fu × Clint << Qh, the hepatic clearance can be estimated from in vivo Clint 
using the well-stirred liver model by a simplified equation defined in equation 6:  
CLh   
 h × fu × Clint
 h  fu × Clint
                                                       (6) 
where fu is the fraction unbound of efavirenz in the plasma (0.029) (Shou et al., 2008), 
CLh is the hepatic blood clearance, and Qh is the hepatic blood flow (86 L/h) (Obach, 
1999). Since IV formulation of efavirenz is not available, CLh of the drug is unknown. 
However, efavirenz is mainly cleared by hepatic metabolism and no major first pass 
metabolism appears to occur, we assumed that the value of oral clearance (CLpo) is 
similar to that of CLh. Thus, efavirenz CLh predicted from in vitro Clint was compared to 
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observed CLpo after administration of a single 600 mg oral dose to healthy volunteers in 
the clinical trial.  
9. Clinical study: efavirenz single-dose pharmacokinetics 
Efavirenz clinical data was obtained from a pharmacokinetic study that was 
conducted as part of a drug interaction trial. In a randomized, placebo controlled 
crossover clinical trial, healthy subjects (n=20) genotyped for the CYP2B6*6 allele 
received a single 600 mg oral dose of efavirenz after 10 day treatment with placebo or 
rifampin. The study was approved by the Institutional Review Board (IRB) of Indiana 
University School of Medicine. Signed and dated written informed-consent forms were 
obtained from each subject. Eligible subjects were randomized to take either a daily 600-
mg oral dose of rifampin or placebo from day 1 through day 10. On day 11, after predose 
blood collection, subjects were given a single 600-mg oral dose of efavirenz on an empty 
stomach. Blood samples were collected at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, and 72 h 
after efavirenz dosing for pharmacokinetic analysis. After a washout period of 11 days, 
subjects started taking rifampin or placebo in a crossover fashion for 10 consecutive days 
and underwent the same procedure as in the first phase of the study. Plasma samples were 
separated by centrifugation at 3,000 rpm for 20 min within an hour of blood collection. 
Plasma samples were immediately stored at -80°C until analysis. Plasma concentrations 
of efavirenz and its metabolites were determined by a validated LC/MS/MS method 
described previously (Ogburn et al., 2010). Data from the placebo treated arm were used 
in the present study. All pharmacokinetic parameters (Cmax, Tmax, AUC 0-∞ and CLpo) 
were calculated by noncompartmental analysis using WinNonlin professional software 
(version 5.01; Pharsight, Mountain View, CA).  
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10. In vitro analysis of efavirenz inhibition of eight human cytochrome P450s 
10.1 Screening of inhibition on multiple CYPs 
Kinetic analysis was performed for each substrate probe reaction before initiation 
of the inhibition experiments, and the data generated were used as a guide for selection of 
the appropriate concentrations of the substrate probes in the subsequent inhibition 
experiments. Thus, the kinetic parameters for the metabolism of each probe substrate 
were determined by incubating a range of different concentrations of the substrate 
(without the inhibitor) at 37°C in duplicate with HLMs (or expressed enzymes) and the 
NADPH-generating system. Phenacetin (5 to 1000 µM), coumarin (0.1 to 50 µM), 
bupropion (1 to 1000 µM), amodiaquine (0.1 to 100 µM), tolbutamide (5 to 500M), S-
mephenytoin (5 to 100 µM), R-omeprazole (1 to 200 µM), dextromethorphan (1 to 200 
µM), and testosterone (1 to 200 µM) were used. Formation rates of metabolite versus the 
substrate concentrations were fit to appropriate enzyme kinetic equations to estimate the 
apparent kinetic parameters. Apparent kinetic constants (Km, Vmax) were estimated by 
fitting formation rates of metabolites versus substrate concentrations to simple single-site 
Michealis-Menten equation by nonlinear regression analysis using SigmaPlot 11.0 (Systat 
Software Inc., Richmond, CA). 
A single isoform-specific substrate concentration at about the respective Km value 
(50 µM phenacetin, 10 µM coumarin, 50 µM bupropion, 25 µM amodiaquine, 150 µM 
tolbutamide, 50 µM S-mephenytoin, 25 µM R-omeprazole, 10 µM dextromethorphan, 
and 10 µM testosterone) was incubated at 37°C in duplicate with HLMs and the 
NADPH-generating system in the absence or the presence of efavirenz concentrations at 
10 and 50 µM, which covered the range of average steady-state Cmax receiving 600mg 
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once daily (Bristol-Myers Squibb Company, June 2012). Processing of the incubation 
mixture and HPLC analysis of the metabolites formed were performed as described 
above. 
Positive control experiments were run in parallel by incubating each probe 
substrate at 37°C in duplicate with HLMs and the NADPH-generating system in the 
absence (control) and the presence of the following isoform-specific inhibitors: 
furafylline (20 µM; specific for CYP1A2), pilocarpine (50 µM; specific for CYP2A6), 
thioTEPA (50 µM; specific for CYP2B6), ticlopidine (5 µM; specific for CYP2B6), 
quercetin (10 µM; specific for CYP2C8), sulfaphenazole (25 µM; specific for CYP2C9), 
ticlopidine (5 µM; specific for CYP2C19), quinidine (1 µM; specific for CYP2D6), and 
ketoconazole (1 µM; specific for CYP3A). The substrate probes and concentrations that 
were used in the screening experiments (see above) were used for these positive control 
experiments. Formation rates of the metabolites in the presence of the isoform-specific 
inhibitor were compared with that for controls in which the inhibitor was replaced with 
vehicle. 
10.2 Determination of inhibition constants (Ki values) 
In pilot experiments, efavirenz showed inhibition on the activities of CYP2B6, 
CYP2C8, CYP2C9, CYP2C19 and CYP3A (by >20% at 50 µM); inhibition on the other 
CYPs (CYP1A2, 2A6, and 2D6) was minimal. Therefore, Dixon plots for the inhibition 
of CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP3A were determined by incubating 
multiple concentrations of the respective substrate probe in the presence and absence of 
multiple concentrations of efavirenz with HLMs and cofactors. Ki values in expressed 
enzymes were determined for two CYP isoforms that showed potent inhibition in pooled 
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HLMs with Ki < 10 µM, i.e. CYP2B6 and CYP2C8. The following isoform-specific 
probe substrate concentrations were used: 25 to 75 µM bupropion for CYP2B6; 10 to 100 
µM amodiaquine for CYP2C8; 50 to 250 µM tolbutamide for CYP2C9; 15 to 75 µM S-
mephenytoin for CYP2C19 and 5 to 50 µM testosterone for CYP3A. The concentrations 
of efavirenz used were 0 to 100 µM. The inhibition data obtained from the pilot 
experiments were used as a guide to generate appropriate probe substrate and test 
inhibitor concentrations for the determination of the Ki values for each isoform. To 
calculate Ki values, the inhibition data were fit to different models of enzyme inhibition 
(competitive, noncompetitive, and uncompetitive) by nonlinear least-squares regression 
analysis with the Prism Version 5.0 software (GraphPad software Inc., San Diego, CA, 
USA). The final model for each data set was selected on the basis of visual inspection of 
Lineweaver-Burk, Dixon, and Eadie-Hofstee plots, as well as the size of the sum of 
squares of residuals, the Akaike information criterion, and Schwartz criterion values.  
10.3 Assessment of time-dependent inhibition 
Efavirenz was reported to be a time-dependent inhibitor of expressed CYP2B6, 
with a KI value of 30 µM (Bumpus et al., 2006). Therefore, time-dependent inhibition 
was tested on eight major CYPs except for CYP2B6 using pooled HLMs. Efavirenz (50 
µM) was pre-incubated in duplicate with HLMs and 200 mM sodium phosphate reaction 
buffer (pH 7.4) (without or with the NADPH-generating system) in the absence of a 
substrate probe for 0, 5, 10, 15 and 30 min at 37°C. The preincubation reaction was 
started by adding the NADPH-generating system. Controls were pre-incubated for 0 min 
without efavirenz and without the NADPH generating system. The total volume of the 
preincubation mixture was 600 µl. After 0, 5, 10, 15 and 30 min of preincubation, 50 µl 
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of preincubation mixture was added to a glass tube containing 950 µl mixture that 
consisted of a substrate (final concentration corresponding to the Vmax), phosphate 
reaction buffer and  NADPH-generating system. The mixture was further incubated for 
the time specific for each assay. The reaction was stopped and processed as described 
above for the co-incubation experiments. 
11. Quantitative prediction of in vivo drug interactions 
  Predictions of in vivo drug interaction potential of efavirenz were made using the 
following equations, which has been described previously (Obach et al., 2006): 
A C I
A C
  
1
fm
1 
 I 
Ki
  (1 fm)
                                                                    ( ) 
where 
A C I
A C
 is the ratio of the AUC of substrate after inhibition to the AUC of the 
uninhibited substrate; fm is the fraction of substrate metabolized by the inhibited CYP 
pathway. The utilities of four different values for in vivo inhibitor concentrations, which 
are the total systemic Cmax, free systemic Cmax, total hepatic inlet Cmax estimated after oral 
administration and free hepatic inlet Cmax in the prediction of drug interactions have been 
compared before and estimation using free hepatic inlet Cmax yielded the most accurate 
predictions of the magnitude of drug interactions (Obach et al., 2006). But efavirenz is 
highly protein bound with fraction unbound in plasma estimated to be 0.029 (Shou et al., 
2008). In order to avoid underestimation of potential risk for drug interaction, total 
hepatic inlet Cmax (Chep,inlet) of efavirenz were used in present study (equation 8), which 
also showed a reasonably good prediction in the previous study (Obach et al., 2006). 
C hep,inlet  C max  
KaFaD
 h
                                                                   (8) 
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Where Cmax is maximum plasma concentration; Ka is the absorption rate constant, which 
is estimated to be 0.3 h
-1
 (Csajka et al., 2003); Fa is the fraction of the inhibitor passing 
through the intestine unchanged; D is the administered therapeutic dose (600 mg/day); 
and Qh is hepatic blood flow (87 L/h) (Walsky et al., 2006). Values of Fa can be estimated 
from oral bioavailability and hepatic extraction. Since both values are not available for 
efavirenz, a value of unity for Fa was assumed as the most cautious possibility (Obach et 
al., 2005; Walsky et al., 2006). There is no evidence that efavirenz enhances the activities 
of CYP2C8 and CYP2C9 in vivo. Therefore, Cmax of efavirenz at steady state was used 
(9.2 -16.6 µM) to predict the AUC changes of CYP2C8 and CYP2C9 substrates (Bristol-
Myers Squibb Company, June 2012). However, efavirenz has been shown to enhance the 
activities of CYP2B6, CYP2C19 and CYP3A upon multiple dosing, suggesting inhibition 
effect may masked by inductive effect of efavirenz in a time-dependent manner. 
Therefore, predicting AUC changes CYP2B6, CYP2C19 and CYP3A substrates was 
estimated using Cmax (4.6-8.4 µM) obtained after the administration of a single 600 mg 
oral dose of efavirenz to 20 healthy volunteers (Xu, et al. 2012). Specifically, we focused 
on substrates that exhibit narrow therapeutic range and thus initiation of efavirenz to 
patients stabilized on these drugs may increase the risk of adverse effects (methadone) or 
failure of therapy (clopidogrel and proguanil). Of note, clopidogrel and proguanil are pro-
drugs that require conversion to pharmacologically active metabolites primarily by 
CYP2C19 (Carrington et al., 1951; Jeppesen et al., 1997; Hulot et al., 2006). For these 
prodrugs that require conversion by CYPC19 to active metabolites, the following 
equation published previously (Lutz and Isoherranen, 2012) was slightly modified to 
predict the extent of inhibition of bioactivation: 
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A C m
A C p
  
f u,p ×Cl f
f u,m ×Cl m
                                                                    ( )         
where 
A C m
A C p
 is the ratio of the AUC of metabolite to the AUC of parent compound. The f 
u,p and f u,m are the plasma fraction unbound of the parent and metabolite. Cl f and Cl m 
are the formation and elimination clearance of metabolite. 
The majority of clopidogrel is metabolized by an esterase (Lins et al., 1999) and 
relative importance of CYP2C19 for the overall elimination of proguanil is much lower 
than it is for the formation of cycloguanil (Jeppesen et al., 1997). Assuming that 
efavirenz does not affect the elimination of metabolite and the change in the AUC of 
parent is negligible, the equation 10 can be derived from equation 7 and 9 as:  
A C m
A C m, I
  
Cl f
Cl f, I
 
1
fm
1 
 I 
Ki
  (1 fm)
                                       (10) 
where 
A C m
A C m, I
 is the ratio of the uninhibited AUC of metabolite to the AUC of metabolite 
with inhibition. 
Cl f
Cl f, I
 is the ratio of the uninhibited formation clearance to the formation 
clearance after inhibition. fm for clopidogrel and proguanil is defined as the fraction of 
active metabolites formed by CYP2C19. Since fm for proguanil is not available in the 
literature, it was estimated using a pharmacogenetic method modified from a recent study 
for CYP2D6 substrate (Tod et al., 2011). The original method was based on the 
observation that the ratio of AUC in poor metabolizer (PM), AUC
SM
, to the AUC in 
extensive metabolizer (EM), AUC
EM
. Assuming that genetic polymorphisms do not affect 
the elimination of metabolite and has limited effects on the AUC of the parent compound, 
the value of fm for proguanil metabolized to cycloguanil by CYP2C19 was estimated 
from a clinical study (Jeppesen et al., 1997) using the following equation: 
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A C 
 M
A C 
PM   
1
1 fm
 M                                                                             (11) 
where 
A C 
 M
A C 
PMis the ratio of metabolite AUC in poor metabolizer (PM) to the metabolite 
AUC in extensive metabolizer (EM).  
12. Statistical analysis  
Statistical comparisons of metabolism and inhibition kinetic parameters among 
genotypes were performed using one-way AN VA with Dunn’s post-hoc test for 
multiple comparison correction. Independent t-test was used to compare parametric data 
from two groups. Mann-Whitney test or Wilcoxon test was performed for nonparametric 
data. Correlation analysis was performed by a nonparametric test (Spearman's rank 
correlation test). All statistical tests were performed using GraphPad. p < 0.05 was 
considered statistically significant. 
The variability and accuracy of extrapolated efavirenz clearance using different 
values of ISEFs by Simcyp and well-stirred liver model were evaluated. Root mean 
square error (RMSE) and mean residual sum (MRS) were calculated based on equation 
12 and 13. A smaller RMSE indicates less variability between the observed and 
extrapolated data. The MRS was sued to measure the bias of different methods. A 
negative value indicates underestimation and a positive value indicates overestimation.  
RMS   
 (predicted CL observd CL)2n1
n
                        (12) 
MRS  
 (predicted CL observed CL)n1
n
                            (13) 
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The overall accuracies of the static prediction using different ISEFs were determined by 
equation 14 (Obach, 1999):  
Average fold error 10  
 log( 
predicted
observed
 )
n
                       (14) 
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CHAPTER III: Altered catalytic properties by the CYP2B6*6 allele may contribute to 
reduced efavirenz metabolism 
1. Introduction 
Efavirenz, a potent non-nucleoside reverse transcriptase inhibitor (NNRTI), 
remains preferred component of antiretroviral therapy (ART) for treatment naïve patients 
despite an emergence of second generation of NNRTIs and new classes of antiretroviral 
agents (Thompson et al., 2012). However, its effective and safe use is compromised by 
the large inter-individual variability in its pharmacokinetics and clinical responses. 
Subsequent to the demonstration that CYP2B6 is the principal clearance mechanism of 
efavirenz in vitro (Ward et al., 2003), a number of clinical studies have documented that 
the genetic polymorphism of CYP2B6 are significantly associated with higher efavirenz 
plasma concentrations (Haas et al., 2004; Tsuchiya et al., 2004; Wang et al., 2006; Rotger 
et al., 2007; Holzinger et al., 2012), intracellular concentrations (Rotger et al., 2005; 
Elens et al., 2010), and/or increased risk to adverse events (Haas et al., 2004; Gounden et 
al., 2010; Yimer et al., 2011; Mugusi et al., 2012).  
The CYP2B6 gene is highly polymorphic (Zanger et al., 2007) as reflected by 37 
associated alleles, many sub-alleles and SNPs 
(http://www.imm.ki.se/CYPalleles/cyp2b6.htm). Of  the variants so far identified, the 
CYP2B6*6 haplotype defined by two non-synonymous single nucleotide polymorphisms 
(SNPs), 516G>T (Q172H) and 785A>G (K262R), is clinically important because this 
allele or the SNP tagging it (G516T) occurs at high frequency in all ethnic populations 
[14-62% (Zanger et al., 2007; Li et al., 2012)] and has been consistently found to be 
associated with increased risk for higher efavirenz exposure and/or adverse effects (Haas 
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et al., 2004; Tsuchiya et al., 2004; Zanger et al., 2007; Gounden et al., 2010; Yimer et al., 
2011; Mugusi et al., 2012). In addition, this variant has also been associated with the 
elimination and/or response of other CYP2B6 substrate drugs including nevirapine 
(Rotger et al., 2005), cyclophosphamide (Nakajima et al., 2007) and methadone (Eap et 
al., 2007).  
Four possible mechanisms have been proposed to contribute to the altered drug 
metabolism by the CYP2B6*6 allele: (1) the CYP2B6*6 allele is associated with a lower 
transcription rate due to linked promoter variants, (2) this variant allele leads to aberrant 
splicing of CYP2B6 pre-mRNA and results in reduced protein expression, (3) this variant 
allele may be associated with altered post-transcriptional modification, e.g. degradation 
of the enzyme, and (4) this variant allele may alter function of the enzyme due to the 
altered protein structure by the amino acid changes.  
Previous study reported that this variant results in aberrant splicing of pre-mRNA 
and thereby reduces CYP2B6 expression and activity, while no promoter variant linked 
with reduced transcription rate has been identified yet (Hofmann et al., 2008). Nitric 
oxide has been shown to play a significant role in the down-regulation of CYP2B6 
protein by a post-transcriptional manner (Aitken et al., 2008), but no evidence has been 
shown that the CYP2B6*6 allele alters this regulation.  
Our hypothesis of that the CYP2B6*6 allele may alter function of the enzyme due 
to the altered protein structure by the amino acid changes is based on the evidence of 
structure-function relationship of CYP2B6. The CYP2B6*6 allele has been associated 
with functional consequences in expressed systems (Ariyoshi et al., 2001; Jinno et al., 
2003; Bumpus and Hollenberg, 2008; Watanabe et al., 2010; Ariyoshi et al., 2011; Zhang 
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et al., 2011b) and human liver microsomes (HLMs) (Lang et al., 2001; Lamba et al., 
2003; Xie et al., 2003; Hesse et al., 2004; Desta et al., 2007). In HLMs, the CYP2B6*6 
allele is associated with reduced total amount of CYP2B6 protein (Xie et al., 2003; Hesse 
et al., 2004; Desta et al., 2007). However, mounting evidence indicate that reduced 
protein expression alone may not explain the functional consequences of this allele. For 
substrates that include cyclophosphamide, this allele is associated with enhanced 
metabolism despite reduced protein expression (Xie et al., 2003), which appears due to 
substantially lower Km in the variant versus wild type protein (Ariyoshi et al., 2011). 
Other in vitro studies, mostly in expression systems, have also reported that the 
CYP2B6*6 allele or the amino acids harbored in it influence catalytic properties, although 
the extent and direction of effect appears to depend on the substrate and the enzyme 
sources used (Ariyoshi et al., 2001; Jinno et al., 2003; Bumpus and Hollenberg, 2008; 
Watanabe et al., 2010; Zhang et al., 2011b). Therefore, in addition to reduced protein 
expression, altered enzyme function by the CYP2B6*6 allele may contribute to altered 
substrate metabolism.  
In this dissertation I explored the mechanism by which the CYP2B6*6 allele alters 
drug metabolism in vitro and tested whether the incorporation of in vitro mechanism of 
reduced efavirenz metabolism by this genetic variant can predict genetic effect on 
efavirenz pharmacokinetics. In this section I tested the hypothesis that the CYP2B6*6 
allele changes catalytic properties, i.e. binding affinity and/or catalytic efficiency and this 
may contribute to reduced efavirenz metabolism. I determined the kinetics of efavirenz 
metabolism to 8-hydroxyefavirenz in expressed CYP2B6.1 and CYP2B6.6 as well as 
HLMs obtained from liver tissues genotyped for the CYP2B6*6 allele. Since the ability of 
 
 
79 
 
cytochrome b5 (Cyt b5) to influence P450-mediated drug oxidation (increase, inhibit or 
no effect) has been described for multiple P450s (Schenkman and Jansson, 2003), I 
utilized the expressed CYP2B6 without coexpression of Cyt b5 first to exclude its 
confounding effects. The results presented here demonstrated that the amino acid changes 
harbored in the CYP2B6*6 allele may reduce efavirenz metabolism by decreasing 
binding affinity and catalytic efficiency.  
2. Results 
2.1 Efavirenz 8-hydroxylation by CYP2B6.1 and CYP2B6.6 proteins without 
coexpression of Cyt b5 
To determine whether the CYP2B6*6 allele alters binding affinity and/or catalytic 
efficiency, both expressed CYP2B6.1 and CYP2B6.6 proteins were included in the 
present study to characterize catalytic properties of the enzymes using efavirenz as a 
probe (see Chapter II-2.1 and II-3.1 for Methods). The kinetic profiles for formation of 
8-hydroxyefavirenz from efavirenz in these proteins are depicted in Figure 3.1. The 
kinetic parameters estimated are summarized in Table 3.1. The Km and Vmax values for 
the formation of 8-hydroxyefavirenz were significantly higher in the CYP2B6.6 than in 
the CYP2B6.1 protein (Table 3.1). The in vitro intrinsic clearance (Vmax/Km or Clint) in 
the CYP2B6.6 protein was significantly lower than in the CYP2B6.1 protein (Table 3.1).  
 
 
80 
 
 
Figure 3.1 Efavirenz concentrations versus formation rate of 8-hydroxyefavirenz in 
microsomes containing cDNA-expressed CYP2B6.1 and CYP2B6.6 without 
coexpression of Cyt b5. Efavirenz (1-200 µM) was incubated with reconstituted systems 
containing either CYP2B6.1 or CYP2B6.6 (15 pmol) and a NADPH-generating system 
for 15 min at 37°C. Formation rate of 8-hydroxyefavirenz (pmol/min/pmol CYP) versus 
substrate concentrations were fit to the simple single-site Michaelis-Menten equation. 
Each point represents mean ± S.D. of three replicates. The curve represents the line of 
best fit. 
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Table 3.1 Kinetic parameters for the formation of 8-hydroxyefavirenz from 
efavirenz in expressed CYP2B6.1 and CYP2B6.6 without coexpression of Cyt b5.  
 CYP2B6.1(-b5) CYP2B6.6 (-b5) 
Efavirenz 8-Hydroxylation   
Vmax (pmol/min/pmol) 1.21 ± 0.15 1.61 ± 0.11** 
Km (µM) 3.2 ± 1.0 8.8 ± 1.6*** 
Clint (µl/min/pmol) 0.39 ± 0.08 0.19 ± 0.04** 
Kinetic data are presented as mean ± S.D. (n=3 incubation were performed in duplicate). 
In vitro Clint was calculated as Vmax/Km. Kinetic parameters for the formation of 8-
hydroxyefavirenz were estimated by fitting the velocity versus substrate concentrations to 
the simple single-site Michaelis-Menten equation. * p < 0.05, **p < 0.01, ***p < 0.001 
compared CYP2B6.6 to CYP2B6.1. 
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2.2 Efavirenz 8-hydroxylation in HLMs genotyped for the CYP2B6*6 allele 
To further evaluate the effect of the CYP2B6*6 allele on efavirenz metabolism in 
vitro, the kinetics of efavirenz 8-hydroxylation were characterized in 15 HLM samples 
with CYP2B6*1/*1, *1/*6 and *6/*6 genotypes (n=5 for each genotype) (see Chapter II-
2.2 and II- 3.1 for Methods). 
In Figure 3.2, efavirenz concentrations versus formation rate of 8-
hydroxyefavirenz in the different genotypes are shown. Formation rates of 8-
hydroxyefavirenz versus efavirenz concentrations were fit into a Michaelis-Menten 
equation to estimate kinetic parameters. The mean ± S.D. of these parameters for each 
genotype are listed in Table 3.2. The kinetic parameters for individual HLM are 
summarized in Table 3.3. None of the kinetic parameters were statistically different 
among the three genotypes, probably due to the high inter-HLMs variability in Vmax and 
Clint for the formation of 8-hydroxyefavirenz, particularly in HLMs with CYP2B6*1/*1 
and *1/*6 (CV of more than 100%); this variability was smaller in HLMs with *6/*6 
genotype (CV of about 30% for Vmax and 65% for Clint). Despite this lack of statistical 
significance, it is noteworthy that the average Vmax in HLMs with CYP2B6*6/*6 
genotype were lower by 71 and 75% compared to values in HLMs with CYP2B6*1/*1 
and *1/*6 genotypes, respectively. The Km values in CYP2B6*6/*6 genotype were higher 
on average by 114% and 58% than that in CYP2B6*1/*1 and *1/*6 genotypes, 
respectively. Accordingly, the Clint values in HLMs with CYP2B6*6/*6 were 83% lower 
compared to that of HLMs with CYP2B6*1/*1 and 62% lower compared to that of HLMs 
with *1/*6 genotype. 
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Figure 3.2 Efavirenz concentrations versus formation rate of 8-hydroxyefavirenz in 
15 human liver microsomal samples with CYP2B6*1/*1, *1/*6 and *6/*6 genotypes 
(n=5 HLMs for each genotype). Efavirenz (1-200 µM) were incubated with human liver 
microsomal samples (0.25mg/ml) with CYP2B6*1/*1, *1/*6 and *6/*6 genotypes (n=5 
HLMs for each genotype) and a NADPH-generating system for 15 min at 37°C in 
duplicate. The formation rate of 8-hydroxyefavirenz (pmol/min/mg protein) versus 
substrate concentrations were fit to the simple single-site Michaelis-Menten equation. 
Each point represented as the average of five individual incubations in human liver 
microsomal samples with the same CYP2B6 genotype. The curve represents the line of 
best fit. 
  
 
 
84 
 
Table 3.2 Kinetic parameters (mean ± S.D.) for the formation of 8-hydroxyefavirenz 
from efavirenz in 15 human liver microsomal samples with CYP2B6*1/*1, *1/*6 and 
*6/*6 genotypes (n=5 HLMs for each genotype).   
 
HLMs 
8-Hydroxyefavirenz 
Vmax (pmol/min/mg 
protein) 
Km (µM) Clint (µl/min/mg 
protein) 
CYP2B6*1/*1 87.1 ± 87.4 11.2 ± 6.7 14.5 ± 22.6 
CYP2B6*1/*6 100.6 ± 143.7 15.2 ± 8.0 6.4 ± 7.8 
CYP2B6*6/*6 25.0 ± 6.7 24.0 ± 31.3 2.4 ± 1.6 
Efavirenz (1-200µM) were incubated with human liver microsomal samples (0.25mg/ml) 
with CYP2B6*1/*1, *1/*6 and *6/*6 genotypes (n=5 HLM for each genotype) and a 
NADPH-generating system at 37°C for 15min in duplicate. Kinetic parameters (Vmax and 
Km) for the formation of 8-hydroxyefavirenz were estimated by fitting the velocity versus 
efavirenz concentrations to the simple single-site Michaelis-Menten equation. In vitro 
Clint was calculated as Vmax/Km. The kinetic parameters (Vmax, Km and Clint) for each 
genotype group are listed in the Table 3.3. The data presented here are mean ±S.D. 
calculated from 5 individual HLMs values for each genotype. 
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Table 3.3 Individual kinetic parameters for the formation of 8-hydroxyefavirenz 
from efavirenz in 15 HLM samples with CYP2B6*1/*1, *1/*6 and *6/*6 genotypes 
(n=5 HLMs for each genotype).  
 
HLMs 
8-Hydroxyefavirenz 
Vmax (pmol/min/mg 
protein) 
Km (µM) Clint (µl/min/mg 
protein) 
CYP2B6*1/*1            
HL-U 62.9 20.6 3.1 
HL-M 24.8 15.5 1.6 
HL-P 110.5 9.2 12.0 
HH-689 10.2 6.6 1.5 
MCV-65 227.1 4.2 54.1 
Mean ±  S.D. 87.1 ± 87.4 11.2 ± 6.7 14.5 ± 22.6 
CYP2B6*1/*6    
HL-S 125.5 11.7 10.7 
HL-C 12.9 11.0 1.2 
HL-O 342.0 19.0 18.0 
MCV-49 11.9 7.1 1.7 
HH-488 10.4 27.3 0.4 
Mean ± S.D. 100.6 ± 143.7 15.2 ± 8.0 6.4 ± 7.8 
CYP2B6*6/*6    
HL-K 32.4 21.5 1.5 
HH-1180 31.1 7.0 4.5 
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IIAM-091698-1 16.6 5.8 2.9 
HH-525 21.0 7.0 3.0 
HH-478 23.6 78.9 0.3 
Mean ± S.D. 24.9 ± 6.7 24.0 ± 31.3 2.4 ± 1.6 
Efavirenz (1-200µM) were incubated with HLM samples (0.25mg/ml) with 
CYP2B6*1/*1, *1/*6 and *6/*6 genotypes (n=5 HLMs for each genotype) and a 
NADPH-generating system at 37°C for 15min in duplicate. Kinetic parameters for the 
formation of 8-hydroxyefavirenz were estimated by fitting the velocity versus efavirenz 
concentrations to the simple single-site Michaelis-Menten equation. Kinetic parameters in 
the individual HLM samples are presented. In vitro Clint was calculated as Vmax/Km. 
Kinetic parameters (Vmax, Km and Clint) are presented as mean ± S.D. calculated from 
values of individual HLMs carrying the same genotype.  
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3. Discussion 
In this section, I explored the hypothesis that altered substrate binding and/or 
catalytic properties by the CYP2B6*6 allele may contribute to reduced efavirenz 
metabolism. Data presented in this chapter have shown that the CYP2B6*6 allele is 
associated with increased efavirenz Km and decreased Clint in expressed CYP2B6 proteins 
and similar trend is also observed in HLMs. These data suggest that the mechanism by 
which the CYP2B6*6 allele is associated with reduced efavirenz metabolism may be in 
part due to amino acid changes that modify catalytic properties of the variant versus wild 
type protein.  
Consistent with previous reports in various expressed systems (Ariyoshi et al., 
2001; Jinno et al., 2003; Bumpus et al., 2006; Raccor et al., 2012), we noted that the Vmax 
values for the formation of 8-hydroxyefavirenz significantly higher in CYP2B6.6 than in 
CYP2B6.1 proteins expressed without Cyt b5. However, Vmax values for the formation of 
8-hydroxyefavirenz were substantially decreased (by 70%) in HLMs with 
CYP2B6*6/*6 genotype versus HLMs with CYP2B6*1/*6 and CYP2B6*1/*1 genotypes. 
Our interpretation is that the expressed variant protein inherently increases catalytic 
activity of efavirenz, whereas the decreased Vmax value in HLMs is probably mainly due 
to reduced protein expression by the CYP2B6*6/*6 genotype (Hesse et al., 2004; Desta et 
al., 2007; Hofmann et al., 2008). The average Km value for the formation of 8-
hydroxyefavirenz in CYP2B6.6 protein expressed without Cyt b5 was increased by 175% 
and in HLMs with CYP2B6*6/*6 genotype was also increased by 58% and 114% than in 
HLMs with CYP2B6*1/*6 and CYP2B6*1/*1 genotypes, respectively. These data concur 
with a recent report (Zhang et al., 2011b). However, since some Km values derived from 
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HLMs with *1/*1 and *1/*6 were outliers and may have skewed the average data, these 
data should be interpreted with caution. 
A series of endeavors have been made by Dr. Halpert’s group to elucidate how 
the two SNPs (K262R and Q172H) harbored in the CYP2B6*6 allele alter binding 
affinity and/or catalytic efficiency of the enzyme (Gay et al., 2010; Shah et al., 2011). 
Considering that the two amino acid mutations are not within the active site of the 
enzyme, it is very likely that they involve in the ligand binding and substrate catalysis 
indirectly. Indeed, a recent publication characterizing the crystal structure of CYP2B6 
genetic variant (Y226H, K262R) indicates that the side chain of residue 172 may interact 
with the residues at active site and thus could affect the orientation of active site residues 
on the I-helix and substrate binding affinity (Gay et al., 2010; Shah et al., 2011). It is 
noteworthy that the other mutated amino acid carried by CYP2B6*6 allele, K262R, is 
located at the G/H loop and is part of a small hydrogen-bonding network (Gay et al., 
2010). The concerted movement of the G and H helices, which could be affected by this 
hydrogen-bonding network, may influence the orientation of active site residues on the G 
helix (Gay et al., 2010). In addition, part region of G helix forms substrate recognition 
sequence and substrate egress channels, which may both affect substrate specificity 
(Cojocaru et al., 2007). Indeed, substrate-dependent effects of the CYP2B6*6 allele on 
pharmacokinetics have been observed in vivo. In vivo, the CYP2B6*6/*6 genotype is 
associated with 3-fold increase in efavirenz exposure compared with CYP2B6*1/*1 
genotype (Rotger et al., 2007), but its effect on plasma exposure of bupropion or 4-
hydroxybupropion was marginal (Kirchheiner et al., 2003) and its effect on exposure of 
cyclophosphamide was opposite (Nakajima et al., 2007). Hence, I hypothesize that the 
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functional consequences of the CYP2B6*6 allele may be substrate-dependent. I next 
tested this hypothesis in Chapter IV by determining the catalytic properties of CYP2B6 
using another traditional in vitro substrate, bupropion, in expressed CYP2B6 and HLMs 
genotyped for the CYP2B6*6 allele.  
K262R may also involve in the interaction between the enzyme and its redox 
partner, CYP reductase (Bumpus and Hollenberg, 2008; Gay et al., 2010). The oxidation 
reaction catalyzed by CYPs requires transferring of two electrons from NADPH. The first 
electron is generally thought to be transferred by CYP reductase, while the second can be 
transferred by either CYP reductase or Cyt b5. That altered electron transfer from CYP 
reductase to CYP2B6 variant proteins may influence substrate metabolism was suggested 
by a recent study (Zhang et al., 2011b). It is, therefore, reasonable to suggest that amino 
acid changes may influence the interaction between the CYPs and electron transfer 
proteins and thus alter the catalysis of substrates in Cyt b5- and substrate-dependent 
manner. I tested this hypothesis in Chapter V by determining the catalytic properties of 
CYP2B6 using efavirenz and bupropion in expressed CYP2B6 with coexpression of Cyt 
b5. 
In summary, the results presented in this section of my dissertation provide in 
vitro evidence that amino acid changes harbored in the CYP2B6*6 allele alter efavirenz 
binding and catalytic efficiency, and therefore may contribute to efavirenz reduced 
metabolism in individuals with the CYP2B6*6/*6 genotype. Specifically, I showed the 
significantly higher Vmax and Km values for 8-hydroxyefavirenz formation and ~2-fold 
lower Clint in expressed CYP2B6.6 protein compared with that of CYP2B6.1 protein. In 
HLMs, CYP2B6*6/*6 genotype was associated with markedly lower Vmax (and moderate 
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increase in Km) and thus lower Clint values for efavirenz metabolism, but no difference in 
catalytic properties was noted between CYP2B6*1/*1 and CYP2B6*1/*6 genotypes. 
Having determined the functional consequences of the CYP2B6*6 allele using efavirenz 
as substrate, I further explore whether the functional consequences of this genetic variant 
is substrate- and Cyt b5-dependent.  
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CHAPTER IV: Substrate-dependent effects on the functional consequences of the 
CYP2B6*6 allele 
1. Introduction 
A number of in vitro studies, mostly in expressed systems, have reported that the 
CYP2B6*6 allele or the amino acids harbored in it influence catalytic properties. 
However, the extent and direction of effect appears to depend on the substrate and the 
enzyme sources used (Table 4.1). It is noteworthy that two recent papers reported the 
altered catalytic properties of CYP2B6 using bupropion and efavirenz by the CYP2B6*6 
allele (Ariyoshi et al., 2011; Zhang et al., 2011b). However, the interesting findings by 
Dr. Zhang’s group should be interpreted with caution, since the N-terminally truncated 
CYP2B6 protein used in their studies had marked reduced Km for bupropion compared 
with that of HLMs (Zanger et al., 2007). In addition, the effects of enzyme source on the 
kinetics also been shown for other CYP isoforms previously (Kumar et al., 2006a; 
Kaspera et al., 2011). Therefore, further study in native CYP2B6 enzyme using different 
expression sources is warranted.       
In this section I tested the hypothesis that the functional consequences of the 
CYP2B6*6 allele may be substrate-dependent. I determined the kinetics of bupropion 
metabolism to 4-hydroxybupropion in expressed CYP2B6.1 and CYP2B6.6 as well as 
HLMs obtained from liver tissues genotyped for the CYP2B6*6 allele. The changes of 
catalytic properties of CYP2B6 using bupropion are compared to that obtained using 
efavirenz as a substrate (presented in the Chapter III).
  
 
 
9
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Table 4.1 Substrate-specific changes in function consequences of the CYP2B6*6 allele 
Substrate % change of 
Vmax   
% change of Km 
 
% change of 
Clint 
Expressed 
System 
Reference 
7-EFC 162.1% 40.2% 88.7%  COS-1 cells  (Jinno et al., 2003) 
7-EFC 41.7%  91.7%  30.8%  E. coli cells (Zhang et al., 2011b) 
Cyclophosphamide 1.4% 39.6% 64.3%  Sf9 insect cells (Ariyoshi et al., 
2011) 
Cyclophosphamide 55.2%  11.1% 40.1%  E. coli cells (Raccor et al., 2012) 
Bupropion 75.0% 300%  56.9%  E. coli cells (Zhang et al., 2011b) 
Efavirenz 19.1% 61.0% 50%  Sf9 insect cells (Ariyoshi et al., 
2011) 
Efavirenz 462.5%  2712.3%  80.0%  E. coli cells (Zhang et al., 2011a) 
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Artemether 316.7%  116.8%  92.0%  COS-7 cells (Honda et al., 2011) 
7-EFC, 7-hydroxy-4-trifluoromethylcoumarin 
Wild type Vmax, Km, Clint = 100%
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2. Results 
2.1 Bupropion 4-hydroxylation by CYP2B6.1 and CYP2B6.6 proteins without 
coexpression of Cyt b5 
To determine whether the CYP2B6*6 allele alters binding affinity and/or catalytic 
efficiency in a substrate-dependent manner, I characterized catalytic properties of 
expressed CYP2B6.1 and CYP2B6.6 using bupropion as a probe (see Chapter II-2.1 
and II-3.1 for Methods). The kinetic profiles for the formation of 4-hydroxybupropion 
from bupropion in these proteins are depicted in Figure 4.1. The kinetic parameters 
estimated are summarized in Table 4.2. As shown in Figure 4.1 and Table 4.2, Vmax value 
for the formation of 4-hydroxybupropion in the CYP2B6.6 protein was significantly 
higher than that estimated from CYP2B6.1 protein, whereas there was no statistically 
significant difference in the Km values between the variant and the wild type proteins. 
Accordingly, the Clint for the formation of 4-hydroxybupropion was significantly 
increased in the CYP2B6.6 protein compared to that of the CYP2B6.1 protein (Table 
4.2). 
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Figure 4.1 Bupropion concentrations versus formation rate of 4-hydroxybupropion 
in microsomes containing cDNA-expressed CYP2B6.1 and CYP2B6.6 without 
coexpression of Cyt b5. Bupropion (10 - 1000 µM) was incubated with reconstituted 
systems containing either CYP2B6.1 or CYP2B6.6 (15 pmol) and a NADPH-generating 
system for 15 min at 37°C. Formation rate of 4-hydroxybupropion (pmol/min/pmol CYP) 
versus substrate concentrations were fit to the simple single-site Michaelis-Menten 
equation. Each point represents mean ± S.D. of three replicates. The curve represents the 
line of best fit. 
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Table 4.2 Kinetic parameters for the formation of 4-hydroxybupropion from 
bupropion in expressed CYP2B6.1 and CYP2B6.6 without coexpression of Cyt b5.  
 CYP2B6.1(-b5) CYP2B6.6 (-b5) 
Bupropion 4-Hydroxylation   
Vmax (pmol/min/pmol) 13.37 ± 0.97 18.55 ± 0.82** 
Km (µM) 64.2 ± 13.4 62.6 ± 7.3 
Clint (µl/min/pmol) 0.21 ± 0.03 0.30 ± 0.03** 
Kinetic data are presented as mean ± S.D. (n=3 incubation were performed in duplicate). 
In vitro Clint was calculated as Vmax/Km. Kinetic parameters for the formation of 4-
hydroxybupropion were estimated by fitting the velocity versus substrate concentrations 
to the simple single-site Michaelis-Menten equation. * p < 0.05, **p < 0.01, ***p < 0.001 
compared CYP2B6.6 to CYP2B6.1. 
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2.2 Bupropion 4-hydroxylation in HLMs genotyped for the CYP2B6*6 allele 
Kinetic analyses for the formation of 4-hydroxybupropion were also performed in 
the same 15 HLM samples that were used for the characterization of efavirenz 
metabolism. In Figure 4.2, bupropion concentrations versus formation rate of 4-
hydroxybupropion in the different genotypes are shown. Formation rates of 4-
hydroxybupropion versus bupropion concentrations were fit into a Michaelis-Menten 
equation to estimate kinetic parameters. The mean ± S.D. of these parameters for each 
genotype are listed in Table 4.3. The kinetic parameters for individual HLM are 
summarized in the Table 4.4. Similar to that observed for the kinetics of 8-
hydroxyefavirenz, the values of Vmax and Clint for the formation of 4-hydroxybupropion 
in HLMs also exhibited a large variability. HLMs with CYP2B6*1/*1 and *1/*6 
genotypes showed higher variability (CV of more than 100%) than that in HLMs with 
*6/*6 (CV of about 60% and 65%, respectively). The average Vmax values for the 
formation of 4-hydroxybupropion were also much lower in HLMs with CYP2B6*6/*6 
genotype than that in wild type and heterozygotes. The HLMs with CYP2B6*1/*1 
exhibited lower average Km values compared with HLMs with CYP2B6*1/*6 and *6/*6, 
although this difference didn’t reach statistical significance (Table 4.3). The Clint in 
CYP2B6*6/*6 genotype was decreased by over 95% when compared with CYP2B6*1/*1 
and CYP2B6*1/*6 (Table 4.3). 
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Figure 4.2 Bupropion concentrations versus formation rate of 4-hydroxybupropion 
in 15 human liver microsomal samples with CYP2B6*1/*1, *1/*6 and *6/*6 
genotypes (n=5 HLMs for each genotype). Bupropion (10-1000µM) were incubated 
with human liver microsomal samples (0.25mg/ml) with CYP2B6*1/*1, *1/*6 and *6/*6 
genotypes (n=5 HLMs for each genotype) and a NADPH-generating system for 15 min at 
37°C in duplicate. The formation rate of 4-hydroxybupropion (pmol/min/mg protein) 
versus substrate concentrations were fit to the simple single-site Michaelis-Menten 
equation. Each point represented as the average of five individual incubations in human 
liver microsomal samples with the same CYP2B6 genotype. The curve represents the line 
of best fit. 
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Table 4.3 Kinetic parameters (mean ± S.D.) for the formation of 4-
hydroxybupropion from bupropion in 15 human liver microsomal samples with 
CYP2B6*1/*1, *1/*6 and *6/*6 genotypes (n=5 HLMs for each genotype).  
 
HLMs 
4-Hydroxybupropion 
Vmax (pmol/min/mg 
protein) 
Km (µM) Clint (µl/min/mg protein) 
CYP2B6*1/*1 492.8 ± 427.9 86.0 ± 75.7 18.8 ± 26.3 
CYP2B6*1/*6 441.6 ± 583.0 212.1 ± 221.1 21.8 ± 44.2 
CYP2B6*6/*6 112.9 ± 66.7 204.2 ± 66.1 0.6 ± 0.5 
 Bupropion (10-1000µM) were incubated with HLM samples (0.25mg/ml) with 
CYP2B6*1/*1, *1/*6 and *6/*6 genotypes (n=5 HLMs for each genotype) and a 
NADPH-generating system at 37°C for 15min in duplicate. Kinetic parameters (Vmax and 
Km) for the formation of 4-hydroxybupropion were estimated by fitting the velocity 
versus bupropion concentrations to the simple single-site Michaelis-Menten. In vitro Clint 
was calculated as Vmax/Km. The kinetic parameters (Vmax, Km and Clint) for each genotype 
group are listed in the Supplemental Table 2. The data presented here are mean ±S.D. 
calculated from 5 individual HLMs values for each genotype. 
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Table 4.4 Individual kinetic parameters for the formation of 4-hydroxybupropion 
from bupropion in 15 HLM samples with CYP2B6*1/*1, *1/*6 and *6/*6 genotypes 
(n=5 HLMs for each genotype).  
 
HLMs 
4-Hydroxybupropion 
Vmax 
(pmol/min/mg 
protein) 
Km (µM) Clint (µl/min/mg protein) 
CYP2B6*1/*1 
HL-U 342.3 92.3 3.7 
HL-M 207.0 90.0 2.3 
HL-P 564.4 22.5 25.1 
HH-689 147.7 205.9 0.7 
MCV-65 1202.7 19.3 62.4 
Mean ± S.D. 492.8 ± 427.9 86.0 ± 75.7 18.8 ± 26.3 
CYP2B6*1/*6 
HL-S 329.9 48.2 6.9 
HL-C 201.9 264.0 0.8 
HL-O 1471.0 14.6 100.6 
MCV-49 88.7 168.0 0.5 
HH-488 116.6 565.7 0.2 
Mean ± S.D. 441.6 ± 583.0 212.9 ± 221.1 21.8 ± 44.2 
CYP2B6*6/*6 
HL-K 81.5 211.6 0.4 
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HH-1180 187.4 188.5 1.0 
IIAM-091698-1 85.4 161.5 0.5 
HH-525 177.3 145.7 1.2 
HH-478 33.1 313.5 0.1 
Mean ± S.D. 112.9 ± 66.7 204.2 ± 66.1 0.6 ± 0.5 
Bupropion (10 - 1000µM) were incubated with HLM samples (0.25mg/ml) with 
CYP2B6*1/*1, *1/*6 and *6/*6 genotypes (n=5 HLMs for each genotype) and a 
NADPH-generating system at 37°C for 15min in duplicate. Kinetic parameters for the 
formation of 4-hydroxybupropion were estimated by fitting the velocity versus bupropion 
concentrations to the simple single-site Michaelis-Menten. In vitro Clint was calculated as 
Vmax/Km. Kinetic parameters (Vmax, Km and Clint) are presented as mean ± S.D. calculated 
from values of individual HLMs carrying the same genotype. 
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3. Discussion 
In this section, I explored the hypothesis that functional consequences of the 
CYP2B6*6 allele may be substrate-dependent. Data presented in this chapter have shown 
that the Vmax and Clint values for 4-hydroxybupropion formation were significantly higher 
in CYP2B6.6 than in CYP2B6.1 protein, with no difference in Km. These changes are 
different from that using efavirenz as a substrate, which is associated with significantly 
higher Vmax and Km values and thus lower Clint in CYP2B6.6 protein. In HLMs, 
CYP2B6*6/*6 genotype was associated with markedly lower Vmax (and moderate 
increase in Km) and thus lower Clint values for 4-hydroxybupropion formation similar to 
that observed in the formation kinetics of 8-hydroxyefavirenz. In addition, different 
effects of the CYP2B6*6 allele on the Km values for 4-hydroxybupropion formation were 
observed between the expressed system and HLMs. These data suggest that the 
CYP2B6*6 allele influences metabolic activity by altering substrate binding and catalytic 
activity in a substrate-dependent manner. The effects of the CYP2B6*6 allele on catalytic 
properties of CYP2B6 seem to be different in expressed protein compared to that in 
HLMs using bupropion.  
 The average Km value for the formation of 4-hydroxybupropion in CYP2B6.6 
protein did not differ from CYP2B6.1, while that for the formation of 8-hydroxyefavirenz 
in CYP2B6.6 protein was markedly increased by 175%. While the average Km value for 
the formation of 8-hydroxyefavirenz in HLMs with CYP2B6*6/*6 genotype was also 
increased by 58% and 114% than in HLMs with CYP2B6*1/*6 and CYP2B6*1/*1 
genotypes, respectively, only a slight increase in Km for bupropion 4-hydroxylation was 
noted in HLMs with *1/*6 or *6/*6 genotypes compared to HLMs with *1/*1 genotype. 
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These results suggest that the amino acid changes harbored in CYP2B6*6 allele may 
influence substrate binding with pronounced effect on efavirenz than bupropion. 
However, since some Km values derived from HLMs with *1/*1 and *1/*6 were outliers 
and may have skewed the average data, these data should be interpreted with caution. 
Our in vitro data concurs with clinical observations. In vivo, the CYP2B6*6/*6 
genotype is associated with >3-fold increase in efavirenz exposure compared to 
CYP2B6*1/*1 genotype (Rotger et al., 2007), but its effect on plasma exposure of 
bupropion or 4-hydroxybupropion was marginal (Kirchheiner et al., 2003). It is well 
recognized that variants in other CYPs, e.g. CYP2C8 and CYP2C9, that change amino 
acids affect metabolic activity in a substrate-dependent manner (Maekawa et al., 2009; 
Kaspera et al., 2011). However, the CYP2B6*6 allele seems unique in that its effect on 
catalytic activity is not only substrate-dependent but also results in opposite effects. This 
variant has been associated with enhanced cyclophosphamide metabolism in vitro (Xie et 
al., 2003; Ariyoshi et al., 2011; Raccor et al., 2012) and in vivo (Nakajima et al., 2007), 
which appears to be primarily driven by the significantly lower Km for cyclophosphamide 
4-hydroxylation in CYP2B6.6 than in CYP2B6.1 proteins (Ariyoshi et al., 2011). The 
CYP2B6*6 allele appears to alter substrate metabolism in two ways: by decreasing (e.g., 
cyclophosphamide) or increasing (e.g., efavirenz) substrate binding (present data; Zhang 
et al., 2011; Ariyoshi et al., 2011) probably due to changes in the three dimensional 
structures of the protein; and by reducing catalytic efficiency secondary to reduced 
protein expression (Desta et al., 2007; Hofmann et al., 2008). Overall, altered substrate 
binding and/or catalytic activity as a result of amino acid changes seem to play a critical 
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role in determining the substrate-dependent functional consequences of the CYP2B6*6 
allele.  
How the two SNPs (K262R and Q172H) harbored in the CYP2B6*6 allele that are 
not within the active site of the enzyme regulate the substrate specificity? It is noteworthy 
that one amino acid carried by CYP2B6*6 allele, K262R, is located at the G/H loop and is 
part of a small hydrogen-bonding network (Gay et al., 2010). The concerted movement of 
the G and H helices, which could be affected by this hydrogen-bonding network, could 
influence the orientation of active site residues on the G helix (Gay et al., 2010). In 
addition, part region of G helix forms substrate recognition sequence and substrate egress 
channels, which may both affect substrate specificity (Cojocaru et al., 2007). 
Data from the present study also implicate that the effects of the CYP2B6*6 allele 
on catalytic properties of CYP2B6 seem to be different in expressed protein compared to 
that in HLMs using bupropion. In HLMs with CYP2B6*6/*6 and CYP2B6*1/*6 
genotype, the average Km values for the formation of 4-hydroxybupropion was increased 
by 137% compared to that in HLMs with CYP2B6*1/*1 genotype, while there is no 
significant difference was noticed between the wild type and variant expressed proteins. 
The disconnect between the metabolism data generated from HLMs and expressed 
enzymes were observed in many other CYPs, e.g. CYP1A2, CYP2C8, CYP2C9, 
CYP2C19, CYP2D6 and CYP3A4 (Venkatakrishnan et al., 2000; Kumar et al., 2006a; 
Chen et al., 2011), but this is the first study that showed the differential magnitude of 
changes in catalytic properties by the genetic variant utilizing the two systems, i.e. 
expressed proteins and genotyped HLMs. This discrepancy can be attributed to intrinsic 
differences between the two in vitro systems including variability in intrinsic activity or 
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turnover number (activity per unit amount of P450 enzyme), differences in the expression 
levels of accessory proteins (primarily CYP reductase and Cyt b5), membrane lipid 
compositions, ionic strength of the in vitro incubation matrix and most importantly the 
abundance of the respective P450 isoforms (Crespi and Miller, 1999; Venkatakrishnan et 
al., 2000). When evaluating the kinetic differences between polymorphic variants, use of 
an expressed enzyme system is often a necessity because of the scarcity of donor material 
available from individual having the genetic variation of interest. Therefore, it is critical 
to determine how directly comparable an expressed enzyme system or a HLM system is 
to the human situation.  
In summary, data presented in this section of my dissertation provide in vitro 
evidence that functional consequences of the CYP2B6*6 allele may be substrate-
dependent. In addition, these data also show that the effects of the CYP2B6*6 allele on 
catalytic properties of CYP2B6 seem to be different in expressed protein compared to 
that in HLMs using bupropion. 
  
 106 
 
CHAPTER V: Cytochrome b5-dependent effects on the functional consequences of the 
CYP2B6*6 allele 
1. Introduction 
Cytochrome (Cyt) b5 is a 16.7-kDa hemoprotein found in the endoplasmic 
reticulum and mitochondrial membrane of hepatocytes. The membrane-bound form of 
Cyt b5 found in the endoplasmic reticulum is also referred to as microsomal Cyt b5 and 
can transfer electrons for a wide array of oxidative reactions catalyzed by CYPs. CYP-
mediated metabolism occurs via a catalytic cycle that involves several steps: 1) substrate 
binding; 2) one-electron addition to the substrate-P450 complex by CYP reductase; 3) 
oxygen binding to the ferrous P450; 4) transfer of a second electron by either CYP 
reductase or Cyt b5 and protonation of the resulting iron-peroxo anion intermediate; 5) 
cleavage of the O–O bond to generate H2O; 6) oxidation of the substrate; and 7) and 
release of product with subsequent regeneration of ferric P450 (Schlichting et al., 2000; 
Ortiz de Montellano and De Voss, 2002; Groves, 2003).  
Cyt b5 anchored by a C-terminal hydrophobic helix, interacts directly with the 
membrane-bound P450s and CYP reductase to alter the rate of P450 catalysis. The 
addition of Cyt b5 to mixture of P450s and CYP reductase results in varied effects on the 
activity of P450-mediated drug oxidation. It appears that Cyt b5 has a rather complex 
interaction with CYP, which is greatly influenced by the form of CYPs, as well as its 
substrate. As has been shown for CYP2C8 (Kaspera et al., 2011), CYP2C9 (Kumar et al., 
2006a) and probably many other CYPs (Venkatakrishnan et al., 2000), several factors 
inherent to specific enzyme sources that include differences in Cyt b5 contents may 
influence in vitro kinetic parameters and inhibition constants in a substrate-dependent 
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manner. Cyt b5 has been reported to activate several CYPs including CYP2B6 (Reed and 
Hollenberg, 2003; Jushchyshyn et al., 2005), but its influence on the catalytic properties 
of CYP2B6.6 protein has not been studied. Therefore, the purpose of the present study 
was to determine the influence of Cyt b5 on metabolic activities of expressed CYP2B6.1 
and CYP2B6.6 proteins. I tested the hypothesis that the functional consequence of the 
CYP2B6*6 allele may be Cyt b5-dependent. I determined the kinetics of efavirenz 
metabolism to 8-hydroxyefavirenz and bupropion metabolism to 4-hydroxybupropion in 
expressed CYP2B6.1 and CYP2B6 with the coexpression of Cyt b5. And the results are 
compared to that obtained from expressed CYP2B6 without coexpression of Cyt b5 
(presented in the Chapter III and Chapter IV). 
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2. Results 
To evaluate the potential effect of Cyt b5 on catalytic properties of the variant 
versus wild type protein, kinetic parameters for the formation of 8-hydroxyefavirenz and 
4-hydroxybupropion were determined in CYP2B6.1 and CYP2B6.6 proteins that were 
co-expressed with Cyt b5 and the results were compared with those data obtained from 
CYP2B6.1 and CYP2B6.6 proteins without coexpression of Cyt b5 (see Chapter II-2.1 
and II-3.1 for Methods). Kinetic profiles for the formation of 8-hydroxyefavirenz and 4-
hydroxybupropion in CYP2B6.1 and CYP2B6.6 proteins are shown in Figure 5.1. The 
corresponding kinetic parameters are summarized in Table 5.1. In contrast to the 
significant changes by the CYP2B6*6 allele observed in expressed system without co-
expression of Cyt b5, the Vmax value for the formation of 8-hydroxyefavirenz was not 
significantly different (p = 0.20) between CYP2B6.1 and CYP2B6.6 proteins co-
expressed with Cyt b5 (Figure 5.1A; Table 5.1). Although the Km value in CYP2B6.6 
protein was higher by 81% than that in the CYP2B6.1 protein and the Clint value was 
decreased by 43% consistent with the data obtained from system without Cyt b5 (Table 
5.1), the differences did not reach a statistically significant level (Figure 5.1A; Table 5.1) 
(p=0.059). When bupropion 4-hydroxylation was used as a reaction probe, a significantly 
lower Vmax value was observed in CYP2B6.6 protein compared to the value obtained 
from the CYP2B6.1 protein (Figure 5.2B; Table 5.1). The Km value was increased from 
90.6 µM in the CYP2B6.1 protein to 110.0 µM in the variant protein, but this did not 
reach a statistically significant difference (p = 0.27). A significant decrease in Clint was 
observed in the CYP2B6.6 protein compared with CYP2B6.1 protein. 
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As described above, the catalytic properties of CYP2B6 appeared to be genotype- 
and Cyt b5-dependent. To gain further insight regarding the differential effect of Cyt b5 
on CYP2B6.1 versus CYP2B6.6 protein, kinetic parameters for efavirenz 8-
hydroxylation and bupropion 4-hydroxylation obtained in the presence of Cyt b5 were 
compared with those values obtained in CYP proteins expressed without Cyt b5 (Table 
5.1). In the CYP2B6.1 protein, none of the kinetic parameters of efavirenz 8-
hydroxylation were significantly different compared to values obtained from CYP2B6.1 
protein without co-expression of Cyt b5. Whereas, co-expression of Cyt b5 with the 
CYP2B6.6 protein significantly decreased the Vmax value for the formation of 8-
hydroxyefavirenz compared to the value obtained from CYP2B6.6 protein without co-
expression of Cyt b5. However, since the Km value was also tended towards decrease in 
the CYP2B6.6 protein, the Clint value in the CYP2B6.6 protein co-expressed with Cyt b5 
was not significantly different than that  obtained from the CYP2B6.6 protein without 
Cyt b5 (Table 5.1). Similar to the findings with efavirenz 8-hydroxylation, differential 
effects of Cyt b5 on the catalytic properties of CYP2B6.1 and CYP2B6.6 were observed 
with bupropion 4-hydroxylation (Table 5.1). Compared to the CYP2B6.1 protein without 
Cyt b5, the CYP2B6.1 protein co-expressed with Cyt b5 exhibited modest increase in the 
Vmax and Km values for the formation of 4-hydroxybupropion, while the Clint tended 
towards decrease (Table 5.1). The presence of Cyt b5 with CYP2B6.6 protein decreased 
the Vmax value to 11.77 pmol/min/pmol P450 from 18.55 pmol/min/pmol P450 in the 
CYP2B6.6 protein without Cyt b5 (p=0.0002) A significant increase was observed in Km 
value of CYP2B6.6 protein co-expressed with Cyt b5 compared to that of CYP2B6.6 
protein co-expressed without Cyt b5. As a result, Clint for the formation of 4-
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hydroxybupropion was significantly decreased in CYP2B6.6 co-expressed with Cyt b5 
(Table 5.1). 
We recognized that recombinant protein systems have limitations, including 
differences in cofactor expression between variants and wild type or even between 
batches of the same protein. In the expressed enzymes used in this experiment, the 
amounts of Cyt b5 expressed in CYP2B6.1 and CYP2B6.6 proteins were slightly 
different (220 and 370 pmol/mg protein, respectively). However, we have observed 
substrate-dependent effects for the CYP2B6*6 allele in the presence of Cyt b5, i.e. no 
significant differences were found in Vmax and Km comparing CYP2B6.1 to CYP2B6.6 
using efavirenz as substrate, while Vmax was significantly lower in CYP2B6.6 using 
bupropion. These data suggest that expression differences in Cyt b5 do not seem to 
significantly contribute to the differences in kinetic parameters observed. 
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Figure 5.1 Efavirenz concentrations versus formation rate of 8-hydroxyefavirenz 
(A) and bupropion concentrations versus formation rate of 4-hydroxybupropion (B) 
in microsomes containing cDNA-expressed CYP2B6.1 and CYP2B6.6 with 
coexpression of Cyt b5. Efavirenz (1 - 200 µM) or bupropion (10 - 1000 µM) was 
incubated with reconstituted systems containing either CYP2B6.1 or CYP2B6.6 with 
coexpression of Cyt b5 (15 pmol) and a NADPH-generating system for 15 min at 37°C. 
The formation rate of 8-hydroxyefavirenz and 4-hydroxybupropion (pmol/min/pmol 
CYP) versus substrate concentrations were fit to the simple single-site Michaelis-Menten 
equation. Each point represents mean ± S.D. of three replicates. The curve represents the 
line of best fit. 
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Table 5.1 Kinetic parameters for the formation of 8-hydroxyefavirenz from efavirenz and 4-hydroxybupropion from 
bupropion in expressed CYP2B6.1 and CYP2B6.6 without and with co-expression of Cyt b5.  
  Without Cyt b5 With Cyt b5  p value (comparing with 
versus without b5) § 
  CYP2B6.1 CYP2B6.6 CYP2B6.1 CYP2B6.6 CYP2B6.1 CYP2B6.6 
Efavirenz 8-Hydroxylation        
        Vmax (pmol/min/pmol)  1.21 ± 0.15 1.61 ± 0.11** 1.02 ± 0.11 0.95 ± 0.02 0.14 0.00002 
Km (µM)  3.2 ± 1.0 8.8 ± 1.6*** 3.4 ± 0.6 6.2 ± 2.6 0.74 0.14 
    Clint (µl/min/pmol)  0.39 ± 0.08 0.19 ± 0.04** 0.30 ± 0.06 0.17 ± 0.07 0.18 0.69 
Bupropion 4-Hydroxylation        
      Vmax (pmol/min/pmol)  13.37 ± 0.97 18.55 ± 0.82** 15.18 ± 0.99 11.77 ± 1.46** 0.04 0.0002 
Km (µM)  64.2 ± 13.4 62.6 ± 7.3 90.6 ± 10.3 110.0 ± 29.8 0.02 0.02 
          Clint (µl/min/pmol)  0.21 ± 0.03 0.30 ± 0.03** 0.17 ± 0.02 0.11 ± 0.04* 0.07 0.0002 
Kinetic data are presented as mean ± S.D. (n=3 incubation were performed in duplicate). In vitro Clint was calculated as 
Vmax/Km. Kinetic parameters for the formation of 8-hydroxyefavirenz and 4-hydroxybupropion were estimated by fitting the 
velocity versus substrate concentrations to the simple single-site Michaelis-Menten equation.  
* p < 0.05, **p < 0.01, ***p < 0.001 compared CYP2B6.6 to CYP2B6.1 with co-expression of Cyt b5, respectively. §Kinetic 
parameters of CYP2B6.1 with and without Cyt b5 as well as CYP2B6.6 with and without Cyt b5 were also compared. 
 113 
 
3. Discussion 
In this section, I explored the hypothesis that functional consequences of the 
CYP2B6*6 allele may be Cyt b5-dependent. Data presented in this chapter have shown 
that Cyt b5 abolished the significant changes of kinetic parameters for the formation of 8-
hydroxyefavirenz by CYP2B6.6 compared to CYP2B6.1, while it reversed the genetic 
effect on the kinetic parameters for the formation of 4-hydroxybupropion. These data 
suggest that Cyt b5 affects catalytic properties in a genotype- and substrate-dependent 
manner and highlight the fact that interpretation of in vitro studies performed with 
expressed proteins may vary depending on the presence or absence of Cyt b5, substrate 
used and underlying genotype.  
The ability of Cyt b5 to influence CYP-mediated drug oxidation (increase, inhibit, 
or no effect) has been described for multiple CYPs (Schenkman and Jansson, 2003). The 
mechanisms by which Cyt b5 might alter substrate metabolism include: providing the 
second electron during the catalytic cycle of CYPs; interacting physically with CYPs and 
thus modifying conformation of the protein, which, in turn, influences interaction with 
the substrate or reductase; or by competing for same binding site with CYP reductase, 
thereby preventing reduction of ferric CYP and initiation of the catalytic cycle (Zhang et 
al., 2008). In this study, Cyt b5 had no impact on CYP2B6.1-catalyzed efavirenz 8-
hydroxylation. However, in sharp contrast to the results obtained from CYP2B6.6 
without Cyt b5, Vmax for efavirenz 8-hydroxylation was significantly reduced by Cyt b5 
(with no effect on Km) in CYP2B6.6 protein, effectively abolishing the genotype-
dependent effect observed in CYP2B6.6 protein expressed without Cyt b5. The kinetic 
properties were different for bupropion 4-hydroxylation. Cyt b5 significantly increased 
 114 
 
the Vmax and Km values for bupropion 4-hydroxylation in CYP2B6.1 protein compared to 
CYP2B6.1 without Cyt b5. In CYP2B6.6, the Km for bupropion 4-hydroxylation was 
significantly increased and Vmax was significantly reduced by Cyt b5, leading to marked 
reduction in Clint in the CYP2B6.6 protein (Table 5.1). For both substrates, CYP2B6.1 
exhibited similar or increased catalytic activities with coexpression of Cyt b5 compared 
to that without Cyt b5, whereas Cyt b5 significantly decreased Vmax values in CYP2B6.6. 
These data suggest an overlapping binding site between CYP reductase and Cyt b5 in 
CYP2B6.6 but probably not in CYP2B6.1. The possibility that the observed effect of Cyt 
b5 could be due to difference in the expression of Cyt b5 or POR among the genotypes 
cannot be excluded. In our study, the POR level was relatively lower in CYP2B6.6 with 
coexpression of Cyt b5 than that without coexpression of Cyt b5. Thus, the possibility 
that the lower expression of POR in the CYP2B6.6 protein may influence the magnitude 
of effect of Cyt b5 among the genotypes and substrates cannot be fully excluded. 
However, variation in kinetic parameters were observed even when the POR level was 
balanced between the variant and wild type protein (Ariyoshi et al., 2011; Zhang et al., 
2011b). However, POR is much less functionally variable in general population than 
hepatic drug-oxidation CYPs (Venkatakrishnan et al., 2000; Huang et al., 2004). 
Although some POR SNPs have been found to affect activities of CYP1A2, CYP2C8, 
CYP2C19 and CYP3A4, no POR SNP has been identified to significantly influence 
CYP2B6 activity up to date (Gomes et al., 2009). Therefore, we believe that the 
differences in kinetics we observed are most likely due to the effect of Cyt b5. Further 
studies are warranted to identify the mechanism underlying the substrate-dependent effect 
of Cyt b5 and to provide insight into the topology of the variant.  
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CHAPTER VI: Altered susceptibility to metabolic inhibition by the CYP2B6*6 allele 
1. Introduction 
I have shown that the CYP2B6*6 allele alters the catalytic properties of CYP2B6 
in a substrate- and Cyt b5-dependent manner in previous chapters (Chapter III, Chapter 
IV and Chapter V). It is likely that the same property of the variant that influences 
substrate metabolism also affects the susceptibility to inhibition. Indeed, it has been 
shown that amino acid substitutions, such as those found in the variant of CYP2B6*6 
allele, may alter the degree of susceptibility to competing metabolic inhibitors for certain 
CYP2B6 variants (Bumpus et al., 2006; Bumpus and Hollenberg, 2008; Talakad et al., 
2009). In addition, differential genotype-dependent inhibition by a battery of inhibitors 
has been reported for the CYP2C9*3 allele (Kumar et al., 2006b), as inhibition profile 
may be dependent on a specific inhibitor-substrate interaction with the CYP proteins. 
Therefore, I tested the hypothesis that the CYP2B6*6 allele is associated with 
altered susceptibility to metabolic inhibition. To test my hypothesis, I initially conducted 
a pilot study where I determined IC50 values for two CYP2B6 inhibitors, clopidogrel 
(Richter et al., 2004) and voriconazole (Jeong et al., 2009) towards efavirenz 8-
hydroxylation in HLMs with CYP2B6*1/*1 and CYP2B6*6/*6. Next I determined 
inhibition constant (Ki) values for the formation of 8-hydroxyefavirenz by voriconazole 
in the HLMs with CYP2B6*1/*1, CYP2B6*1/*6 and CYP2B6*6/*6 genotype.  
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2. Results 
2.1 Determination of IC50 values for the inhibition of CYP2B6 by voriconazole and 
clopidogrel in HLMs with CYP2B6*1/*1 and CYP2B6*6/*6 genotype 
To test whether susceptibility to metabolic inhibitors differs between HLMs that 
carry the CYP2B6*6 allele and the wild type, inhibition potency of voriconazole and 
clopidogrel towards efavirenz 8-hydroxylation was determined in HLMs obtained from 
tissues genotyped for the CYP2B6*6 allele (see Chapter II-2.3 and II-5 for Methods). 
Inhibition of CYP2B6 by voriconazole and clopidogrel in HLMs with CYP2B6*1/*1 and 
CYP2B6*6/*6 is shown in Figure 6.1 A and B, respectively. IC50 values for voriconazole 
inhibition in HLMs with CYP2B6*1/*1 and CYP2B6*6/*6 were 0.40 and 0.16 µM, 
respectively. IC50 value for clopidogrel inhibition of efavirenz 8-hydroxylation in HLMs 
with CYP2B6*1/*1 (IC50= 0.14 µM) was also higher than that in HLMs with 
CYP2B6*6/*6 (IC50= 0.05 µM).  
2.2 Determination of Ki values for the inhibition of CYP2B6 by voriconazole in HLMs 
with CYP2B6*1/*1, CYP2B6*1/*6 and CYP2B6*6/*6 genotype 
I next determined Ki values for the inhibition on 8-hydroxylation of efavirenz by 
voriconazole in HLMs with CYP2B6*1/*1 (n=5), CYP2B6*1/*6 (n=6) and CYP2B6*6/*6 
(n=5) genotype (see Chapter II-2.3 and II-5 for Methods). The Ki values were 
determined here because the IC50 value could be influenced by the substrate 
concentration and other experimental conditions used. Representative Dixon plots for the 
inhibition of efavirenz 8-hydroxylation in the HLMs with *1/*1, *1/*6 and *6/*6 
genotypes are shown in Figure 6.2. The individual Ki values for the formation of 8-
hydroxyefavirenz by voriconazole in the 16 HLM samples are listed in the Table 6.1. As 
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shown in Figure 6.3, there was a statistically significant difference among the Ki values 
estimated from the three genotypes (p = 0.04). There was no significant difference 
between the Ki values estimated from CYP2B6*1/*6 (average Ki value = 1.55 µM) and 
CYP2B6*6/*6 (average Ki value = 1.64 µM) (p = 0.85). But the Ki values estimated from 
HLMs with CYP2B6*6/*6 (p = 0.04) and CYP2B6*1/*6 (p = 0.04) genotypes were both 
significantly lower than that estimated from CYP2B6*1/*1 genotype (average Ki value = 
3.03 µM) (Figure 6.3). When the data from HLMs with CYP2B6*6/*6 and CYP2B6*1/*6 
genotypes were combined and compared against HLMs with the CYP2B6*1/*1 genotype, 
the Ki values for the inhibition of efavirenz 8-hydroxylation by voriconazole in the HLMs 
with CYP2B6*1/*6 + *6/*6 genotypes was significantly lower (p = 0.009) than those 
observed in HLMs with CYP2B6*1/*1 genotype. 
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Figure 6.1 Inhibition of CYP2B6 by voriconazole (A) and clopidogrel (B) in HLMs 
with CYP2B6*1/*1 and CYP2B6*6/*6.  favirenz (10 μM) was incubated with HLMs 
(0.25 mg/ml) and the NADPH-generating system for 15 min without or with 
voriconazole (0 to 4 µM) and clopidogrel (0 to 2.5 µM). Each point represents the mean 
of duplicate. 
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Figure 6.2 Representative Dixon plots for the inhibition on 8-hydroxylation of 
efavirenz by voriconazole in HLMs with CYP2B6*1/*1 (A), CYP2B6*1/*6 (B) and 
CYP2B6*6/*6 (C). Efavirenz (10 to 100 µM) was incubated with HLMs (0.25 mg/ml; 
IU 5, IU 73 and HL-G) and the NADPH-generating system at 37°C for 15 min without or 
with voriconazole (0.1 to 10 µM). Each point represents the mean of duplicate. The line 
represents the best fit for the data. 
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Figure 6.3 The Ki values for the formation of 8-hydroxyefavirenz by voriconazole in 
the HLMs with CYP2B6*1/*1, CYP2B6 *1/*6 and *6/*6 genotype. The horizontal 
line indicates the median Ki value and the box covers the 25
th
 to 75
th
 percentiles. Dots 
represent the Ki values generated using each individual human liver microsomal samples. 
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Table 6.1 Individual Ki values for the formation of 8-hydroxyefavirenz by 
voriconazole in the 16 HLM samples with CYP2B6*1/*1, *1/*6 and *6/*6 genotypes. 
HLMs Genotype Ki (µM) 
IU-5 CYP2B6*1/*1 3.20 
IU-58 CYP2B6*1/*1 4.72 
IU-59 CYP2B6*1/*1 1.84 
IU-61 CYP2B6*1/*1 3.10 
HL-F CYP2B6*1/*1 2.29 
Mean ± S.D.  3.03 ± 1.10 
IU-31 CYP2B6*1/*6 1.15 
IU-33 CYP2B6*1/*6 0.81 
IU-65 CYP2B6*1/*6 2.89 
IU-73 CYP2B6*1/*6 0.58 
HL-E CYP2B6*1/*6 1.08 
HL-S CYP2B6*1/*6 2.76 
Mean ± S.D.  1.55 ± 1.01 
IU-6 CYP2B6*6/*6 1.92 
IU-42 CYP2B6*6/*6 2.28 
IU-84 CYP2B6*6/*6 1.06 
HL-K CYP2B6*6/*6 1.11 
HL-G CYP2B6*6/*6 1.85 
Mean ± S.D.  1.64 ± 0.54 
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3. Discussion 
In this section I explored the hypothesis that the CYP2B6*6 allele is associated 
with altered susceptibility to metabolic inhibition. Data presented in this chapter have 
shown that inhibition of efavirenz 8-hydroxylation by voriconazole was greater in HLMs 
with CYP2B6*6 allele (Ki = 1.6 ± 0.8 µM) than HLMs with CYP2B6*1/*1 genotype (Ki 
= 3.0 ± 1.1 µM). These data suggest that the CYP2B6 variant protein is more susceptible 
to metabolic inhibition than the wild type. This suggestion is further supported by our 
data using clopidogrel as an inhibitor (2.8-fold lower IC50). 
I have shown that the CYP2B6*6 allele alters the catalytic property of CYP2B6 in 
a substrate- and Cyt b5-dependent manner in previous chapters (Chapter III, Chapter 
IV and Chapter V). The same property of the variant that influences substrate 
metabolism seems also to confer susceptibility to inhibition. However, our data are in 
contrast to a previous study reporting decreased susceptibility of CYP2B6.6 protein to 
metabolic inhibition (Talakad et al., 2009). I speculate that several factors could 
contribute to this discrepancy, including the different type and composition of the 
proteins, substrates and inhibitors used in our study versus the other study. It has been 
shown that K262R, one of the amino acid mutations carried by the CYP2B6*6 allele, 
loses the mechanism-based inactivation by different CYP2B6 inhibitors (Bumpus et al., 
2006; Shebley and Hollenberg, 2007; Bumpus and Hollenberg, 2008). This alteration of 
inhibition profile by the variant allele has been suggested be related to the altered electron 
transfer and the addition of Cyt b5 can facilitate inactivation of the enzyme (Bumpus and 
Hollenberg, 2008). Previous studies have revealed the differences in the expression levels 
of Cyt b5 between the expressed CYP proteins and HLMs (Venkatakrishnan et al., 2000; 
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Huang et al., 2004). Therefore, it is very likely that the different amount of Cyt b5 in the 
two systems, i.e. expressed CYP2B6 protein in Talakad’s versus HLMs in ours, may 
result in the opposite changes observed for the inhibition susceptibility by the CYP2B6*6 
allele. The fact that the presence of Cyt b5 influences the alteration of catalytic properties 
by the CYP2B6*6 allele (see Chapter V) also lends more support to this notion. It is also 
worthwhile to note that the results generated in Talakad’s study using N-terminal 
modified CYP2B6 protein should be interpreted with caution, since altered catalytic 
properties of such kind of modified CYP2B6 protein have been reported before (Zanger 
et al., 2007). Different substrate probe reactions used in two studies, i.e. O-deethylation 
of 7-methoxy-4-(trifluoromethyl)coumarin, versus 8-hydroxylation of efavirenz, could 
also contribute to the discrepancy, because the evidence of substrate-dependent inhibition 
has been shown for a number of CYP isoforms, e.g. CYP3A4 (Kenworthy et al., 1999), 
CYP2C8 (VandenBrink et al., 2011a), CYP2C9 (Kumar et al., 2006b), CYP2C19 (Foti 
and Wahlstrom, 2008) and CYP2D6 (Vandenbrink et al., 2011b). We included 
clopidogrel as a CYP2B6 inhibitor in the present study, since it was used in Talakad’s 
study. In contrast to 6-fold increase in Ki with clopidogrel (Talakad et al., 2009), 2.8-fold 
lower IC50 was observed by the variant protein in the present study. However, clopidogrel 
is not a selective CYP2B6 inhibitor. It has been found to inhibit the activity of CYP2A6 
(Walsky and Obach, 2007) that appears to contribute to the overall clearance of efavirenz 
by being the sole catalyst of efavirenz 7-hydroxylation, a pathway that accounts on 
average for ~23% of efavirenz metabolism, and by participating (~20-30%) in efavirenz 
8-hydroxylation (Ogburn et al., 2010). Therefore, we further confirmed the greater 
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inhibition susceptibility by the variant protein using voriconazole as a CYP2B6 inhibitor, 
because it has marginal inhibition effect on CYP2A6 (Jeong et al., 2009). 
The phenomenon of genotype-dependent inhibition has also been reported for 
other polymorphic CYPs, e.g. CYP2C9, CYP2C19 and CYP2D6. In contrast to the 
increased susceptibility to inhibition by the CYP2B6 variant observed in the present 
study,  a greater degree of inhibition susceptibility of wild type CYP2C19 and CYP2D6 
enzyme compared with variant forms have been consistently observed in humans 
(Hamelin et al., 2000; Lessard et al., 2001; Lindh et al., 2003; Uno et al., 2006). The 
variant alleles of CYP2C19, as well as those of CYP2D6, in the above studies cause 
either a splicing defect or a frame shift resulting in either premature termination of 
translation or a truncated protein. Thus, the genotype-dependent inhibition results for 
CYP2C19 and CYP2D6 polymorphisms identified in those studies would be expected for 
those CYP isoforms, whose polymorphisms result in the expression of inactive proteins, 
such that no residual activity is present to be inhibited. But for CYPs whose variant is 
associated with reduced activity, e.g. CYP2B6.6 and CYP2C9.3, it is important to take 
both genotype and fraction metabolized by a given pathway when predicting genotype-
dependent drug-drug interaction (Kumar et al., 2008). 8-hydroxylation of efavirenz which 
is mainly mediated by CYP2B6 has been estimated to account for about 80% of total 
clearance of efavirenz independent of CYP2B6*6 genotype from in vitro metabolism data 
(estimation based on the formation kinetics of 7, 8-hydroxyefavirenz in HLMs with 
CYP2B6*1/*1, CYP2B6*1/*6 and CYP2B6*6/*6 genotype; formation kinetics of 8-
hydroxyefavirenz presented in Chapter III and formation kinetics of 7-hydroxyefavirenz 
presented in Chapter VII). Thus, the inhibition of CYP2B6 activity by other co-
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administered medications in the anti-HIV regimen may result in the disproportionately 
marked reduction of efavirenz metabolism in slow metabolizers but probably not in the 
extensive metabolizers. However, the prediction of the impact of genotype-dependent 
inhibition on efavirenz exposure is further complicated by its ability to induce its own 
metabolism (autoinduction) at steady state (Zhu et al., 2009). A clinical study is ongoing 
to evaluate the genotype-dependent inhibition by voriconazole on efavirenz 
pharmacokinetics in our laboratory. This knowledge is potentially clinically important 
because differential dosage adjustments may be needed in individuals with the 
CYP2B6*6 genotype compared with the more prevalent wild type-expressing individuals, 
when a known interacting drug is co-administered. 
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CHAPTER VII: CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation 
(IVIVE) of efavirenz clearance: comparison between models and enzyme preparations 
1. Introduction 
CYP2B6 plays a more important role than previously estimated in the metabolism 
of a growing list of drugs. It fully or partially metabolizes 8-13% of clinically important 
drugs (e.g., efavirenz, nevirapine, methadone, cyclophosphamide, ketamine, bupropion 
and propofol) as well as a long list of other xenobiotics of toxicological significance (Mo 
et al., 2009). Until recently, progress on the clinical relevance of this enzyme was 
hampered by the lack of selective and safe in vivo probes of its activity. Research on the 
clinical link between CYP2B6 metabolic status and drug disposition was accelerated 
subsequent to our demonstration of CYP2B6 as the main clearance mechanism of 
efavirenz (Ward et al., 2003). 8-Hydroxylation catalyzed predominantly by CYP2B6, 
with minor contributions from CYP1A2, CYP2A6 and CYP3A4/5, represents the main 
clearance pathway of efavirenz (Ward et al., 2003). CYP2A6-catalyzed 7-hydroxylation 
and UGT 2B7-mediated N-glucuronidation are minor metabolic pathways of the drug 
(Belanger et al., 2009; Ogburn et al., 2010; Cho et al., 2011). Emerging evidence suggest 
that the large interindividual variability in efavirenz exposure and clinical responses may 
be primarily attributed to the large variability in CYP2B6 protein expression (20- to 280-
fold) and activity (25- to 100-fold) among human livers, in part due to extensive genetic 
polymorphisms in the CYP2B6 gene and non-genetic factors, e.g., induction and 
inhibition drug interactions (Zanger et al., 2007). As described in Chapter III, the 
CYP2B6 gene is highly polymorphic and the CYP2B6*6 allele is by far the most frequent 
allele across populations and functionally relevant among all the variants (Zanger et al., 
 127 
 
2007). It is established that variants in the CYP2B6 gene, particularly the CYP2B6*6 
allele, are associated with efavirenz clearance (Tsuchiya et al., 2004; Rotger et al., 2007), 
CNS side effects (Haas et al., 2004), hepatic toxicity (Yimer et al., 2011), treatment 
discontinuation (Wyen et al., 2011), virological failure (Motsinger et al., 2006), and drug 
interactions (Ngaimisi et al., 2011). Thus, efavirenz is not only an in vitro and in vivo 
activity probe, but can also serve as a prototype model drug for evaluating the clinical 
relevance of CYP2B6 genetic polymorphisms. Other substrates for which CYP2B6 
metabolic status is a major determinant of the clearance, drug interaction and response 
and/or toxicity include nevirapine, methadone, cyclophosphamide, bupropion, ketamine, 
propofol and sibutramine (Zanger et al., 2007).  
Our previous study has shown an association between the CYP2B6*6 allele with 
reduced CYP2B6 amount in HLMs (Desta et al., 2007), probably due to the aberrant 
splicing of pre-mRNA of CYP2B6 (Lamba et al., 2003; Hofmann et al., 2008). We have 
shown this allele also influences metabolic activity by altering substrate binding and 
catalytic activity in vitro, an effect that was highly dependent on the enzyme source used 
(expressed versus HLMs) in Chapter III. Taking all these findings together, the reduced 
efavirenz metabolism in individuals with the CYP2B6*6/*6 genotype may be due to both 
reduced protein expression and altered binding affinity and catalytic efficiency. In order 
to test whether the mechanism that identified in vitro also applies to in vivo, I explored 
the hypothesis that the incorporation of in vitro efavirenz metabolism data predicts 
genetic effect of the CYP2B6*6 allele on efavirenz pharmacokinetics by in vitro-in vivo 
extrapolation (IVIVE) in the present chapter.  
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Often, in vitro-in vivo extrapolation (IVIVE) is a well accepted and cost effective 
approach to quantitatively predict human drug metabolism in vivo, potential for 
metabolism-mediated drug interactions and genotype-phenotype associations in both 
industry and academic research. However, its success depends on the use of relevant in 
vitro systems that accurately and reliably generate high quality kinetic parameters as well 
as the selection of appropriate models for prediction. Several conventional modeling 
approaches have been used in the IVIVE. The well-stirred liver model (Obach, 1999; Ito 
and Houston, 2005) is probably the most widely employed liver model to predict average 
metabolic clearance with some success (Rowland et al., 2011). However, this model has 
limitations, particularly when attempts to predict inter-subject variability in drug 
exposure are made. In contrast to the well-stirred liver model, physiologically-based 
pharmacokinetic (PBPK) modeling can be utilized to predict the full time-concentration 
profile, the complexities of oral drug absorption, and likely the inter-individual variability 
in pharmacokinetics (Rowland et al., 2011). PBPK models divide the body into 
anatomically and physiologically meaningful compartments connected by the circulatory 
system, using system-specific parameters to describe the absorption, distribution, 
metabolism, and elimination (ADME) processes. These physiological parameters are 
coupled with drug-specific data such as physicochemical parameters to predict the 
plasma and tissue concentration versus time profiles of a compound. 
The enzyme sources and their composition used may influence precise estimation 
of kinetic parameters. Enzyme sources that include hepatocytes, human liver fractions 
such as HLMs, and expressed enzymes are standard in vitro systems for IVIVE of drug 
clearance and potential drug interactions. Due to the limited availability of well-
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characterized HLMs and hepatocytes with specific genotype information, expressed 
CYP2B6 variant and wild type proteins are often employed to determine the influence of 
pharmacogenetics on substrate metabolism and interaction. However, our previous study 
and data from other investigators indicate that kinetic profiles of CYP2B6 substrates are 
highly affected by the enzyme sources used (Ariyoshi et al., 2011; Zhang et al., 2011a; 
Xu et al., 2012). The same is true, when the impact of genetics on the activity of other 
enzymes (e.g., CYP2C9 and CYP2C8) is evaluated (Kumar et al., 2006a; Kaspera et al., 
2011).  
Pharmacogenetics-based IVIVE of efavirenz pharmacokinetics may be further 
complicated not only by its large inter-individual variability (Csajka et al., 2003; Rotger 
et al., 2007) but also its ability to enhance its own metabolism (autoinduction) upon 
multiple doses (Zhu et al., 2009), probably through induction of CYP2B6 (Faucette et al., 
2007). The effect of efavirenz autoinduction on its exposure also appears to be CYP2B6 
genotype-dependent (Ngaimisi et al., 2011). To exclude these confounding variables at 
steady state, prediction of efavirenz pharmacokinetics following a standard 600 mg oral 
dose should first be established. 
In the present study, we have used rich in vitro efavirenz kinetic data set 
generated under the same experimental conditions from expressed CYP2B6.1 and 
CYP2B6.6 proteins as well as HLMs derived from liver tissues genotyped for the 
CYP2B6*6 allele to: 1) predict efavirenz exposure after a single 600 mg oral dose of 
efavirenz in healthy volunteers; 2) systematically evaluate which enzyme sources (HLMs 
versus expressed CYP2B6) may better predict efavirenz exposure; and 3) compare the 
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performance of PBPK and well-stirred liver model in the prediction of mean efavirenz 
clearance for individuals with CYP2B6*1/*1, *1/*6 and *6/*6 genotype.  
2. Results 
2.1 In vitro metabolism data of efavirenz 
In two HLMs (HH-488, a *1/*6 carrier; and HH-478, a *6/*6 carrier), incubation 
of efavirenz did not produce quantifiable 7-hydroxyefavirenz (Table 7.1). Kinetics for the 
formation of 7-hydroxyefavirenz were determined in the rest of HLMs. Formation rates 
of 7-hydroxyefavirenz versus efavirenz concentrations were fit into a simple single-site 
Michaelis-Menten equation to estimate kinetic parameters (Vmax and Km) for individual 
HLM. The mean Clint of 7-hydroxylation calculated from individual HLM with the same 
genotype are shown in Table 2.2 (Materials and Method). The Clint values for the 
formation of  8-hydroxyefavirenz in expressed CYP2B6 and HLMs were reported in our 
recent publication and used in the present simulation (Xu et al., 2012). 
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Table 7.1 Kinetic parameters for the formation of 7-hydroxyefavirenz from 
efavirenz in 15 HLM samples with CYP2B6*1/*1, *1/*6 and *6/*6 genotypes (n=5 
HLMs for each genotype). 
HLMs 7-Hydroxyefavirenz 
       Vmax          Km     Clint 
CYP2B6*1*1    
HL-U 27.67 43.32 0.64 
HL-M 14.89 19.32 0.77 
HL-P 11.85 12.39 0.96 
HH-689 6.18 11.66 0.53 
MCV-65 20.15 7.30 2.76 
Mean 16.15 18.80 1.13 
S.D. 8.19 14.39 0.92 
CYP2B6*1/*6    
HL-S 79.21 19.24 4.12 
HL-C 4.13 16.01 0.26 
HL-O 49.36 66.94 0.74 
MCV-49 9.52 10.92 0.87 
HH-488 ND ND ND 
Mean 35.56 28.28 1.50 
S.D. 35.41 26.00 1.77 
CYP2B6*6/*6    
HL-K 38.13 41.84 0.91 
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HH-1180 27.06 11.00 2.46 
IIAM-091698-1 8.09 22.17 0.36 
HH-525 8.99 7.22 1.25 
HH-478 ND ND ND 
Mean 20.57 20.56 1.25 
S.D. 14.61 15.54 0.89 
Increasing concentrations of efavirenz (1 - 200µM) were incubated with HLM samples 
(0.25mg/ml) with CYP2B6*1/*1, *1/*6 and *6/*6 genotypes (n=5 HLMs for each 
genotype) and a NADPH-generating system at 37°C for 15min in duplicate. Kinetic 
parameters for the formation of 7-hydroxyefavirenz were estimated by fitting the velocity 
versus efavirenz concentrations to the simple single-site Michaelis-Menten equation. 
Kinetic parameters in the individual HLM samples are presented. In vitro Clint was 
calculated as Vmax/Km. Vmax, pmol/min/mg protein; Km, µM; Clint, µl/min/mg protein. 
ND: not detected. 
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2.2 Efavirenz pharmacokinetics 
The pharmacokinetic parameters following a single 600 mg oral dose of efavirenz 
are summarized in Table 7.3 and are consistent with a previous study (Haas et al., 2009). 
The values for efavirenz CLpo of individuals with CYP2B6 wild type (n=8) and 
heterozygotes (n=9) were 8.5 (5
th
 to 95
th
 percentile: 5.4- 13.4) L/h and 8.3 (4.7-11.5) L/h, 
respectively. Correspondingly, the AUC0-∞ were 80.0 (45.3- 110.6) mg/L•h and 81.6 
(52.3- 132.8) mg/L•h, respectively. The efavirenz CLpo for individuals with 
CYP2B6*6/*6 (n=3) was 5.9 (5.6-6.4) L/h and the AUC0-∞ was 101.7 (93.9- 106.4) 
mg/L•h. Although the difference in the values of CLpo between individuals with 
CYP2B6*1/*1 & *1/*6 and CYP2B6*6/*6 did not reach statistical significance (p= 0.23) 
probably mainly due to the small size of the study, it was associated with 30% reduction 
in CLpo and 27% increase in AUC0-∞ of homozygtes compared with wild type. 
2.3 Prediction of efavirenz single oral dose pharmacokinetics using HLM Clint by PBPK 
Modeling 
Compartmental absorption transit (CAT) model with a full PBPK model fitted 
efavirenz time-concentration profile best based on visual predictive checks and therefore 
were selected to perform simulations in the present study. The simulated versus observed 
efavirenz pharmacokinetics of individuals with CYP2B6*1/*1, *1/*6 and *6/*6 using in 
vitro Clint determined in HLMs with corresponding genotypes are shown in Figure 7.1. 
The corresponding observed and Simcyp-simulated pharmacokinetic parameters are 
summarized in Table 7.2. For individuals with CYP2B6*1/*1 genotype, Simcyp-
predicted values of Cmax, Tmax, AUC 0-∞ and CLpo were in good agreement with observed 
values (Table 7.2). For individuals with CYP2B6*1/*1 genotype, predicted mean values 
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of Cmax, Tmax, AUC0-∞ and CLpo were in good agreement with observed values (Table 
7.2). However, the PBPK model under-predicted efavirenz CLpo for individuals with 
CYP2B6*1/*6 genotype [simulated: 4.7± 3.2 L/h versus observed: 8.3± 2.8 L/h] and 
*6/*6 [simulated: 2.2± 1.4 L/h versus observed: 5.9± 0.5 L/h] using HLM data. The 
predicted mean of CLpo for individuals with CYP2B6*1/*6 and CYP2B6*6/*6 was 43% 
and 63% lower than that obtained from the clinical trial, respectively. Accordingly, the 
predicted mean AUC 0-∞ for individuals with CYP2B6*1/*6 and CYP2B6*6/*6 genotypes 
was 103.2% and 200.0% higher than the observed values. Individuals with CYP2B6*6/*6 
genotype were predicted to have a 74% reduction in mean CLpo compared to individuals 
with CYP2B6*1/*1 genotype, while a smaller extent of reduction (~30%) was observed 
in the clinical trial.  
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Figure 7.1 Observed  and PBPK-predicted efavirenz  (EFV) concentration-time 
profile after a single 600 mg oral dose of efavirenz in individuals with CYP2B6*1/*1 
(A), CYP2B6*1/*6 (B) and CYP2B6*6/*6  (C) genotypes using in vitro Clint 
determined in HLMs obtained from liver tissues with corresponding CYP2B6*6 
genotypes. Symbols represent the observed efavirenz plasma concentrations (0-72 h) 
from healthy volunteers after a single 600 mg oral dose of efavirenz with CYP2B6*1/*1 
(n=8), CYP2B6*1/*6 (n=9) and CYP2B6*6/*6 (n=3) genotypes. The solid line represent 
the mean of simulated efavirenz plasma concentrations, while the dashed lines represent 
the 5
th
 and 95
th
 percentile of simulated efavirenz plasma concentrations. 20 trials were 
simulated for each genotype.  
  
 
1
3
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Table 7.2 Observed and simulated pharmacokinetic parameters for a single 600 mg oral dose of efavirenz in 20 healthy 
subjects by PBPK model (All the values are presented as mean±S.D.). 
  Pharmacokinetic Parameters 
  Tmax (h) Cmax (mg/L) AUC0-∞ (mg•h/L) CLpo (L/h) 
Observed CYP2B6*1/*1 (n=8) 2.3± 1.0  2.3± 0.7 79.8± 28.4 8.5± 3.4 
Predicted CYP2B6*1/*1 HLM 2.0 ± 0.4 1.8± 0.4 75.6± 43.1 8.5± 6.9 
Predicted CYP2B6.1(Simcyp) 2.0± 0.4 1.8± 0.4 175.1± 83.5  4.1± 2.2 
Predicted CYP2B6.1 (VISEF) 2.0± 0.4 1.8± 0.4 84.3± 57.2 9.8± 6.9 
Predicted CYP2B6.1 (CLISEF) 1.9±0.3 1.6± 0.4 39.0± 35.2 24.3± 20.8 
Observed CYP2B6*1/*6 (n=9) 2.6± 1.7 1.7± 0.5  81.6± 33.7 8.3± 2.8 
Predicted  CYP2B6*1/*6 HLM 2.1± 0.4  2.0± 0.3 165.8± 94.1 4.7± 3.2 
Observed CYP2B6*6/*6 (n=3) 2.7± 1.5 2.4± 0.2  101.7± 7.9 5.9± 0.5 
Predicted CYP2B6*6/*6 HLM 2.1± 0.4 2.2± 0.3 305.1± 135.8  2.2± 1.4 
Predicted CYP2B6.6 (Simcyp) 2.1± 0.4 1.9± 0.3  235.9± 98.8 2.8± 1.6 
Predicted CYP2B6.6 (VISEF) 2.0± 0.4 2.0± 0.4 136.0± 83.8  6.6± 6.4 
Predicted CYP2B6.6 (CLISEF) 2.0± 0.4 2.1± 0.4 183.7± 93.3 4.2±3.1 
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2.3 Predicted efavirenz single oral dose pharmacokinetics using expressed CYP2B6 Clint 
by PBPK Modeling 
The simulated versus observed efavirenz pharmacokinetics of individuals with 
CYP2B6*1/*1and CYP2B6*6/*6 using in vitro Clint determined in expressed CYP2B6.1 
and CYP2B6.6 are shown in Figure 7.2. The corresponding observed and Simcyp-
simulated pharmacokinetic parameters are summarized in Table 7.2. PBPK model 
predicted the mean values of Cmax and Tmax for individuals with CYP2B6*1/*1 and 
CYP2B6*6/*6 reasonably well. However, it under-predicted efavirenz mean CLpo for 
individuals with CYP2B6*1/*1 [simulated: 4.1± 2.2 versus observed:  8.5± 3.4 L/h and 
CYP2B6*6/*6 [simulated: 2.8± 1.6 L/h versus observed: 5.9± 0.5 L/h] (Table 7.2). The 
predicted mean of CLpo for individuals with CYP2B6*1/*1 and CYP2B6*6/*6 genotypes 
was 52% and 53% lower than that observed in the clinical trial, respectively. 
Accordingly, the predicted mean of AUC 0-∞ for individuals with CYP2B6*1/*1 and 
CYP2B6*6/*6 genotypes was 119.4% and 132.0% higher than that observed in the 
clinical trial, respectively. Individuals with CYP2B6*6/*6 genotype were predicted to 
have a 32% reduction in mean CLpo compared to individuals with CYP2B6*1/*1. 
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Figure 7.2 Observed and PBPK-predicted efavirenz  (EFV) concentration-time 
profile after a single 600 mg oral dose of efavirenz in individuals with CYP2B6*1/*1 
(A) and CYP2B6*6/*6  (B) genotypes using in vitro Clint generated from expressed 
CYP2B6.1 and CYP2B6.6 proteins. Symbols represent the observed efavirenz plasma 
concentrations (0-72 h) from healthy volunteers after a single 600 mg oral dose of 
efavirenz with CYP2B6*1/*1 (n=8) and CYP2B6*6/*6 (n=3) genotypes. The solid line 
represent the mean of simulated efavirenz plasma concentrations, while the dashed lines 
represent the 5
th
 and 95
th
 percentile of simulated efavirenz plasma concentrations. 20 
trials were simulated for each genotype. 
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2.4 Recalculation of ISEFs 
Previous study indicates that ISEF values may vary widely depending on CYP 
expression system, HLM preparations, probe substrate selected, and/or assay conditions 
used in each laboratory (Proctor et al., 2004). Thus, the under-prediction of CLpo using in 
vitro Clint in expressed CYP2B6 may indicate that the default settings of ISEFs for 
CYP2B6 in Simcyp may not apply to our system. Therefore, ISEFs of expressed 
CYP2B6.1 and CYP2B6.6 were calculated on the basis of Vmax and Clint estimated from 
the kinetics of bupropion 4-hydroxylation determined in the HLMs and expressed CYPs 
from our previous publication (Xu et al., 2012). The ISEF values determined on the basis 
of Vmax (VISEF) and Clint (CLISEF) for CY2B6 are shown in Table 7.3. For CYP2B6.1, 
the VISEF value was 1.9 and CLISEF value was 6.5. For CYP2B6.6, the VISEF value 
was 1.6 and CLISEF value was 0.9. The same simulations were performed as described 
above to evaluate the effect of different ISEF values on the prediction of efavirenz CLpo. 
The simulated key pharmacokinetic parameters are summarized in Table 7.2. The  
predicted population median, 5
th
 and 95
th
 percentile  (using Clint determined in expressed 
CYP2B6.1 and CYP2B6.6 correcting for Simcyp ISEF, recalculated VISEF and CLISEF) 
versus observed CLpo are shown in Figure 7.3. For expressed CYP2B6.1, the prediction 
using VISEF reasonably captured the observed values of efavirenz CLpo, while under-
prediction using Simcyp ISEFs and over-prediction using CLISEF were observed. For 
expressed CYP2B6.6, simulations using recalculated VISEF and CLISEF both improved 
the prediction of efavirenz CLpo for individuals with the CYP2B6*6/*6 genotype.  
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Table 7.3 Recalculation of ISEFs. 
 VISEF CLISEF Simcyp 
CYP2B6.1 1.9 6.5 0.43 
CYP2B6.6 1.6 0.9 NA 
VISEF: calculated on the basis of Vmax. 
CLISEF: calculated on the basis of Clint. 
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Figure 7.3 Observed and PBPK-predicted efavirenz oral clearance (CLpo) after a 
single 600 mg oral dose of efavirenz in individuals with CYP2B6*1/*1 and 
CYP2B6*6/*6 genotypes using in vitro Clint determined in expressed CYP2B6.1 and 
CYP2B6.6 correcting for different values of ISEFs. The simulations of CLpo were 
performed incorporating default values of ISEFs for expressed CYP2B6 and CYP2A6 
built in the Simcyp (Simcyp), ISEF determined on the basis of Vmax (VISEF) and Clint 
(CLISEF). Horizontal black lines represent the 95
th
 percentile, median and 5
th
 percentile 
of simulations. Horizontal red line represents the mean of simulations. Symbols represent 
CLpo estimated from pharmacokinetics observed in the individuals with CYP2B6*1/*1 
(n=8) and CYP2B6*6/*6 (n=3) in the clinical trial. 20 trials were simulated for each 
genotype.  
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2.5 Prediction of efavirenz CLpo by Well-stirred liver model 
The predicted efavirenz CLh of individuals with CYP2B6*1/*1, *1/*6 and *6/*6 
extrapolated from in vitro Clint determined in the HLMs with corresponding genotypes by 
well-stirred liver model are shown in Table 7.4. The predicted efavirenz CLh of 
individuals with CYP2B6*1/*1 and *6/*6 extrapolated from in vitro Clint determined in 
expressed CYP2B6.1 and CYP2B6.6 correcting for different ISEF values are also shown 
in Table 7.4. The predicted CLh extrapolated from Clint in HLMs and expressed enzymes 
with different ISEFs were compared with the observed mean CLpo of individuals carrying 
the same CYP2B6*6 genotype in clinical trial (Table 7.4). Predictions using expressed 
CYP2B6 corrected for CLISEFs by well-stirred liver model showed best prediction in 
terms of accuracy and variability. Predictions using Simcyp ISEFs were associated with 
largest variability and average fold error. Predictions using HLMs, Simcyp ISEFs and 
VISEFs all tended to underestimate efavirenz CLpo. 
2.6 Comparison of predictions by PBPK and Well-stirred liver model 
The performances of efavirenz CLpo and CLh prediction by PBPK and well-stirred 
liver model using HLM and expressed systems were evaluated by comparing predicted 
with observed mean efavirenz clearance (Table 7.4). Since IV formulation of efavirenz is 
not available, bioavailability of the drug is unknown. Thus, efavirenz CLh was predicted 
by well-stirred liver model and used for comparison in Table 7.4. Predictions using 
expressed CYP2B6 corrected for CLISEFs by PBPK model showed best prediction in 
terms of accuracy and variability. Predictions using Simcyp ISEFs were associated with 
largest variability and average fold error by well-stirred liver model. In general, PBPK 
model had better prediction of mean CLpo than well-stirred liver model with the 
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exception of that when Simcyp ISEFs were used. Well-stirred liver model had 
comparable prediction to Simcyp model when CLISEF was corrected for the expressed 
system. The tendency of over-prediction and/or under-prediction was the same by PBPK 
and well-stirred liver model except that when VISEFs were used. IVIVE using HLM data 
tended to underestimate efavirenz CLpo using both models.  
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Table 7.4 Prediction of efavirenz oral clearance (CLpo) and hepatic clearance (CLh) from in vitro data generated in 
expressed CYP2B6 and genotyped HLMs by PBPK and well-stirred liver model. 
  PBPK model  Well-stirred liver model 
  Predicted 
Mean 
CLpo 
RMSE MRS Average 
fold error 
 Predicted 
Mean CLh 
RMSE MRS Average 
fold 
error 
HLMs   3.0 -2.5 2.3   4.3 -4.2 4.1 
 CYP2B6*1/*1 8.5     5.8    
 CYP2B6*1/*6 4.7     3.0    
 CYP2B6*6/*6 2.1     1.4    
rhCYPs 
(Simcyp ISEF) 
  3.8 -3.8 3.2   5.5 -5.4 6.1 
 CYP2B6.1 4.1     2.2    
 CYP2B6.6 2.8     1.3    
rhCYPs 
(New  VISEF) 
  7.8 6.1 2.2   2.8 -2.7 2.5 
  
 
1
4
5 
 CYP2B6.1 16.3     6.7    
 CYP2B6.6 4.9     2.4    
rhCYPs 
(New CLISEF) 
  1.7 0.6 0.1   2.9 0.2 0.7 
 CYP2B6.1 9.0     11.5    
 CYP2B6.6 4.8     3.2    
Simcyp ISEF: Simcyp-default ISEF values. New VISEF: ISEF values determined on the basis of Vmax obtained from our 
study. New CLISEF: ISEF values determined on the basis of CLint obtained from our study. RMSE, MRS and average fold 
error were calculated by comparing the predicted efavirenz mean clearance using PBPK and well-stirred liver model to 
observed mean values. Since IV formulation of efavirenz is not available, bioavailability of the drug is unknown. Thus, 
efavirenz CLh was predicted by well-stirred liver model and used for comparison.
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3. Discussion 
In this section I explored the hypothesis that the incorporation of in vitro 
efavirenz metabolism data predicts genetic effect of the CYP2B6*6 allele on efavirenz 
pharmacokinetics by IVIVE. We have shown that 1) expressed CYP2B6 system has 
provided improved prediction of efavirenz clearance following a single dose compared to 
genotyped HLMs with more accuracy achieved by PBPK model than well-stirred liver 
model; 2) the most reliable predictions were achieved by recalculating ISEFs for 
CYP2B6.1 and CYP2B6.6 using metabolism data generated from expressed CYP2B6. 
These findings suggest that: 1) expressed CYP2B6 system seems superior to HLMs in 
pharmacogenetics-based IVIVE of drug clearance; 2) it may be critical to establish ISEFs 
for wild type and variant proteins when expressed enzymes are used for IVIVE; and 3) 
expressed CYP2B6 may be a reliable system to investigate the effect of CYP2B6*6 allele 
on metabolism of CYP2B6 substrates.  
HLMs and expressed CYPs are the most commonly utilized in vitro systems in 
predicting drug clearance during drug discovery and development. Generally, HLMs are 
considered to be more physiologically relevant than expressed system. However, its use 
is limited by the availability, variable quality of tissues and variability between donors 
(Hallifax et al., 2010). Indeed, there is a large viability in Clint and catalytic activity of 
efavirenz 8-hydroxylation determined in HLMs even within the same genotype (Desta et 
al., 2007; Xu et al., 2012). In our study, for the first time, we compared the utility of these 
two in vitro systems in pharmacogenetics-based IVIVE under the same experimental 
condition. Expressed CYP2B6 system using recalculated CLISEFs captured the mean 
values of efavirenz CLpo with better accuracy and less variability than HLMs (Table 7.4). 
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Taking a closer look into the results, the wild type HLMs actually provided comparable 
prediction of efavirenz clearance for individuals with the CYP2B6*1/*1 genotype. The 
inferiority of HLMs in pharmacogenetics-based IVIVE is primarily due to its under-
prediction of efavirenz clearance for individuals with CYP2B6*1/*6 and *6/*6, which 
can be attributed to several factors. Firstly, altered binding affinity and catalytic 
efficiency secondary to reduced protein expression may both contribute to reduced 
efavirenz metabolism in HLMs with the CYP2B6*6/*6 genotype (Xu et al., 2012). The 
default unit of HLM Clint in Simcyp is normalized to mg microsomal protein. Simcyp 
default setting of CYP2B6 expression amount is 17 pmol/mg protein in CYP2B6 
extensive metabolizer (EM) versus 6 pmol/mg in CYP2B6 poor metabolizer (PM). Thus, 
additive effect of reduced protein expression by the CYP2B6*6 allele on catalytic 
efficiency and overall extrapolated Clint may lead to the under-prediction of efavirenz 
clearance in homozygote. Secondly, the mechanism by which the CYP2B6*6 allele 
influences the function of heterozygote is not fully understood. The under-prediction of 
efavirenz clearance in heterozygote is just expected regarding the discrepancy between in 
vitro and in vivo observed for several CYP2B6 substrates in heterozygote. Both CYP2B6 
expression and efavirenz metabolism are found to be reduced in HLMs with 
CYP2B6*1/*6 compared to wild type (Desta et al., 2007; Xu et al., 2012). However, the 
phenotypes of heterozygote and wild type are overlapping for a number of CYP2B6 
substrates including efavirenz, methadone and cyclophosphamide in vivo (Tsuchiya et al., 
2004; Crettol et al., 2005; Nakajima et al., 2007). Thirdly, only the CYP2B6*6 allele was 
genotyped in those human liver tissues where HLMs were prepared. Therefore, the 
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possibility that those liver samples also contain other unknown CYP2B6 genetic variants 
with reduced functions cannot be excluded.  
While genotyped HLMs have the aforementioned limitations and confounding 
factors, expressed system has been used for pharmacogenetics-based IVIVE of 
pharmacokinetics and/or pharmacodynamics for several polymorphic CYPs, e.g. 
CYP2C9 (Dickinson et al., 2007a; Kusama et al., 2009), CYP2D6 (Dickinson et al., 
2007b) and CYP2B6 (Siccardi et al., 2012). Despite the success in predicting phenotypes 
for wild type, very limited success was obtained for homozygote (Dickinson et al., 
2007b; Siccardi et al., 2012). We speculate that the over-prediction of efavirenz clearance 
for individuals carrying the CYP2B6*6/*6 genotype in the recent study by Siccardi et al. 
could be due to that the reduced efavirenz binding affinity and catalytic efficiency by the 
CYP2B6*6 allele was not taken into account in their model (Siccardi et al., 2012). The 
importance of considering functional changes by the CYP2B6 variants in 
pharmacogenetics-based IVIVE is further supported by the fact that not only reduced 
protein expression but also the altered catalytic properties may contribute to the altered 
substrate metabolism by the CYP2B6*6 allele in vitro (Jinno et al., 2003; Watanabe et al., 
2010; Ariyoshi et al., 2011; Zhang et al., 2011a; Xu et al., 2012). Furthermore, the 
present study that incorporated altered catalytic efficiency of CYP2B6.6 protein showed 
significantly improved prediction of efavirenz clearance for individuals with 
CYP2B6*6/*6 genotype. Therefore, it is essential to obtain a comprehensive 
understanding of the mechanisms by which the genetic variants alter substrate 
metabolisms and incorporate them into the modeling exercise for successes in 
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pharmacogenetics-based IVIVE of pharmacokinetics and/or pharmacodynamics for drugs 
metabolized by polymorphic CYPs.  
The initial under-prediction of efavirenz clearance using metabolism data 
generated from expressed CYP2B6 propels us to explore the possible in vitro factors that 
could contribute to the under-prediction, including unbound fraction in expressed 
CYP2B6 (fumic) and ISEFs, etc. Several predictive equations for fumic determined by drug 
lipophilicity and protein concentrations have been developed (Austin et al., 2002; 
Hallifax and Houston, 2006; Turner et al., 2007). The protein concentrations used in 
HLM and CYP2B6 incubations were 0.25 mg/ml ~1 mg/ml and thus fumic of efavirenz 
was estimated to be 0.2~0.4. A published fumic value of 0.3 with reasonably good 
prediction of efavirenz clearance (Rekic et al., 2011) was contained in that range and 
therefore was used in the present study. However, the uncertainties on fumic 
determinations contribute to the under-prediction of clearance cannot be excluded. ISEF 
is the other important factor with great impact on the extrapolation of clearance from 
expressed CYPs. It has been employed to account for the difference in turnover number 
(activity per unit amount of P450) between expressed CYPs and HLMs (Proctor et al., 
2004) and successfully used for IVIVE to predict in vivo clearance in a number of studies 
(Howgate et al., 2006; Dickinson et al., 2007a; Dickinson et al., 2007b; Siccardi et al., 
2012). ISEFs have been shown to depend on the expressed systems, HLM preparations, 
substrates used and assay conditions (Proctor et al., 2004). Especially considering the 
substrate-dependent effects on the alteration of substrate binding and catalytic activity by 
the CYP2B6*6 allele (Jinno et al., 2003; Watanabe et al., 2010; Ariyoshi et al., 2011; 
Zhang et al., 2011a; Xu et al., 2012), it is very likely that the ISEFs determined using 
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other CYP2B6 substrate, e.g. bupropion and cyclophosphamide, may not be applied to 
efavirenz. Furthermore, the ISEF values are determined on the basis of enzyme 
abundance, Km and Vmax (Proctor et al., 2004), which all have been shown to be altered 
by the CYP2B6*6 allele (Hofmann et al., 2008; Zhang et al., 2011a; Xu et al., 2012). 
Therefore, it is important to test the effect of this allele on ISEFs of CYP2B6. Indeed, 
incorporation of recalculated CLISEF greatly improved the prediction of efavirenz 
clearance by PBPK and well-stirred liver model. PBPK model using CLISEF showed the 
best prediction in terms of accuracy and bias, probably due to that CLISEF accounts for 
the differences in efavirenz Km from expressed and HLM systems. This result highlights 
the importance of establishing ISEFs for individual CYP isoform and its variant proteins 
using specific substrate when general values of ISEFs did not work.  
In the present study, PBPK model performed generally better prediction for mean 
values of efavirenz CLpo compared to well-stirred liver model, when the same metabolic 
data and extrapolation factors were used. But it is worthy of notice that well-stirred liver 
model had very comparable prediction to PBPK model when CLISEF was used, 
supporting its utility in IVIVE when only limited resources are available. A 
comprehensive knowledge of drug properties, physiological and anatomical compositions 
of human body is a necessity to achieve good prediction by PBPK model, which may not 
be available in early drug development. Therefore, well-stirred liver model may still 
retain its important role in IVIVE because of its simplicity. 
Although PBPK modeling requires much more information about the drug and in 
vivo system than well-stirred liver model as mentioned above, a particular strength of 
PBPK modeling is the capability, with the use of Monte Carlo methods, to predict not 
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only the mean values of pharmacokinetics but also the variability in it beyond observed 
limits and to anticipate the subpopulation who are likely to be associated with extreme 
pharmacokinetics (Rowland et al., 2011). The prediction of the variability is particularly 
important for drugs that are associated with a large interindividual variability in 
pharmacokinetics and thus pharmacodynamics like efavirenz (Csajka et al., 2003; Haas et 
al., 2004). It appears that PBPK model captured the variability of efavirenz CLpo in wild 
type comparing the simulated 5
th
 and 95
th
 percentile with observed values in the present 
and previous studies (Haas et al., 2009). But it seems to overestimate the variability 
associated with efavirenz CLpo of individuals carrying CYP2B6*6/*6 genotype. Whether 
this overestimation is due to the overestimated variability associated with CYP2B6 
expression or other physiological parameters in homozygotes warrant further 
investigation.  
In summary, we systematically investigated the predictability of expressed 
CYP2B6 and HLMs genotyped for the CYP2B6*6 allele in pharmacogenetics-based 
IVIVE of efavirenz clearance under the same experimental conditions. PBPK and well-
stirred liver models are able to predict efaivirenz single-dose pharmacokinetics 
incorporating the in vitro mechanisms underlying the reduced efavirenz metabolism by 
the CYP2B6*6 allele in a genotype-based manner. We provided evidence that expressed 
CYPs seems to be a better system than HLMs for pharmacogenetics-based IVIVE of 
CYP2B6 substrates using efavirenz as an example. Expressed CYP2B6 may be a useful 
tool to study the effect of CYP2B6 genetic polymorphism on the substrate metabolism in 
the early drug development. We also showed the importance of establishing ISEFs for 
specific substrate and variant proteins in the prediction of drug clearance using expressed 
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CYP2B6. PBPK model developed in the present study can be a base model for the 
simulation of efavirenz steady-state pharmacokinetics, and drug-drug interactions. 
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CHAPTER VIII: In vitro analysis and quantitative prediction of efavirenz inhibition of 
eight Cytochrome P450s (CYPs) 
1. Introduction 
The propensity for clinically important drug-drug interactions of efavirenz is high, 
because it is always used in combination therapy and in concert with drugs directed at the 
treatment of opportunistic infections, cancers and other HIV-related co-morbidities. The 
alterations in pharmacokinetics of co-administered drugs by efavirenz lead to either lack 
of efficiency or adverse drug reactions of the victim drug (Deeks and Perry, 2010). In 
order to predict and avoid adverse drug interactions with efavirenz-based therapy, it is 
important to identify mechanisms underlying those drug interactions. 
Efavirenz is known to alter the pharmacokinetics of a long list of co-administered 
drugs [Product Information of Efavirenz (Sustiva), Bristol-Myers Squibb Company, June 
2012], probably by modulating the activities of multiple drug metabolizing enzymes 
and/or drug transporters. Efavirenz is predominantly cleared mainly by CYP2B6-
mediated 8-hydroxylation, with small contribution from other CYPs (e.g., CYP2A6, 
CYP3A and CYP1A2) (Ward et al., 2003; Ogburn et al., 2010). Two minor pathways, 
efavirenz 7-hydroxylation and N-glucuronidation, are predominantly catalyzed by 
CYP2A6 (Ogburn et al., 2010) and UGT2B7 (Belanger et al., 2009), respectively. 
Efavirenz, through activation of constitutive androstane receptor (CAR) and/or pregnane 
X receptor (PXR), enhances the expression of multiple enzymes regulated by these 
nuclear receptors, including CYP2B6, CYP2C19 and CYP3A (Hariparsad et al., 2004; 
Faucette et al., 2007). Therefore, many drug interactions associated with efavirenz at 
steady state including decreased exposures of methadone (Clarke et al., 2001), statins 
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(Gerber et al., 2005), omeprazole (Michaud et al., 2012b), voriconazole (Liu et al., 2008), 
proguanil (van Luin et al., 2010) and etravirine (Boffito et al., 2009), and protease 
inhibitors (Staszewski et al., 1999) can be primarily explained by the inductive effect of 
efavirenz. Furthermore, efavirenz enhances its own metabolism (auto-induction) upon 
repeated administration compared to a single dose (Zhu et al., 2009), probably through 
induction of CYP2B6 and other enzymes involved in its metabolism (Ward et al., 2003; 
Belanger et al., 2009; Ogburn et al., 2010). Besides induction, there is in vitro evidence 
that efavirenz may directly inhibit the activities of certain CYPs (Hesse et al., 2001; von 
Moltke et al., 2001; Bumpus et al., 2006; Parikh et al., 2007). Indeed, scattered clinical 
cases of adverse drug interactions, e.g., with amodiaquine (German et al., 2007), warfarin 
(Bonora et al., 2008) and phenytoin (Robertson et al., 2005) suggest that efavirenz may 
alter the pharmacokinetics of co-administered drugs through inhibition of CYPs.  
A comprehensive inhibitory analyses that encompass all major drug-metabolizing 
CYPs are important because: a) not all pharmacokinetic drug interactions involving 
efavirenz can be explained by the known inductive effect of efavirenz and by the CYPs 
studied so far; and b) the in vitro studies describing inhibition of CYPs by efavirenz 
provide only qualitative information, without generating in vitro inhibition parameters 
that will allow quantitative prediction of in vivo condition and without taking the 
contribution of time-dependent inactivation into account. In addition, the net effect on the 
pharmacokinetics of co-administered drugs seems to depend on its varied potencies of 
inhibition and induction on individual CYP isoform. In order to better predict in vivo 
drug-drug interactions associated with such mixed mechanisms, it is necessary to 
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simultaneously take reversible inhibition, time-dependent inhibition, and induction into 
account.  
The purpose of present study was to systematically evaluate the in vitro inhibitory 
potency of efavirenz on eight major human CYP isoforms and determine the mechanisms 
involved. For those isoforms that were inhibited in pilot experiments, inhibition constants 
(Ki values) were estimated with which the extent of in vivo drug interactions was 
quantitatively predicted. 
2. Results 
2.1 Screening for inhibition of multiple CYPs by efavirenz 
The inhibitory effect of efavirenz at 10 and 50 µM on the activities of eight CYP 
isoforms in pooled HLMs is shown in Figure 8.1. Efavirenz was a potent inhibitor of 
CYP2B6 (by 90% at 10 and 50 µM). It also showed inhibition of CYP2C8, CYP2C9 and 
CYP2C19 by >20% at 10 µM and by >50% at 50 µM. Efavirenz only showed weak 
inhibition on the activity of CYP3A (testosterone β-hydroxylation) by 10% at 10 µM and 
by 40% at 50 µM. 
The activity of CYP2C19 was assessed using two substrates (R-omeprazole and 
S-mephenytoin) since substrate-dependent effect on CYP2C19 inhibition profile was 
observed previously (Foti and Wahlstrom, 2008). In the present study, efavirenz inhibited 
CYP2C19 activity by 35% and 70% at 10 and 50 µM, when S-mephenytoin was used as 
a substrate (Figure 8.1), but its effect on CYP2C19-mediated R-omeprazole 5-
hydroxylation was marginal (by 10% at 50 µM efavirenz) (data not shown). This result is 
consistent with a previous report that S-mephenytoin is more sensitive to CYP2C19 
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inhibition than R-omeprazole (Foti and Wahlstrom, 2008). Therefore, S-mphenytoin was 
used as a substrate of CYP2C19 in subsequent inhibition experiment. 
We have in vivo evidence that efavirenz reduces CYP1A2 activity, as measured 
by caffeine metabolism: compared to a single efavirenz dose (600 mg orally), 
pretreatment with efavirenz (600 mg/day for 17 days) significantly decreased 
concentration ratio of paraxanthine/caffeine at 6 hour (P<0.0001) (Metzger et al., 2012). 
However, the present in vitro data derived from pooled HLMs did not indicate that 
efavirenz inhibits CYP1A2 activity (Figure 8.1). Therefore, we tested whether the major 
metabolite of efavirenz, 8-hydroxyefavirenz, contributes to inhibition of CYP1A2 and 
showed that 8-hydroxyefavirenz inhibited CYP1A2 by 20% up to 10µM (Figure 8.2), 
which suggests that other alternative mechanisms should account for the reduced 
CYP1A2 activity that we observed in vivo. 
The inhibitory effect of efavirenz on the activity of CYP2A6 and CYP2D6 was 
negligible (less than 10% at both efavirenz concentrations) (Figure 8.1). 
2.2 Estimation of Ki values 
In order to obtain quantitative prediction of magnitude of drug interaction in vivo, 
further experiments were performed to determine the Ki values for the inhibition of 
CYP2B6, 2C8, 2C9 and 2C19 by efavirenz. Although relatively weak inhibition of 
CYP3A was observed by efavirenz, Ki value was determined in pooled HLMs because a 
previous study reported that the value of IC50 is around 20 µM using midazolam as a 
substrate (von Moltke et al., 2001).   
Of all the CYPs tested, CYP2B6 was the most sensitive to efavirenz inhibition 
(Table 8.1). Visual inspection of the Dixon plot and further analysis of the parameters of 
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the enzyme inhibition models suggested that the inhibition data fit well to a competitive 
type of inhibition. The Ki values estimated by using a nonlinear regression model for 
competitive enzyme inhibition of CYP2B6-catalyzed bupropion 4-hydroxylation in 
pooled HLMs and CMV negative HLMs were 2.96 ± 0.67 µM and 0.39 ± 0.10 µM, 
respectively. Ki value determined in expressed CYP2B6 was 1.38 ± 0.09 µM. 
Representative Dixon plots for the inhibition of CYP2B6 in CMV negative HLMs and 
expressed CYP2B6 are shown in Figure 8.3A and 3B, respectively. 
Inhibition of CYP2C8 by efavirenz was determined in two HLMs and expressed 
CYP2C8. As shown in Table 8.1, efavirenz showed potent competitive inhibition of 
CYP2C8 activity in pooled HLMs (Ki = 4.78 ± 2.24 µM). The second HLMs was 
obtained from human liver tissues with the CYP2C8*3/*3 genotype and the Ki value 
(4.80 ± 0.35 µM) derived from this HLM was not different from that derived from pooled 
HLMs (Table 8.1). Efavirenz exhibited similar competitive inhibition in expressed 
CYP2C8 with an estimated Ki value of 6.05 ± 2.86 µM (Table 8.1). In Figure 8.4, Dixon 
plots for the inhibition of CYP2C8-catalyzed N-desethylation of amodiaquine by 
efavirenz in pooled HLMs (Figure 8.4A), HLMs with CYP2C8*3/*3 genotype (Figure 
8.4B) and expressed CYP2C8 (Figure 8.4C) are shown.   
Efavirenz was found to be a moderate inhibitor of CYP2C9 (Ki =19.46 ± 2.78 
µM; Table 8.1 and Figure 8.5) and CYP2C19 (21.31±2.57 µM; Table 8.1 and Figure 
8.6), and a weak inhibitor of CYP3A (Ki = 40.33 ± 0.33 µM; Table 8.1 and Figure 8.7).  
2.3 Time-dependent inactivation  
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As shown in Figure 8.8, efavirenz preincubation for 30 min only marginally 
inhibited the activity of those CYPs tested. Shorter preincubation times (5-15 min) were 
also tested, but did not show any indication of time-dependent inactivation.   
2.4 Quantitative prediction of in vivo drug interactions 
The predicted ratios of 
A C I
A C
 for each substrate co-administered with a single dose 
or multiple doses of efavirenz are listed in Table 8.2. Compared to control (without 
efavirenz), a single 600 mg oral dose of efavirenz was predicted to result in 3-fold 
changes in the exposure of methadone (CYP2B6 substrate). Also, based on the inhibition 
data generated using S-mephenytoin hydroxylation as a marker of CYP2C19, we 
predicted lower AUCs of active metabolites of clopidogrel and proguanil (by 17%-29% 
and 29%-33% respectively), and higher omeprazole AUC (by 1.4- to 1.6-fold) in 
extensive metabolizer of CYP2C19. However, when data generated using R-omeprazole 
5-hydroxylation is used, no inhibition could be predicted in vivo. Based on our in vitro 
data, a single dose of efavirenz is unlikely to alter the pharmacokinetics of CYP3A 
substrates.  
After multiple doses of efavirenz, the AUC of CYP2C8 and CYP2C9 substrates 
was predicted to be 3.5- to 4.4-fold higher (CYP2C8 substrate: amodiaquine) and 1.7- to 
2.0-fold higher (CYP2C9 substrates: phenytoin and S-warfarin) compared to controls 
(without efavirenz).  
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Figure 8.1 Inhibition of CYP isoforms by efavirenz in pooled HLMs. A substrate 
probe at a single concentration was incubated with pooled HLMs and cofactors in the 
absence (control) or the presence of efavirenz (10 and 50 µM) for times and with protein 
concentrations that were linear for the respective reaction described in detail in Material 
and Methods. The specific concentrations of each probe used are illustrated in Materials 
and Methods. Each point represented the average of duplicate incubations. EFV, 
efavirenz. 
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Figure 8.2 Inhibition of CYP1A2 by 8-hydroxyefavirenz in pooled HLMs. Phenacetin 
(50 µM) was incubated with pooled HLMs (1 mg/ml) and cofactors in the absence 
(control) or the presence of 8-hydroxyefavirenz (0.5 to 10 µM) at 37°C for 30 min. Each 
point represented the average of duplicate incubations. 8OHEFV, 8-hydroxyefavirenz. 
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Figure 8.3 Dixon plots for the inhibition of bupropion 4-hydroxylation by efavirenz 
in CMV Negative HLMs (A) and expressed CYP2B6 (B). Bupropion (25 to 75 µM) 
was incubated with CMV negative HLMs (0.25 mg/ml) or expressed CYP2B6 (5 pmol) 
and cofactors at 37°C for 15 min with or without efavirenz (0-1 µM). Each point 
represented the average of duplicate incubations. The line represents the best fit for the 
data. 
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Figure 8.4 Dixon plots for the inhibition of amodiaquine desethylation by efavirenz 
in pooled HLMs (A), HLMs with CYP2C8*3/*3 genotype (B) and expressed 
CYP2C8 (C). Amodiaquine (10 to 100 µM) was incubated with pooled HLMs (0.1 
mg/ml) or HLMs with CYP2C8*3/*3 genotype (0.1 mg/ml) and cofactors at 37°C for 15 
min with or without efavirenz (0-50 µM). Expressed CYP2C8 (26 pmol) was used in the 
inhibition study. Each point represented the average of duplicate incubations. The line 
represents the best fit for the data. 
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Figure 8.5 Dixon plot for the inhibition of tolbutamide 4-hydroxylation by efavirenz 
in pooled HLMs. Tolbutamide (50 to 250 µM) was incubated with pooled HLMs (1 
mg/ml) and cofactors at 37°C for 15 min with or without efavirenz (0-100 µM). The line 
represents the best fit for the data. 
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Figure 8.6 Dixon plot for the inhibition of S-mephenytoin 4-hydroxylation by 
efavirenz in pooled HLMs. S-mephenytoin (15 to 75 µM) was incubated with pooled 
HLMs (1 mg/ml) and cofactors at 37°C for 15 min with or without efavirenz (0-100 µM). 
The line represents the best fit for the data. 
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Figure 8.7 Dixon plot for the inhibition of testosterone β-hydroxylation by efavirenz 
in pooled HLMs. Testosterone (5 to 50 µM) was incubated with pooled HLMs (0.25 
mg/ml) and cofactors at 37°C for 15 min with or without efavirenz (0-50 µM). The line 
represents the best fit for the data. 
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Figure 8.8 Time-dependent inhibition of CYP isoforms by efavirenz in pooled 
HLMs. Efavirenz (50 µM) was preincubated in duplicate with HLMs and phosphate 
reaction buffer (pH 7.4) (without or with the NADPH-generating system) in the absence 
of a substrate probe for 0, 5, 10, 15 and 30 min at 37°C. Controls were preincubated for 0 
min without efavirenz and without the NADPH generating system. Protein concentrations 
and the specific concentrations of each probe used are illustrated in Materials and 
Methods. Each point represents the average of duplicate incubations. 
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Table 8.1 Ki values of efavirenz for the inhibition of CYPs in HLMs and expressed 
CYPs. 
CYP Isoform  Substrate Systems Ki value (µM) 
(inhibition model) 
CYP2B6 Bupropion pooled HLMs 2.96 ± 0.67 
(competitive) 
  CMV negative HLMs 0.39 ± 0.10 
(competitive) 
  expressed CYP2B6 1.38 ± 0.09 
(competitive) 
CYP2C8 Amodiaquine pooled HLMs 4.78 ± 2.24 
(competitive) 
  HLMs with 
CYP2C8*3/*3  
4.80 ± 0.35 
(competitive) 
  expressed CYP2C8 6.05 ± 2.86 
(competitive) 
CYP2C9  Tolbutamide pooled HLMs 19.46 ± 2.78  
(non-competitive) 
CYP2C19 S-mephenytoin pooled HLMs 21.31±2.57 
(competitive) 
CYP3A Testosterone pooled HLMs 40.33 ± 0.33 
(competitive) 
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Table 8.2 Prediction of changes in AUC of CYP2B6, 2C9 and 2C19 substrates in 
vivo by efavirenz.  
 fm  Predicted 
AUC Ratio 
 Reported AUC 
Ratio 
Methadone 0.75 (Shou et al., 2008)  2.9 - 3.1  N.A. 
Amodiaquine 0.93 (Li et al., 2002)  3.5 - 4.4  2.15 – 4.02 
(German et al., 
2007) 
Phenytoin 0.90 (Giancarlo et al., 2001)  1.7 - 2.0  N.A. 
S-Warfarin 0.91(Obach et al., 2006)  1.7 - 2.0  N.A. 
Omeprazole 0.87 (Obach et al., 2006)  1.4 -1.6  N.A. 
Proguanil* 0.84  29% ~33%
 
  
Clopidogrel* 0.56-0.64 (Boulenc et al., 
2011) 
 17% ~29%  N.A. 
Plasma concentrations of efavirenz after a single dose were used to predict its effect on 
AUC change of methadone, omeprazole and the active metabolites of proguanil and 
clopidogrel. Plasma concentrations upon multiple doses were used for predicting AUC 
change of amodiaquine, phenytoin and S-warfarin. *: The value of percentage change in 
the AUC of active metabolite (1-  
A C m, I
A C m,
 ) was predicted. N.A.: not available 
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3. Discussion 
In this section I explored the hypothesis that efavirenz alters pharmacokinetics of 
co-administered drugs by inhibiting CYPs activities. We have shown that efavirenz is a 
potent competitive inhibitor of CYP2B6 (average Ki= 1.68 µM in HLMs and Ki= 1.38 
µM in expressed CYP2B6) and CYP2C8 (Ki = 4.78 µM in pooled HLMs and Ki = 4.80 
μM in HLMs with CYP2C8*3/*3 genotype). In pooled HLMs, efavirenz showed 
moderate inhibition of CYP2C9 (Ki= 19.46 µM) CYP2C19 (Ki= 21.31 µM), and a weak 
inhibitor of CYP3A (Ki= 40.33 µM). Inhibition of CYP1A2, CYP2A6 and CYP2D6 by 
efavirenz was marginal. No time-dependent inactivation of the CYP isoforms tested was 
observed. Based on the in vitro to in vivo quantitative prediction, efavirenz is expected to 
: a) increase the AUC of methadone (CYP2B6 substrate) by 2.9- to 3.1-fold, omeprazole 
by 1.4- to 1.6-fold (CYP2C19 substrate),and may also lower the AUC of active 
metabolites of some pro-drugs (e.g. clopidogrel and proguanil ) by up to 30% during 
initiation of efavirenz-based anti-HIV therapy; and b) increase the AUC of amodiaquine 
by 3-fold (CYP2C8 substrate) and phenytoin and warfarin by 1.7- to 2.0-fold (CYP2C9 
substrates) during a single dose or multiple doses of efavirenz. Our data suggest that 
efavirenz may increase the risk for adverse effects by increasing the exposure of the 
parent drug or reduce efficacy by diminishing the formation of pharmacologically active 
metabolites from prodrugs. 
Of the CYPs tested, CYP2B6 was most sensitive to efavirenz inhibition with Ki 
value of 1.7 M in HLMs and ~1.38 µM in expressed CYP2B6. Although the ability of 
efavirenz to inhibit CYP2B6 was previously reported (Hesse et al., 2001; Bumpus et al., 
2006), the present data provide key information that allowed in vivo quantitative 
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prediction of the magnitude of interaction. The high inhibition potency of efavirenz in our 
study is worth commenting. Efavirenz has a higher binding affinity to CYP2B6 with Km 
values of 13 ~ 20 µM (Ward et al., 2003; Ogburn et al., 2010) than bupropion with Km 
values of 90 ~ 130 µM (Faucette et al., 2000; Hesse et al., 2000). Thus, it is plausible that 
the high inhibition potency of efavirenz on bupropion hydroxylation could be due to the 
fact that efavirenz has higher binding affinity to CYP2B6 than bupropion. Similar 
mechanism contributing to high inhibition potency has been reported for CYP2D6 
(Vandenbrink et al., 2011b). To put the in vitro inhibition data on CYP2B6 into 
perspective, it is important to point out that efavirenz enhances its own metabolism upon 
multiple doses preferentially through CAR-mediated induction of CYP2B6 (Oswald et 
al., 2012). Efavirenz also enhances the metabolism of co-administered CYP2B6 
substrates, including methadone (Clarke et al., 2001; Kharasch et al., 2012) and 
bupropion (Robertson et al., 2008). Considering the high inhibition potency of efavirenz, 
a substantial increase in AUC of CYP2B6 substrates and potentially the risk to adverse 
effects may be expected, when efavirenz-based therapy is initiated in patients who are 
stabilized on CYP2B6 substrates. We predicted approximately 2.9- to 3.1-fold increase in 
methadone AUC, when a single 600 mg oral dose of efavirenz is co-administered. 
However, during chronic administration, inhibition of CYP2B6 by efavirenz appears to 
be masked by its marked induction and the net effect becomes induction.  
Our study demonstrates that efavirenz inhibits CYP2C8-mediated amodiaquine 
desethylation with Ki values of 4.78 and 6.05 µM in pooled HLMs and expressed 
CYP2C8 respectively, which broadly concurs with an IC50 of 4M reported in expressed 
CYPs (Parikh et al., 2007). The inhibition potency of efavirenz in HLMs with the 
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CYP2C8*3/*3 genotype, the most frequent and functionally relevant variant in 
Caucasians (Daily and Aquilante, 2009), was not different from that observed in pooled 
HLMs. The possibility of substrate-dependent interaction cannot be fully excluded 
(Kaspera et al., 2011), but our data suggest that the CYP2C8*3 allele does not seem to 
alter susceptibility to efavirenz inhibition. We expect 3-fold higher AUC of 
amodiaquine and probably other substrates such as chloroquine, certain anti-diabetics, 
montelukast and rosiglitazone (Totah and Rettie, 2005; Lai et al., 2009), when co-
administered with efavirenz. A clinical study that was designed to evaluate drug 
interactions between anti-malarials and efavirenz-based anti-HIV therapy was 
prematurely discontinued after the first two subjects developed hepatotoxicity (German et 
al., 2007). A 2.2- to 4-fold increase in amodiaquine AUC was also noted (German et al., 
2007) and it is highly likely that this interaction occurred through inhibition of CYP2C8, 
as predicted from our in vitro data.   
Our data showed that efavirenz inhibits CYP2C9 activity (Ki= 19.46 µM) with 
1.7- to 2-fold predicted increase in AUC of drugs mainly cleared by CYP2C9, consistent 
with an in vitro study reporting an IC50 value of 15M (von Moltke et al., 2001). This 
enzyme is involved in the metabolism of more than 100 currently used drugs, including 
drugs with narrow therapeutic range, e.g., oral anticoagulants, oral hypoglycemic agents 
and phenytoin (Rettie and Jones, 2005). Therefore, co-administration of efavirenz may 
likely increase the risks to adverse effects of these drugs, which is supported by clinical 
cases of inhibition drug interactions of efavirenz with the CYP2C9 substrate phenytoin 
(Robertson et al., 2005) and warfarin (Bonora et al., 2008).  
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We found that the extent of CYP2C19 inhibition by efavirenz was substrate-
dependent: modest inhibition of S-mephenytoin 4-hydroxylation (Ki= 21.31 µM) and 
marginal inhibition of R-omeprazole 5-hydroxylation consistent with  a previous study 
reporting that R-omeprazole is less sensitive to CYP2C19 inhibitors than S-mephenytoin 
(Foti and Wahlstrom, 2008). The clinical relevance of efavirenz inhibition on CYP2C19 
and the mechanism of substrate-dependent inhibition remain unclear, but this interaction 
may be important for prodrugs that require bioactivation by CYP2C19. For example, at a 
single dose or acute dosing, efavirenz may inhibit the formation of active metabolite of 
clopidogrel by CYP2C19 and to some extent by CYP2B6 and CYP2C9 (Kazui et al., 
2010). Provided that efavirenz is a potent inhibitor of CYP2B6 and a moderate inhibitor 
of CYP2C19 and CYP2C9 (present data), it is likely that administration of efavirenz to 
patients stabilized on clopidogrel may result in substantially reduced formation of active 
metabolite and lack of efficacy. At steady state, efavirenz may be a mixed inhibitor and 
inducer of CYP2C19 (Michaud et al., 2012b), although induction appears to predominate 
as shown with the enhanced metabolism of CYP2C19 substrates including voriconazole 
(Liu et al., 2008), omeprazole (Michaud et al., 2012b), etravirine (Boffito et al., 2009). 
Contradictory effects were observed in another CYP2C19 substrate proguanil, with 
decreased proguanil exposure co-administered with 600 mg/day efavirenz for 1 month 
(van Luin et al., 2010) and increased proguanil exposure co-administered with 400 
mg/day efavirenz for 9 days (Soyinka and Onyeji, 2010). This discrepancy may be due to 
differences in dose regimens, duration of treatment and study populations.   
Efavirenz-mediated in vivo inhibition of CYP3A seems unlikely given the high Ki 
value (Ki= 40M) observed in the present study. Using triazolam as a substrate, another 
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study reported lower IC50 values (17-20M) (von Moltke et al., 2001), but the 
significance of in vivo inhibition of CYP3A, if any, is likely marginal. Efavirenz, through 
activation of PXR/CAR, induces CYP3A in vitro (Hariparsad et al., 2004; Faucette et al., 
2007) and in vivo (Mouly et al., 2002; Michaud et al., 2012b). Hence, efavirenz enhances 
the elimination of many CYP3A substrates, including protease inhibitors, statins (Gerber 
et al., 2005), calcium channel blockers and anti-fungals [Product Information of 
Efavirenz (Sustiva), Bristol-Myers Squibb Company, June 2012]. Therefore, induction 
drug interactions between efavirenz and CYP3A substrates appear to predominate at 
steady-state.  
CYP1A2, CYP2A6 and UGT2B7 all have been shown to be involved in efavirenz 
metabolism (Ward et al., 2003; Belanger et al., 2009). Efavirenz is not only a substrate 
but also a moderate inhibitor of UGT2B7 (Belanger et al., 2009), while no reversible 
inhibition or time-dependent inhibition by efavirenz was observed for CYP1A2 and 
CYP2A6 in the present study. The drug interaction with CYP2A6 substrates mediated by 
efavirenz inhibition seems very unlikely, but the possibility of efavirenz inhibiting the 
metabolism of CYP1A2 substrates can’t be excluded, because the preliminary results 
from our laboratory showed that efavirenz reduces CYP1A2 activity as measured by 
caffeine metabolism in vivo.  
The use of efavirenz is made difficult by high interindividual variability in its 
disposition and by often unpredictable and complex drug interactions. The extent of drug 
interactions with
 
efavirenz varies greatly among individuals, and interpatient differences 
in efavirenz exposure contribute to this variability. Efavirenz exposure is governed by 
complex factors: efavirenz is mainly cleared by CYP2B6, with some contribution from 
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accessory pathways catalyzed by enzymes that include CYP2A6, CYP1A2, CYP3A and  
UGT2B7 (Ward et al., 2003; Belanger et al., 2009; di Iulio et al., 2009; Kwara et al., 
2009a; Ogburn et al., 2010; Cho et al., 2011); efavirenz activates CAR and PXR, induces 
CYP2B6 (and other drug disposition genes) and autoinduces its own metabolism  
(Oswald et al., 2012) upon repeated administration; and efavirenz is a potent inhibitor of 
CYP2B6 with no effect on CYP2A6 and CYP1A2 (present study) and a moderate 
inhibitor of UGT2B7 in vitro (Belanger et al., 2009). These complex inhibition/induction 
processes and genetic variations of CYP2B6 would likely contribute to variable efavirenz 
exposure and drug interactions. The net effect of efavirenz on drug interactions 
(induction versus inhibition) in vivo is likely to be dependent on: duration of efavirenz 
administration (acute versus chronic); genetic and nongenetic factors; and the potency 
with which efavirenz induces or inhibits drug metabolizing enzymes. Although predicting 
the extent and direction of drug interactions with efavirenz in vivo might be difficult for 
the individual patient, general comments could be made based on our data and the 
literature. During initiation of efavirenz-based therapy, it is expected that efavirenz 
reduces the elimination of CYP2B6, CYP2C8, CYP2C9 and CYP2C19 substrates. Mixed 
induction/inhibition occurs upon repeated administration of efavirenz, but the net effect 
of efavirenz appears to be induction for CYP2B6 and CYP2C19, while inhibition appears 
to dominate for CYP2C8 and CYP2C9. Induction appears the main mechanism for 
efavirenz interactions involving CYP3A. Together, efavirenz’s complex interaction with 
enzymes involved in its own metabolism and the metabolism of co-administered drugs 
may contribute to the large interindividual variability of efavirenz exposure and 
unpredictable drug interactions associated with it. 
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CHAPTER IX: Conclusions and future directions 
1. Conclusions 
The major focuses of this dissertation were to determine the mechanisms: 1) by 
which the CYP2B6*6 allele reduced efavirenz metabolism in vitro, and 2) by which 
efavirenz alters the pharmacokinetics of co-administered drugs. Results from this 
dissertation provided evidence that amino acid changes harbored in the CYP2B6*6 allele 
may reduce efavirenz metabolism by decreasing binding affinity and catalytic efficiency. 
The functional consequences of the CYP2B6*6 allele appears to be substrate- and Cyt b5-
dependent. Additionally, this dissertation found that CYP2B6 variant protein is more 
susceptible to metabolic inhibition than the wild type. Moreover, data from this 
dissertation also showed that models incorporating in vitro mechanisms of reduced 
efavirenz metabolism by the CYP2B6*6 allele can predict efavirenz clearance in 
pharmacogenetics-based manner. Finally, results from this dissertation demonstrated that 
efavirenz may alter pharmacokinetics of co-administered drugs by inhibiting the activities 
of CYP2B6, 2C8, 2C9 and 2C19. Based on the major findings outlined above, four 
overarching conclusions can be drawn concerning the body of work presented in this 
dissertation: 1) the CYP2B6*6 allele alters catalytic properties, i.e. binding affinity and/or 
catalytic efficiency, and susceptibility to metabolic inhibition that may contribute to 
reduced efavirenz metabolism by this variant allele, 2) the functional consequences of the 
CYP2B6*6 allele is substrate- and Cyt b5-dependent, 3) incorporation of in vitro 
mechanism of reduced efavirenz metabolism by the CYP2B6*6 allele can predict 
efavirenz clearance after a single oral dose in pharmacogenetics-based manner, and 4) 
efavirenz may alter the pharmacokinetics of co-administered medications by inhibiting 
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the activities of CYP2B6, 2C8, 2C9 and 2C19. Each of these overarching conclusions is 
discussed in the section which follows. 
A. The CYP2B6*6 allele alters catalytic properties, i.e. binding affinity and/or catalytic 
efficiency, and susceptibility to metabolic inhibition that may contribute to reduced 
efavirenz metabolism by this variant allele 
The CYP2B6*6 allele is clinically important because this allele or the SNP 
tagging it (G516T) occurs at high frequency in all ethnic populations [14-62% (Zanger et 
al., 2007)] and has been associated with functional consequences in expressed systems 
(Ariyoshi et al., 2001; Jinno et al., 2003; Bumpus and Hollenberg, 2008; Watanabe et al., 
2010; Ariyoshi et al., 2011; Zhang et al., 2011b) and human liver microsomes (HLMs) 
(Lang et al., 2001; Lamba et al., 2003; Xie et al., 2003; Hesse et al., 2004; Desta et al., 
2007). In HLMs, the CYP2B6*6 allele is associated with reduced total amount of 
CYP2B6 protein (Xie et al., 2003; Hesse et al., 2004; Desta et al., 2007). The G516T 
SNP was predicted to disrupt an exonic splicing enhancer in silico (Lamba et al., 2003). 
Subsequently, Hofmann et al. provided evidence that this variant indeed affects splicing 
and thereby reduces CYP2B6 expression and activity (Hofmann et al., 2008). However, 
mounting evidence indicate that reduced protein expression alone may not explain the 
functional consequences of this allele. For substrates that include cyclophosphamide, this 
allele is associated with enhanced metabolism despite reduced protein expression (Xie et 
al., 2003), which appears due to substantially lower Km in the variant versus wild type 
protein (Ariyoshi et al., 2011).   
As part of this dissertation I examined the influence of the CYP2B6*6 allele on 
catalytic properties measured by efavirenz 8-hydroxylation (Ward et al., 2003) as a probe 
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of activity using expressed enzymes and HLMs obtained from liver tissue samples 
genotyped for the CYP2B6*6 allele (Chapter III). The results presented in this thesis 
demonstrated that that the CYP2B6*6 allele is associated with decreasing binding affinity 
and/or catalytic activity using efavirenz as a substrate. Consistent with previous reports in 
various expressed systems (Ariyoshi et al., 2001; Jinno et al., 2003; Bumpus et al., 2006; 
Raccor et al., 2012), we noted that the Vmax values for the formation of 8-
hydroxyefavirenz significantly higher in CYP2B6.6 than in CYP2B6.1 proteins 
expressed without Cyt b5. However, Vmax values for the formation of 8-hydroxyefavirenz 
were substantially decreased (by 70%) in HLMs with CYP2B6*6/*6 genotype versus 
HLMs with CYP2B6*1/*6 and CYP2B6*1/*1 genotypes. Our interpretation is that the 
expressed variant protein inherently increases catalytic activity of efavirenz, whereas the 
decreased Vmax value in HLMs is probably mainly due to reduced protein expression by 
the CYP2B6*6/*6 genotype (Hesse et al., 2004; Desta et al., 2007; Hofmann et al., 2008). 
Consequently, additional experiments are needed to quantify the amount of CYP2B6 
protein in human liver samples genotyped for the CYP2B6*6 allele and determine 
whether the decreased Vmax value in HLMs is due to reduced protein expression and/or 
reduced catalytic activity of the variant protein.  
In addition, it has been shown that amino acid substitutions, such as those found 
in the variant of CYP2B6*6 allele, may also alter the degree of susceptibility to 
competing metabolic inhibitors for certain CYP2B6 variants (Bumpus et al., 2006; 
Bumpus and Hollenberg, 2008; Talakad et al., 2009). As part of the dissertation, I 
explored whether the CYP2B6*6 allele is associated with altered susceptibility to 
metabolic inhibition. The fact that the Ki values for CYP2B6 inhibition by voriconazole 
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was significantly lower in HLMs with CYP2B6*6 allele than in those with the 
CYP2B6*1/*1 genotype suggests that the variant protein is more susceptible to metabolic 
inhibition than the wild type (Chapter VI). 
The greater inhibition susceptibility by the variant protein may contribute to 
marked reduction of efavirenz metabolism and thus elevated efavirenz exposure in 
individuals with CYP2B6*6/*6 genotype, when a known interacting drug is co-
administered. Taking the data presented in this dissertation together, the CYP2B6*6 allele 
alters catalytic properties, i.e. binding affinity and/or catalytic efficiency, and 
susceptibility to metabolic inhibition that may contribute to reduced efavirenz 
metabolism by this variant allele. 
The suggestion of genotype-based efavirenz dose reduction in individuals with the 
CYP2B6*6/*6 is primarily based on pharmacogenetic association study in humans. The 
in vitro mechanisms by which the CYP2B6*6 allele reduced efavirenz metabolism 
identified in this dissertation indicates that amino acid changes harbored in this allele 
variant may alter the protein structure and thus lead to altered catalytic properties of the 
enzyme. The causal relationship between the genetic variation and reduced efavirenz 
metabolism shown in this dissertation lends support to the implement of dose adjustment 
based on the CYP2B6*6 genotype in anti-HIV treatment.  
Efavirenz exposure is governed by complex factors: efavirenz is mainly cleared 
by polymorphic CYP2B6, with some contribution from accessory pathways catalyzed by 
enzymes that include CYP2A6, CYP1A2, CYP3A and  UGT2B7 (Ward et al., 2003; 
Belanger et al., 2009; di Iulio et al., 2009; Kwara et al., 2009a; Ogburn et al., 2010; Cho 
et al., 2011); efavirenz activates CAR and PXR, induces CYP2B6 (and other drug 
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disposition genes) and autoinduces its own metabolism  (Oswald et al., 2012) upon 
repeated administration in a genotype-dependent manner (Ngaimisi et al., 2011); 
efavirenz is a potent inhibitor of CYP2B6 with no effect on CYP2A6 and CYP1A2 
(present study) and a moderate inhibitor of UGT2B7 in vitro (Belanger et al., 2009); and 
the inhibition susceptibility of CYP2B6 is also dependent on the CYP2B6*6 genotype. 
These complex inhibition/induction processes and genetic variations of CYP2B6 would 
likely contribute to variable efavirenz exposure and drug interactions. 
Efavirenz may serve as an effective probe of CYP2B6 and CYP2A6 activity in 
vitro and in vivo due to their primary contribution to efavirenz 8-hydroxylation and 7-
hydroxylation, respectively (Ward et al., 2003; Ogburn et al., 2010). Clinical studies are 
ongoing in our laboratory to clarify the precise contribution of CYP2A6 and CYP2B6 in 
efavirenz metabolism using genetic and drug interactions as markers.  
B. The functional consequences of the CYP2B6*6 allele is substrate- and Cyt b5-
dependent 
A number of in vitro studies, mostly in expressed systems, have reported that the 
CYP2B6*6 allele or the amino acids harbored in it influence catalytic properties. 
However, the extent and direction of effect appears to depend on the substrate and the 
enzyme sources used. Therefore, I hypothesized that the functional consequences of the 
CYP2B6*6 allele may be substrate-dependent. I determined the kinetics of bupropion 
metabolism to 4-hydroxybupropion in the same expressed CYP2B6 and HLMs used for 
the characterization of efavirenz kinetics in Chapter IV. I found that the CYP2B6*6 
allele may influence substrate binding with pronounced effect on efavirenz than 
bupropion. The data presented in Chapter III and Chapter IV in conjunction with the 
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previous studies suggest that the CYP2B6*6 allele alters catalytic properties in a 
substrate-dependent manner.  
Several factors inherent to specific enzyme sources that include differences in Cyt 
b5 contents may influence in vitro kinetic parameters and inhibition constants in 
substrate-dependent manner. Cyt b5 has been reported to activate several CYPs including 
CYP2B6 (Reed and Hollenberg, 2003; Jushchyshyn et al., 2005), but its influence on the 
catalytic properties of CYP2B6.6 protein has not been studied. I examined the influence 
of Cyt b5 on the catalytic properties of expressed CYP2B6.1 and CYP2B6.6 by 
determining the kinetics of efavirenz and bupropion in CYP2B6 enzymes coexpressed 
with Cyt b5 (Chapter V). Our data show that Cyt b5 affects catalytic properties of 
CYP2B6 in genotype- and substrate-dependent manner and highlight the fact that 
interpretation of in vitro studies performed with expressed proteins may vary depending 
on the presence or absence of Cyt b5, substrate used and underlying genotype. 
In addition, I also found that for both substrates, CYP2B6.1 exhibited similar or 
increased catalytic activities with co-expression of Cyt b5 compared to that without Cyt 
b5, whereas Cyt b5 significantly decreased Vmax values in CYP2B6.6. These data suggest 
an overlapping binding site between CYP reductase and Cyt b5 in CYP2B6.6 but 
probably not in CYP2B6.1.  
A recent study characterizing the crystal structure of CYP2B6 genetic variant 
(Y226H, K262R) also supports our hypothesis that the amino acid changes harbored in 
the CYP2B6*6 allele may influence the interaction between the CYPs and electron 
transfer proteins and thus alter the catalysis of substrates in Cyt b5- and substrate-
dependent manner. The two SNPs (K262R and Q172H) harbored in the CYP2B6*6 allele 
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are not within the active site of the enzyme. The two amino acid mutations harbored by 
the CYP2B6*6 allele may indirectly involve in the ligand binding and substrate catalysis. 
The side chain of residue 172 may interact with the residues at active site and thus could 
affect binding affinity (Gay et al., 2010). It is noteworthy that the other mutated amino 
acid carried by CYP2B6*6 allele, K262R, is located at the G/H loop, which may involve 
in the interaction between the enzyme and its redox partner, CYP reductase (Bumpus and 
Hollenberg, 2008; Gay et al., 2010). The oxidation reaction catalyzed by CYPs requires 
transferring of two electrons from NADPH. The first electron is generally thought to be 
transferred by CYP reductase, while the second can be transferred by either CYP 
reductase or Cyt b5. That altered electron transfer from CYP reductase to CYP2B6 
variant proteins may influence substrate metabolism was suggested by a recent study 
(Zhang et al., 2011b). Therefore, the functional consequences of the CYP2B6*6 allele 
may be substrate- and Cyt b5-dependent. 
C. Incorporation of in vitro mechanism of reduced efavirenz metabolism by the 
CYP2B6*6 allele predicts efavirenz clearance after a single oral dose in 
pharmacogenetics-based manner 
I showed that the reduced efavirenz metabolism in individuals with the 
CYP2B6*6/*6 genotype may be due to decreasing altered binding affinity and catalytic 
efficiency (Chapter III). I tested that whether the incorporation of in vitro efavirenz 
metabolism data predicts genetic effect of the CYP2B6*6 allele on efavirenz clearance by 
in vitro-in vivo extrapolation (IVIVE) in this dissertation. I found that PBPK and well-
stirred liver models are able to predict efaivirenz clearance after a single oral dose by 
incorporating the in vitro mechanisms underlying the reduced efavirenz metabolism by 
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the CYP2B6*6 allele in a pharmacogenetics-based manner. In addition, I povided 
evidence that expressed CYPs seems to be a better system than HLMs for 
pharmacogenetics-based IVIVE of CYP2B6 substrates using efavirenz as an example. 
These data suggest that expressed CYP2B6 may be a useful tool to study the effect of 
CYP2B6 genetic polymorphism on the substrate metabolism in the early drug 
development. 
D. Efavirenz may alter the pharmacokinetics of co-administered medications by 
inhibiting the activities of CYP2B6, 2C8, 2C9 and 2C19 
Efavirenz is known to alter the pharmacokinetics of a long list of co-administered 
drugs, probably by modulating the activities of multiple drug metabolizing enzymes 
and/or drug transporters. However, not all pharmacokinetic drug interactions involving 
efavirenz can be explained by the known inductive effect of efavirenz and by the CYPs 
studied so far. Therefore, I systematically evaluated the in vitro inhibitory potency of 
efavirenz on eight major human CYP isoforms and determine the mechanisms involved 
(Chapter VIII). I found that efavirenz is a potent competitive inhibitor of CYP2B6 and 
CYP2C8, a moderate inhibitor of CYP2C9 and CYP2C19, and a weak inhibitor CYP3A. 
Inhibition of CYP1A2, CYP2A6 and CYP2D6 by efavirenz was marginal. No time-
dependent inactivation of the CYP isoforms tested was observed. Based on the in vitro to 
in vivo quantitative prediction, it is expected that efavirenz reduces the elimination of 
CYP2B6, CYP2C8, CYP2C9 and CYP2C19 substrates during initiation of efavirenz-
based therapy. Mixed induction/inhibition occurs upon repeated administration of 
efavirenz, but the net effect of efavirenz appears to be induction for CYP2B6 and 
CYP2C19, while inhibition appears to dominate for CYP2C8 and CYP2C9. Induction 
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appears the main mechanism for efavirenz interactions involving CYP3A. Our data 
suggest that efavirenz may increase the risk for adverse effects by increasing the 
exposure of the parent drug or reduce efficacy by diminishing the formation of 
pharmacologically active metabolites from prodrugs. Together, efavirenz’s complex 
interaction with enzymes involved in its own metabolism and the metabolism of co-
administered drugs may contribute to the large interindividual variability of efavirenz 
exposure and unpredictable drug interactions associated with it. 
2. Future directions 
Based on the findings of my work, it would be valuable to further evaluate the following 
directions in the future:  
1. To quantify CYP2B6 protein amount in human liver samples genotyped for the 
CYP2B6*6 allele.   
2. To identify the mechanism underlying the substrate-dependent effect of Cyt b5 and to 
provide insight into the topology of the variant.  
3. To study the genotype-dependent inhibition of CYP2B6 inhibition using other 
CYP2B6 substrates and inhibitors. 
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